{
  "$schema": "https://json-schema.org/draft/2020-12/schema",
  "schemaVersion": "4.0.0",
  "instanceType": "StudyDocument",
  "id": "USDM-H-34-20260112200008",
  "name": "Protocol Extraction: H-34",
  "sourceDocument": {
    "documentId": "DOC-1631EBB12EFD1A40",
    "filename": "CIP_H-34_v.2.0_05Nov2024_fully signed.pdf",
    "sha256Hash": "1631ebb12efd1a40607a5d74efaa19432ae640830e6dbdf91a99b400f016fc4b",
    "byteSize": 3306285,
    "uploadTimestamp": "2026-01-12T20:00:08.007755",
    "pageCount": 58
  },
  "extractionMetadata": {
    "extractionTimestamp": "2026-01-12T20:00:08.208757",
    "pipelineVersion": "3.1",
    "primaryModel": "gemini-2.5-pro",
    "agentCount": 16,
    "successfulAgents": [
      "study_metadata",
      "arms_design",
      "endpoints_estimands_sap",
      "adverse_events",
      "safety_decision_points",
      "concomitant_medications",
      "biospecimen_handling",
      "laboratory_specifications",
      "informed_consent",
      "pro_specifications",
      "data_management",
      "site_operations_logistics",
      "quality_management",
      "withdrawal_procedures",
      "imaging_central_reading",
      "pkpd_sampling"
    ],
    "failedAgents": [],
    "qualitySummary": {
      "study_metadata": {
        "overallScore": 0.8675,
        "fromCache": false
      },
      "arms_design": {
        "overallScore": 1.0,
        "fromCache": false
      },
      "endpoints_estimands_sap": {
        "overallScore": 0.8591554054054055,
        "fromCache": false
      },
      "adverse_events": {
        "overallScore": 0.9180916030534351,
        "fromCache": false
      },
      "safety_decision_points": {
        "overallScore": 1.0,
        "fromCache": false
      },
      "concomitant_medications": {
        "overallScore": 1.0,
        "fromCache": false
      },
      "biospecimen_handling": {
        "overallScore": 1.0,
        "fromCache": false
      },
      "laboratory_specifications": {
        "overallScore": 0.9963503649635036,
        "fromCache": false
      },
      "informed_consent": {
        "overallScore": 0.973775806451613,
        "fromCache": false
      },
      "pro_specifications": {
        "overallScore": 0.9227186671715258,
        "fromCache": false
      },
      "data_management": {
        "overallScore": 0.9,
        "fromCache": false
      },
      "site_operations_logistics": {
        "overallScore": 0.917797356828194,
        "fromCache": false
      },
      "quality_management": {
        "overallScore": 0.932761692650334,
        "fromCache": false
      },
      "withdrawal_procedures": {
        "overallScore": 0.9,
        "fromCache": false
      },
      "imaging_central_reading": {
        "overallScore": 0.9951456310679613,
        "fromCache": false
      },
      "pkpd_sampling": {
        "overallScore": 0.7984631147540985,
        "fromCache": false
      }
    },
    "averageQualityScore": 0.9363599776466296
  },
  "study": {
    "instanceType": "Study",
    "id": "H-34",
    "name": "DELTA REVISION CUP",
    "officialTitle": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup.",
    "version": "2.0",
    "provenance": {
      "section_number": null,
      "page_number": 1,
      "text_snippet": "Short title: DELTA REVISION CUP\nProtocol ID: H-34\nDate / Version: 05 November 2024 v. 2.0."
    },
    "studyPhase": {
      "code": "C15603",
      "decode": "Phase 4",
      "codeSystem": "NCI Thesaurus",
      "codeSystemVersion": "24.03e",
      "provenance": {
        "section_number": null,
        "page_number": 10,
        "text_snippet": "Study type and design: Post-market, open label, observational, prospective, longitudinal cohort study conducted in patients who have to perform a total hip arthroplasty with Delta Revision Acetabular Cup."
      }
    },
    "studyType": {
      "code": "C142615",
      "decode": "Observational",
      "codeSystem": "NCI Thesaurus",
      "codeSystemVersion": "24.03e",
      "provenance": {
        "section_number": null,
        "page_number": 10,
        "text_snippet": "Study type and design: Post-market, open label, observational, prospective, longitudinal cohort study"
      }
    },
    "studyProtocolVersions": [
      {
        "versionNumber": "2.0",
        "versionDate": "2024-11-05",
        "provenance": {
          "section_number": null,
          "page_number": 4,
          "text_snippet": "v. 2.0 05 November 2024"
        }
      },
      {
        "versionNumber": "1.1",
        "versionDate": "2020-09-28",
        "provenance": {
          "section_number": null,
          "page_number": 4,
          "text_snippet": "The protocol version and protocol date have been revised from v. 1.1 dated 28 September 2020 to v. 2.0 dated 05 November 2024"
        }
      },
      {
        "versionNumber": "1.0",
        "versionDate": "2020-02-04",
        "provenance": {
          "section_number": null,
          "page_number": 5,
          "text_snippet": "The protocol version and protocol date have been revised from v.1.0 dated 04.February.2020 to v.1.1 dated 28.September.2020."
        }
      }
    ],
    "studyPopulation": {
      "targetDisease": {
        "name": "Revision total hip arthroplasty",
        "provenance": {
          "section_number": "6.1",
          "page_number": 21,
          "text_snippet": "The Delta Revision acetabular cup is indicated for revision surgery and bone deficiency treatment both cavitary and segmentary."
        }
      },
      "ageRange": {
        "minAge": 18,
        "maxAgeNoLimit": true,
        "unit": "years",
        "provenance": {
          "section_number": null,
          "page_number": 11,
          "text_snippet": "2. Age \u2265 18 years old."
        }
      },
      "sex": {
        "allowed": [
          {
            "code": "C20197",
            "decode": "Male",
            "provenance": {
              "section_number": null,
              "page_number": 11,
              "text_snippet": "1. Male or female."
            },
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "24.03e"
          },
          {
            "code": "C16576",
            "decode": "Female",
            "provenance": {
              "section_number": null,
              "page_number": 11,
              "text_snippet": "1. Male or female."
            },
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "24.03e"
          }
        ]
      },
      "keyInclusionSummary": {
        "values": [
          "Age \u2265 18 years old",
          "Adult patients in whom a decision has already been made to perform a total hip arthroplasty with DELTA Revision acetabular cup as per indication for use",
          "Patient is able to comply with the protocol",
          "Must give written informed consent"
        ],
        "provenance": {
          "section_number": null,
          "page_number": 11,
          "text_snippet": "Inclusion criteria\nPatients must meet the following criteria for study entry:\n1. Male or female.\n2. Age \u2265 18 years old.\n3. All patients must give written informed consent approved by the study site's Institutional Review Board (IRB)/Ethical Committee (EC).\n4. Adult patients in whom a decision has already been made to perform a total hip arthroplasty with DELTA Revision acetabular cup as per indication for use.\n5. Patient is able to comply with the protocol."
        }
      },
      "keyExclusionSummary": {
        "values": [
          "Adult patients with any DELTA Revision acetabular cup contraindication for use as reported in the current local Instruction for use",
          "For female patients, current pregnancy and/or lactation or planning a pregnancy"
        ],
        "provenance": {
          "section_number": null,
          "page_number": 11,
          "text_snippet": "Exclusion criteria\nA patient will not be included in the study if they meet any of the following criteria:\n1. Adult patients with any DELTA Revision acetabular cup contraindication for use as reported in the current local Instruction for use.\n2. For female patients, current pregnancy and/or lactation or planning a pregnancy."
        }
      },
      "provenance": {
        "section_number": "5",
        "page_number": 18,
        "text_snippet": "The patient population for this study will include adult subjects in whom the decision to perform a hip arthroplasty with DELTA Revision acetabular cup must be taken prior to, and independently from the decision to include the patient into the study."
      }
    },
    "studyMilestones": {
      "estimatedDurations": {
        "enrollmentPeriodMonths": 60,
        "followUpPeriodMonths": 24,
        "totalStudyDurationMonths": 84,
        "provenance": {
          "section_number": "3.2",
          "page_number": 17,
          "text_snippet": "The expected duration of patient participation in the study will be around 2 years, with an expected recruitment period of 60 months."
        }
      },
      "provenance": {
        "section_number": "3.2",
        "page_number": 17,
        "text_snippet": "The expected duration of patient participation in the study will be around 2 years, with an expected recruitment period of 60 months."
      }
    },
    "studyDesignInfo": {
      "designType": "Single Group",
      "randomization": {
        "isRandomized": false,
        "provenance": {
          "section_number": null,
          "page_number": 10,
          "text_snippet": "Study type and design: Post-market, open label, observational, prospective, longitudinal cohort study"
        }
      },
      "blinding": {
        "blindingType": "Open-label",
        "provenance": {
          "section_number": null,
          "page_number": 10,
          "text_snippet": "Study type and design: Post-market, open label, observational, prospective, longitudinal cohort study"
        }
      },
      "targetEnrollment": 49,
      "plannedSites": 1,
      "countries": {
        "values": [
          "Italy"
        ],
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "Sponsor:\nLimaCorporate S.p.A.\nVia Nazionale, 52\n33038 Villanova di San Daniele\nUdine, Italy"
        }
      },
      "provenance": {
        "section_number": null,
        "page_number": 11,
        "text_snippet": "Sample size: Total enrollment assuming a 40% loss to follow-up is 29/0.60 \u2248 49 subjects.\nExpected number of study centres: 1"
      }
    },
    "therapeuticArea": {
      "value": "Orthopaedics",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "Lima Corporate\nOrthopaedic motion"
      }
    },
    "indication": {
      "value": "Revision total hip arthroplasty",
      "provenance": {
        "section_number": "6.1",
        "page_number": 21,
        "text_snippet": "The Delta Revision acetabular cup is indicated for revision surgery and bone deficiency treatment both cavitary and segmentary."
      }
    },
    "sponsorName": {
      "value": "LimaCorporate S.p.A.",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "Sponsor:\nLimaCorporate S.p.A."
      }
    },
    "extensionAttributes": [
      {
        "name": "extractionMetadata",
        "value": {
          "extractedAt": "2024-07-01T12:00:00Z",
          "modelVersion": "gemini-1.5-flash"
        }
      }
    ]
  },
  "domainSections": {
    "studyDesign": {
      "moduleId": "arms_design",
      "instanceType": "StudyDesign",
      "data": {
        "id": "H-34-arms-design",
        "instanceType": "StudyDesign",
        "name": "H-34 Study Design",
        "provenance": {
          "section_number": "Protocol Synopsis",
          "page_number": 10,
          "text_snippet": "Study type and design: Post-market, open label, observational, prospective, longitudinal cohort study conducted in patients who have to perform a total hip arthroplasty with Delta Revision Acetabular Cup."
        },
        "studyArms": [
          {
            "id": "ARM01",
            "instanceType": "StudyArm",
            "name": "DELTA Revision Acetabular Cup",
            "label": "Observational Cohort",
            "description": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup.",
            "provenance": {
              "section_number": "Protocol Synopsis",
              "page_number": 11,
              "text_snippet": "Treatment: Total hip arthroplasty with DELTA Revision acetabular cup.\nThis is an observational study designed to reflect real life clinical practice as closely as possible. Thus, clinicians are free to choose the method to implant and total hip arthroplasty in accordance with the current local Delta Revision acetabular cup Indication for Use and current clinical practice"
            },
            "armType": {
              "code": "C174266",
              "decode": "Experimental",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "allocationRatio": 1,
            "plannedSubjects": 49,
            "interventions": [
              {
                "id": "INT01",
                "instanceType": "StudyIntervention",
                "name": "DELTA Revision acetabular cup",
                "type": "Device",
                "provenance": {
                  "section_number": null,
                  "page_number": 1,
                  "text_snippet": "Study devices: DELTA Revision acetabular cup"
                },
                "role": {
                  "decode": "Investigational",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"
                },
                "manufacturer": "LimaCorporate S.p.A.",
                "isBlinded": false,
                "isPlacebo": false,
                "isComparator": false
              }
            ]
          }
        ],
        "studyEpochs": [
          {
            "id": "EPOCH01",
            "instanceType": "StudyEpoch",
            "name": "Screening",
            "description": "Pre-operative visit for eligibility screening and baseline assessments.",
            "provenance": {
              "section_number": "Protocol Synopsis",
              "page_number": 11,
              "text_snippet": "Time-points: Pre-operative Visit (Screening)."
            },
            "epochType": {
              "code": "C48262",
              "decode": "Screening",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 1
          },
          {
            "id": "EPOCH02",
            "instanceType": "StudyEpoch",
            "name": "Treatment",
            "description": "Intra-operative implantation of the DELTA Revision acetabular cup and post-operative discharge period.",
            "provenance": {
              "section_number": "Protocol Synopsis",
              "page_number": 11,
              "text_snippet": "Time-points: Intra-operative/Discharge visit (Enrollment visit)."
            },
            "epochType": {
              "code": "C101526",
              "decode": "Treatment",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 2
          },
          {
            "id": "EPOCH03",
            "instanceType": "StudyEpoch",
            "name": "Follow-up",
            "description": "Follow-up visits at 2 months, 6 months, 1 year, and 2 years after surgery to assess safety, clinical, and radiographic outcomes.",
            "provenance": {
              "section_number": "Protocol Synopsis",
              "page_number": 11,
              "text_snippet": "Time-points: Follow-up (FU) visits as per standard of care: 2 months, 6 months, 1 year, 2 years after surgery."
            },
            "epochType": {
              "code": "C99158",
              "decode": "Follow-up",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 3,
            "durationDays": 730
          }
        ],
        "studyCells": [
          {
            "id": "CELL01",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH01",
            "provenance": {
              "section_number": "Protocol Synopsis",
              "page_number": 11,
              "text_snippet": "Time-points: Pre-operative Visit (Screening)."
            },
            "interventionIds": []
          },
          {
            "id": "CELL02",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH02",
            "provenance": {
              "section_number": "Protocol Synopsis",
              "page_number": 11,
              "text_snippet": "Time-points: Intra-operative/Discharge visit (Enrollment visit)."
            },
            "interventionIds": [
              "INT01"
            ]
          },
          {
            "id": "CELL03",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH03",
            "provenance": {
              "section_number": "Protocol Synopsis",
              "page_number": 11,
              "text_snippet": "Time-points: Follow-up (FU) visits as per standard of care: 2 months, 6 months, 1 year, 2 years after surgery."
            },
            "interventionIds": [
              "INT01"
            ]
          }
        ],
        "designMetadata": {
          "id": "DESIGN01",
          "provenance": {
            "section_number": null,
            "page_number": 1,
            "text_snippet": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
          },
          "designType": {
            "code": "C49666",
            "decode": "Single Group",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "24.03e"
          },
          "isRandomized": false,
          "blindingType": "Open-label",
          "whoIsBlinded": [],
          "isPlaceboControlled": false,
          "isActiveControlled": false,
          "stratificationFactors": []
        }
      },
      "_agentDocumentation": {
        "agentId": "arms_design",
        "displayName": "Treatment Arms & Study Design",
        "instanceType": "StudyDesign",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts the complete treatment design including study arms, epochs, dosing regimens,\n    randomization configuration, and drug supply requirements. This is the primary source\n    for IRT/IWRS and drug supply management system configuration.",
        "scope": "- Study arms (experimental, comparator, placebo)\n    - Treatment epochs (screening, treatment, follow-up)\n    - Study cells (arm \u00d7 epoch matrix)\n    - Dosing regimens (dose, frequency, route, cycle length)\n    - Dose modification rules and triggers\n    - Randomization details (ratio, stratification, block size, algorithm)\n    - Drug supply kit configurations",
        "keySectionsAnalyzed": [
          "Section 4: Study Design",
          "Section 5: Study Population",
          "Section 6: Study Drug/Treatment",
          "Section 7: Dose Modifications",
          "Section 9: Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "Study Arms",
            "description": "Complete arm definitions with interventions, types, and allocation ratios",
            "dataPath": "studyArms[]",
            "downstreamUses": [
              "IRT arm configuration",
              "EDC treatment assignment forms",
              "Drug supply forecasting"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Generate IRT arm configuration from study arms",
                "sourceDataPath": "studyArms[]",
                "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
                "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
              },
              {
                "ruleId": "EDC_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate treatment assignment dropdown options",
                "sourceDataPath": "studyArms[].name",
                "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dosing Regimens",
            "description": "Dose, unit, frequency, route, cycle length, dose calculation basis",
            "dataPath": "studyArms[].interventions[].dosingRegimen",
            "downstreamUses": [
              "Drug accountability forms",
              "IRT dispensing rules",
              "Pharmacy manual generation"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DISP_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT dispensing rules from dosing regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
                "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
                "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
              },
              {
                "ruleId": "EDC_DOSE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dispensed dose against protocol regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
                "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stratification Factors",
            "description": "Randomization stratification with levels and definitions",
            "dataPath": "designMetadata.stratificationFactors[]",
            "downstreamUses": [
              "IRT stratification setup",
              "EDC stratification CRF",
              "Analysis programming"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT stratification from protocol factors",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
                "example": "ECOG (0-1, 2) \u00d7 Prior Therapy (Yes, No) = 4 strata"
              },
              {
                "ruleId": "EDC_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate stratification CRF fields",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dose Modification Rules",
            "description": "Reduction levels, triggers, hold/resume criteria",
            "dataPath": "studyArms[].interventions[].doseModifications",
            "downstreamUses": [
              "EDC dose modification forms",
              "Safety alert rules",
              "Medical monitor dashboards"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DOSEMOD_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dose modification follows protocol levels",
                "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
                "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Supply Configuration",
            "description": "Kit types, dispensing schedule, supply model",
            "dataPath": "designMetadata.drugSupply",
            "downstreamUses": [
              "IRT kit management",
              "Depot configuration",
              "Supply chain forecasting"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Randomization & Trial Supply Management",
                "description": "Generate kit configuration and depot requirements",
                "sourceDataPath": "designMetadata.drugSupply",
                "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Interactive Response Technology",
          "Interactive Web Response System",
          "Randomization & Trial Supply Management",
          "Electronic Data Capture",
          "Drug Supply Management"
        ],
        "automationUseCases": [
          "Auto-generate IRT randomization and drug dispensing configuration",
          "Create EDC treatment assignment and dose modification CRFs",
          "Configure drug supply forecasting models",
          "Generate pharmacy manuals and dispensing instructions",
          "Set up stratification factor data entry forms",
          "Configure enrollment caps by stratum/region"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "safety_decision_points",
            "pkpd_sampling",
            "biospecimen_handling"
          ],
          "crossReferences": [
            "concomitant_medications",
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "TA",
          "TE",
          "TI",
          "TV",
          "EX",
          "EC"
        ],
        "regulatoryRelevance": "ICH M11 Section 6 (Treatment), CTD Module 2.7.1",
        "schemaFile": "arms_design_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Generate IRT arm configuration from study arms",
            "sourceDataPath": "studyArms[]",
            "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
            "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
          },
          {
            "ruleId": "EDC_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate treatment assignment dropdown options",
            "sourceDataPath": "studyArms[].name",
            "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
            "example": null
          },
          {
            "ruleId": "IRT_DISP_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT dispensing rules from dosing regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
            "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
            "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
          },
          {
            "ruleId": "EDC_DOSE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dispensed dose against protocol regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
            "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
            "example": null
          },
          {
            "ruleId": "IRT_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT stratification from protocol factors",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
            "example": "ECOG (0-1, 2) \u00d7 Prior Therapy (Yes, No) = 4 strata"
          },
          {
            "ruleId": "EDC_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate stratification CRF fields",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
            "example": null
          },
          {
            "ruleId": "EDC_DOSEMOD_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dose modification follows protocol levels",
            "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
            "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
            "example": null
          },
          {
            "ruleId": "IRT_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Randomization & Trial Supply Management",
            "description": "Generate kit configuration and depot requirements",
            "sourceDataPath": "designMetadata.drugSupply",
            "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_ARMS_SAFETY_001",
            "name": "Dosing + Safety Rules \u2192 Complete Dose Management",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining dosing regimens with safety thresholds and lab triggers enables intelligent dose management",
            "combinedInsight": "Protocol doses + reduction levels + lab thresholds = Automated dose recommendation engine",
            "automationEnabled": "EDC can suggest appropriate dose level based on current labs and AEs",
            "exampleOutput": "{\"current_dose\": \"400mg\", \"recommended_action\": \"REDUCE to 300mg\", \"trigger\": \"ANC < 1000\", \"confidence\": 0.95}"
          },
          {
            "synergyId": "SYN_ARMS_SOA_001",
            "name": "Arms + SOA \u2192 Visit-Based Dispensing",
            "agentsInvolved": [
              "arms_design",
              "soa_schedule"
            ],
            "description": "Arm-specific dosing matched to visit schedule enables precise dispensing rules",
            "combinedInsight": "Which drug, what dose, at which visits = Complete dispensing matrix",
            "automationEnabled": "IRT auto-dispense based on visit and arm assignment",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_ARMS_001",
            "name": "Arm Allocation Total",
            "agentsInvolved": [
              "arms_design"
            ],
            "validationType": "consistency",
            "description": "Verify arm allocations sum to 100%",
            "checkLogic": "SUM(studyArms[].allocationPercentage) == 100",
            "severity": "error"
          },
          {
            "ruleId": "VAL_ARMS_002",
            "name": "Dose Levels Consistency",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels in arms match safety decision points",
            "checkLogic": "arms.doseModifications.levels SUBSET_OF safety.dose_modification_levels.levels",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Interactive Response Technology",
            "configType": "randomization_module",
            "description": "Complete IRT randomization configuration",
            "dataSources": [
              "studyArms[].id",
              "studyArms[].name",
              "studyArms[].allocationPercentage",
              "designMetadata.stratificationFactors[]",
              "designMetadata.randomizationRatio"
            ],
            "outputFormat": "IRT vendor import (Medidata RTSM, Oracle Siebel CTMS, Parexel ClinPhone)",
            "exampleConfig": {
              "study_arms": [
                {
                  "code": "A",
                  "name": "Drug A + Chemo",
                  "ratio": 2
                },
                {
                  "code": "B",
                  "name": "Placebo + Chemo",
                  "ratio": 1
                }
              ],
              "stratification_factors": [
                {
                  "name": "ECOG Status",
                  "levels": [
                    "0-1",
                    "2"
                  ]
                },
                {
                  "name": "Prior Therapy",
                  "levels": [
                    "Yes",
                    "No"
                  ]
                }
              ],
              "block_size": [
                3,
                6
              ],
              "randomization_method": "permuted_block"
            }
          }
        ]
      }
    },
    "endpointsEstimandsSAP": {
      "moduleId": "endpoints_estimands_sap",
      "instanceType": "EndpointsEstimandsSAP",
      "data": {
        "id": "H-34-endpoints-estimands-sap",
        "instanceType": "EndpointsEstimandsSAP",
        "name": "H-34 Endpoints, Estimands & SAP",
        "documentType": "protocol",
        "protocol_endpoints": {
          "objectives": [
            {
              "id": "objective-001",
              "instanceType": "Objective",
              "name": "Primary Clinical Outcome Objective",
              "text": "To assess the clinical outcomes of the DELTA Revision acetabular cup used in real life settings over a period of 2 years",
              "level": {
                "code": "C85826",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-001"
              ],
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 10,
                "text_snippet": "Primary objectives\n- To assess the clinical outcomes of the DELTA Revision acetabular cup used in real life settings over a period of 2 years"
              }
            },
            {
              "id": "objective-002",
              "instanceType": "Objective",
              "name": "Secondary Radiographical and Clinical Outcome Objective",
              "text": "To assess the radiographical and clinical outcomes of the DELTA Revision acetabular cup used in real life settings over a period of 2 years",
              "level": {
                "code": "C85827",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-002",
                "endpoint-003",
                "endpoint-005"
              ],
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 10,
                "text_snippet": "Secondary objectives\n- To assess the radiographical and clinical outcomes of the DELTA Revision acetabular cup used in real life settings over a period of 2 years"
              }
            },
            {
              "id": "objective-003",
              "instanceType": "Objective",
              "name": "Secondary Safety Objective",
              "text": "To evaluate the safety profile of the DELTA Revision acetabular cup used in real life settings over a period of 2 years",
              "level": {
                "code": "C85827",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-006"
              ],
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 10,
                "text_snippet": "Secondary objectives\n- To evaluate the safety profile of the DELTA Revision acetabular cup used in real life settings over a period of 2 years"
              }
            },
            {
              "id": "objective-004",
              "instanceType": "Objective",
              "name": "Secondary Baseline Data Objective",
              "text": "To describe baseline data (demographic data, primary diagnosis, aetiology, affected side, type of surgery and intra-operative data) of patients with Delta Revision acetabular cup",
              "level": {
                "code": "C85827",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [],
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 10,
                "text_snippet": "Secondary objectives\n- To describe baseline data (demographic data, primary diagnosis, aetiology, affected side, type of surgery and intra-operative data) of patients with Delta Revision acetabular cup"
              }
            }
          ],
          "endpoints": [
            {
              "id": "endpoint-001",
              "instanceType": "Endpoint",
              "name": "Harris Hip Score (HHS)",
              "label": "Primary Endpoint",
              "text": "The evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant.",
              "purpose": "To assess clinical outcome based on pain and function.",
              "level": {
                "code": "C98747",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25513",
                "decode": "Continuous Variable",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Harris Hip Score",
              "assessor": "Investigator/Physiotherapist",
              "primary_timepoint_weeks": 104,
              "assessment_timepoints_weeks": [
                0,
                8,
                26,
                52,
                104
              ],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 10,
                "text_snippet": "Primary endpoints:\nThe evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant."
              }
            },
            {
              "id": "endpoint-002",
              "instanceType": "Endpoint",
              "name": "Range of Motion (ROM)",
              "label": "Secondary Endpoint",
              "text": "Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant.",
              "purpose": "To assess hip joint function.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25513",
                "decode": "Continuous Variable",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Physical Examination",
              "assessor": "Investigator/Physiotherapist",
              "primary_timepoint_weeks": 104,
              "assessment_timepoints_weeks": [
                0,
                8,
                26,
                52,
                104
              ],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 10,
                "text_snippet": "Secondary endpoints:\n- Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;"
              }
            },
            {
              "id": "endpoint-003",
              "instanceType": "Endpoint",
              "name": "Oxford Hip Score (OHS)",
              "label": "Secondary Endpoint",
              "text": "Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant.",
              "purpose": "To assess patient-reported disability.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25513",
                "decode": "Continuous Variable",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Oxford Hip Score Questionnaire",
              "assessor": "Patient",
              "primary_timepoint_weeks": 104,
              "assessment_timepoints_weeks": [
                0,
                8,
                26,
                52,
                104
              ],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 10,
                "text_snippet": "Secondary endpoints:\n- Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;"
              }
            },
            {
              "id": "endpoint-004",
              "instanceType": "Endpoint",
              "name": "Implant Survivorship",
              "label": "Secondary Endpoint",
              "text": "Survivorship of the implant (Kaplan-Meier estimate) at 2 years of follow-up after surgery.",
              "purpose": "To assess the durability of the implant.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Kaplan-Meier analysis",
              "assessor": "Investigator",
              "primary_timepoint_weeks": 104,
              "assessment_timepoints_weeks": [
                104
              ],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 10,
                "text_snippet": "Secondary endpoints:\n- Survivorship of the implant (Kaplan-Meier estimate) at 2 years of follow-up after surgery;"
              }
            },
            {
              "id": "endpoint-005",
              "instanceType": "Endpoint",
              "name": "Radiographic Implant Evaluation",
              "label": "Secondary Endpoint",
              "text": "Radiographic implant evaluation and stability assessment of the DELTA Revision acetabular cup at discharge, 2 months, 6 months, 1 year, and 2 years after the implant.",
              "purpose": "To assess implant stability and bone integration.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25284",
                "decode": "Ordinal Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "X-ray evaluation for radiolucent lines, loosening, migration, and heterotopic ossification.",
              "assessor": "Investigator/Radiologist",
              "primary_timepoint_weeks": 104,
              "assessment_timepoints_weeks": [
                0,
                8,
                26,
                52,
                104
              ],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 10,
                "text_snippet": "Secondary endpoints:\n- Radiographic implant evaluation and stability assessment of the DELTA Revision acetabular cup at the following timepoints: at discharge, 2 months, 6 months, 1 year, and 2 years after the implant"
              }
            },
            {
              "id": "endpoint-006",
              "instanceType": "Endpoint",
              "name": "Incidence of Adverse Events",
              "label": "Secondary Safety Endpoint",
              "text": "Incidence, type and severity of all the Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Device Effects (ADEs) and Serious Adverse Device Effects (SADEs) at intraoperatively, discharge, 2 months, 6 months, 1 year and 2 years after the implant.",
              "purpose": "To evaluate the safety profile of the device.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25463",
                "decode": "Count Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Adverse Event Reporting",
              "assessor": "Investigator",
              "primary_timepoint_weeks": 104,
              "assessment_timepoints_weeks": [
                0,
                8,
                26,
                52,
                104
              ],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 10,
                "text_snippet": "Secondary endpoints:\n- Incidence, type and severity of all the Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Device Effects (ADEs) and Serious Adverse Device Effects (SADEs) at intraoperatively, discharge, 2 months, 6 months, 1 year and 2 years after the implant."
              }
            }
          ],
          "estimands": [
            {
              "id": "estimand-001",
              "instanceType": "Estimand",
              "name": "Primary Estimand for HHS Change from Baseline",
              "text": "Mean change from pre-operative baseline to 2 years post-implant in Harris Hip Score (HHS) in patients undergoing total hip arthroplasty with the DELTA Revision acetabular cup.",
              "endpoint_id": "endpoint-001",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "description": "Total hip arthroplasty with DELTA Revision acetabular cup"
                },
                "comparator_arm": null,
                "provenance": {
                  "section_number": "Protocol Synopsis",
                  "page_number": 11,
                  "text_snippet": "Treatment\nTotal hip arthroplasty with DELTA Revision acetabular cup."
                }
              },
              "population": {
                "analysis_population_id": "population-001",
                "description": "All enrolled patients who received the DELTA Revision acetabular cup.",
                "provenance": {
                  "section_number": "3.1",
                  "page_number": 16,
                  "text_snippet": "The study will enroll approximately 49 adult subjects in whom the decision to implant DELTA Revision acetabular cup must be taken prior to, and independently from the decision to include the patient into the study."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-001",
                "description": "Change from pre-operative baseline in Harris Hip Score (HHS) at 2 years post-implant.",
                "provenance": {
                  "section_number": "10.1",
                  "page_number": 42,
                  "text_snippet": "The primary endpoint is to assess the change in the Harris Hip Score (HHS) from pre-operative baseline up to 2 years after surgery."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-001",
                  "name": "Patient lost to follow-up or withdrawal",
                  "description": "Patient does not complete the 2-year follow-up visit for any reason, leading to missing HHS data.",
                  "strategy": {
                    "code": "C178902",
                    "decode": "While on Treatment Strategy",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "strategy_rationale": "The primary analysis is a paired T-test, which implicitly uses a complete case analysis, excluding patients with missing data for the 2-year timepoint.",
                  "provenance": {
                    "section_number": "10.3",
                    "page_number": 42,
                    "text_snippet": "Assuming a 40% loss to follow-up, total enrolment for this study is set at 49 subjects."
                  }
                }
              ],
              "summary_measure": {
                "code": "C25464",
                "decode": "Mean",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "provenance": {
                "section_number": "10.1",
                "page_number": 42,
                "text_snippet": "The primary endpoint is to assess the change in the Harris Hip Score (HHS) from pre-operative baseline up to 2 years after surgery. A 20 point increase in the HHS is considered a minimal clinically relevant change for the purposes of this study. The specific hypotheses to be tested are:\nHo: D \u2264 20\nHa: D > 20"
              }
            }
          ],
          "analysis_populations": [
            {
              "id": "population-001",
              "instanceType": "AnalysisPopulation",
              "name": "Full Analysis Set",
              "label": "FAS",
              "text": "All patients who undergo total hip arthroplasty with the DELTA Revision acetabular cup and are enrolled in the study.",
              "population_type": {
                "code": "C71105",
                "decode": "Full Analysis Set",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "inclusion_criteria": [
                "Male or female, Age \u2265 18 years old",
                "Provided written informed consent",
                "Decision made to perform a total hip arthroplasty with DELTA Revision acetabular cup prior to and independent of study enrollment",
                "Able to comply with the protocol"
              ],
              "exclusion_criteria": [
                "Any DELTA Revision acetabular cup contraindication for use",
                "Current pregnancy and/or lactation or planning a pregnancy"
              ],
              "is_primary_for_endpoints": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004",
                "endpoint-005",
                "endpoint-006"
              ],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "Protocol Synopsis",
                "page_number": 11,
                "text_snippet": "Inclusion criteria\nPatients must meet the following criteria for study entry:\n1. Male or female.\n2. Age \u2265 18 years old.\n3. All patients must give written informed consent...\n4. Adult patients in whom a decision has already been made to perform a total hip arthroplasty with DELTA Revision acetabular cup...\n5. Patient is able to comply with the protocol.\n\nExclusion criteria\n1. Adult patients with any DELTA Revision acetabular cup contraindication for use...\n2."
              }
            }
          ],
          "provenance": {
            "section_number": "2, 4",
            "page_number": 15,
            "text_snippet": "2 Objectives\n\n2.1 Primary objectives\nThe primary objective for this study is to assess the clinical outcomes of the DELTA Revision acetabular cup used in real life settings over a period of 2 years."
          }
        },
        "sap_analyses": {
          "sensitivity_analyses": [],
          "statistical_methods": [
            {
              "id": "method-001",
              "instanceType": "StatisticalMethod",
              "name": "Primary Endpoint Analysis Method",
              "description": "A standard one-sided paired T-test will be used to test the hypothesis that the mean change from baseline in HHS at 2 years is greater than 20 points.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "model_type": "Paired T-test",
              "stratification_factors": [],
              "covariates": [],
              "alpha": 0.05,
              "multiplicity": null,
              "software_package": "SAS version 9.3 or higher",
              "procedure": null,
              "provenance": {
                "section_number": "10.4",
                "page_number": 43,
                "text_snippet": "For the primary endpoint, a standard one-sided paired T-test will be used to test the hypotheses shown above in section 10.1. The test statistic is:\nt = D-20 / SD/\u221an\nWhere\nSD = \u221a\u03a3(Di \u2212 D)2 / n \u2212 1\nand t follows a T-distribution with n-1 degrees of freedom. A significant increase in HHS will be claimed if the p-value from this test is less than or equal to 0.05"
              }
            },
            {
              "id": "method-002",
              "instanceType": "StatisticalMethod",
              "name": "Secondary Endpoints Analysis Method",
              "description": "Secondary endpoints (ROM, OHS, radiographic evaluation) will be summarized using descriptive statistics. Continuous variables will be summarized using mean, standard deviation, N, and range. Categorical variables will be summarized using frequencies and proportions.",
              "for_endpoint_ids": [
                "endpoint-002",
                "endpoint-003",
                "endpoint-005"
              ],
              "model_type": "Descriptive Statistics",
              "stratification_factors": [],
              "covariates": [],
              "alpha": null,
              "multiplicity": null,
              "software_package": "SAS version 9.3 or higher",
              "procedure": null,
              "provenance": {
                "section_number": "10.4",
                "page_number": 43,
                "text_snippet": "Secondary Endpoints\nThe secondary endpoints of range of motion, Oxford Hip Score, and radiographic evaluation and stability assessment will be summarized using descriptive statistics at each follow-up time point indicated in section 4.2. Continuous variable will be summarized using the mean, standard deviation, N, and range. Categorical variable will be summarized frequencies and proportions."
              }
            },
            {
              "id": "method-003",
              "instanceType": "StatisticalMethod",
              "name": "Implant Survivorship Analysis Method",
              "description": "Survival of the implant at 2 years will be calculated using Kaplan-Meier methods. Observations will be censored at two years if the implant survives longer.",
              "for_endpoint_ids": [
                "endpoint-004"
              ],
              "model_type": "Kaplan-Meier",
              "stratification_factors": [],
              "covariates": [],
              "alpha": null,
              "multiplicity": null,
              "software_package": "SAS version 9.3 or higher",
              "procedure": null,
              "provenance": {
                "section_number": "10.4",
                "page_number": 43,
                "text_snippet": "Survival of the implant at 2 years will be calculate using Kaplan-Meier methods. If the implant survives longer than two years, the observation will be censored at two years."
              }
            },
            {
              "id": "method-004",
              "instanceType": "StatisticalMethod",
              "name": "Safety Analysis Method",
              "description": "All adverse events, serious adverse events, adverse device effects, and serious adverse device effects will be summarized using frequencies and percentages and presented in tabular form.",
              "for_endpoint_ids": [
                "endpoint-006"
              ],
              "model_type": "Descriptive Statistics",
              "stratification_factors": [],
              "covariates": [],
              "alpha": null,
              "multiplicity": null,
              "software_package": "SAS version 9.3 or higher",
              "procedure": null,
              "provenance": {
                "section_number": "10.4",
                "page_number": 43,
                "text_snippet": "All adverse events, serious adverse events, adverse device effects, and serious adverse device effects will summarized using frequencies and percentages and presented in tabular form."
              }
            }
          ],
          "subgroup_analyses": [],
          "multiplicity_adjustment": {},
          "missing_data_handling": {
            "primary_method": "Complete Case Analysis",
            "method_description": "For the primary endpoint, the paired T-test will only include subjects with both a pre-operative baseline and a 2-year post-implant HHS value. No imputation methods are specified.",
            "assumptions": [
              "Missing completely at random (MCAR)"
            ],
            "provenance": {
              "section_number": "10.3",
              "page_number": 42,
              "text_snippet": "A standard one-sided paired T-test with a sample size of 29 pairs will afford 90% power to detect an increase of 20 points on the HHS test. Assuming a 40% loss to follow-up, total enrolment for this study is set at 49 subjects."
            }
          },
          "provenance": {
            "section_number": "10",
            "page_number": 41,
            "text_snippet": "10 Statistical considerations\nAll analyses will be performed using SAS version 9.3 or higher."
          }
        },
        "extraction_statistics": {
          "objectives_count": 4,
          "endpoints_count": 6,
          "estimands_count": 1,
          "populations_count": 1,
          "sensitivity_analyses_count": 0,
          "statistical_methods_count": 4,
          "subgroup_analyses_count": 0,
          "has_multiplicity_adjustment": false,
          "has_missing_data_strategy": true
        },
        "provenance": {
          "section_number": "N/A",
          "page_number": 1,
          "text_snippet": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
        }
      },
      "_agentDocumentation": {
        "agentId": "endpoints_estimands_sap",
        "displayName": "Endpoints, Estimands & SAP",
        "instanceType": "EndpointsEstimandsSAP",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts study objectives, endpoints, estimands (per ICH E9 R1), analysis populations,\n    and statistical analysis specifications. This is the definitive source for programming\n    analysis datasets and statistical outputs.",
        "scope": "- Primary, secondary, and exploratory objectives\n    - Endpoint definitions with outcome types and assessment methods\n    - ICH E9(R1) compliant estimands with intercurrent event strategies\n    - Analysis populations (ITT, mITT, PP, Safety)\n    - Sensitivity and subgroup analyses\n    - Multiplicity adjustment strategy\n    - Missing data handling",
        "keySectionsAnalyzed": [
          "Section 2: Study Objectives and Endpoints",
          "Section 3: Study Objectives",
          "Section 8: Statistical Considerations",
          "Section 9: Statistical Analysis Plan",
          "Appendix: Statistical Analysis Plan (if separate)"
        ],
        "keyInsights": [
          {
            "name": "Primary Endpoints",
            "description": "Primary efficacy endpoints with outcome type, timepoints, and assessment method",
            "dataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "downstreamUses": [
              "Primary analysis programming",
              "Sample size validation",
              "DSMB reporting"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_EP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADaM ADEFF specification from primary endpoint",
                "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
                "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Estimands",
            "description": "ICH E9(R1) estimands with treatment comparison, population, variable, ICE strategies",
            "dataPath": "protocol_endpoints.estimands[]",
            "downstreamUses": [
              "Analysis programming specifications",
              "SAP finalization",
              "Regulatory submission narrative"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAP_EST_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate SAP estimand section from extracted estimands",
                "sourceDataPath": "protocol_endpoints.estimands[]",
                "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Analysis Populations",
            "description": "ITT, mITT, PP, Safety population definitions with inclusion/exclusion criteria",
            "dataPath": "protocol_endpoints.analysis_populations[]",
            "downstreamUses": [
              "ADSL derivation",
              "Population flag programming",
              "CSR population tables"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_POP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADSL population flags from definitions",
                "sourceDataPath": "protocol_endpoints.analysis_populations[]",
                "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
                "example": "ITTFL = 'Y' if randomized and received \u22651 dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Statistical Methods",
            "description": "Model specifications, covariates, multiplicity adjustment",
            "dataPath": "sap_analyses.statistical_methods[]",
            "downstreamUses": [
              "Analysis program templates",
              "Validation programming",
              "TLF shells"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Subgroup Analyses",
            "description": "Pre-specified subgroup definitions and analysis methods",
            "dataPath": "sap_analyses.subgroup_analyses[]",
            "downstreamUses": [
              "Forest plot programming",
              "Subgroup TLF generation",
              "Regulatory response preparation"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate CDISC ADaM dataset specifications from estimands",
          "Auto-create TLF shells from endpoint definitions",
          "Pre-configure statistical analysis programs",
          "Generate SAP templates with population definitions",
          "Create endpoint assessment CRFs in EDC",
          "Configure DSMB reporting data cuts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "pro_specifications",
            "imaging_central_reading"
          ],
          "crossReferences": [
            "adverse_events",
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "ADSL",
          "ADEFF",
          "ADTTE"
        ],
        "regulatoryRelevance": "ICH E9(R1), ICH M11 Sections 2-3, CTD Module 2.7.3/2.7.6",
        "schemaFile": "endpoints_estimands_sap_schema.json",
        "automationRules": [
          {
            "ruleId": "ADAM_EP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADaM ADEFF specification from primary endpoint",
            "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
            "example": null
          },
          {
            "ruleId": "SAP_EST_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate SAP estimand section from extracted estimands",
            "sourceDataPath": "protocol_endpoints.estimands[]",
            "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
            "example": null
          },
          {
            "ruleId": "ADAM_POP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADSL population flags from definitions",
            "sourceDataPath": "protocol_endpoints.analysis_populations[]",
            "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
            "example": "ITTFL = 'Y' if randomized and received \u22651 dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_EP_SOA_001",
            "name": "Endpoints + SOA \u2192 Assessment Schedule Validation",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "soa_schedule"
            ],
            "description": "Endpoint timepoints matched to SOA visits ensures all assessments are scheduled",
            "combinedInsight": "Primary endpoint at Week 12 + SOA Week 12 visit with efficacy assessment = Validated schedule",
            "automationEnabled": "Auto-verify SOA includes all required endpoint assessments",
            "exampleOutput": null
          },
          {
            "synergyId": "SYN_EP_AE_001",
            "name": "Endpoints + AEs + Withdrawal \u2192 Complete Estimand Definition",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "adverse_events",
              "withdrawal_procedures"
            ],
            "description": "Combining endpoint definitions with AE handling and withdrawal reasons enables complete ICE specification",
            "combinedInsight": "What happens to endpoint when subject discontinues due to AE = Complete intercurrent event strategy",
            "automationEnabled": "Generate regulatory-ready estimand framework documentation",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_EP_001",
            "name": "Endpoint-Objective Linkage",
            "agentsInvolved": [
              "endpoints_estimands_sap"
            ],
            "validationType": "completeness",
            "description": "Every endpoint must link to at least one objective",
            "checkLogic": "FOR EACH endpoint: EXISTS objective WHERE endpoint.id IN objective.endpoint_ids",
            "severity": "error"
          }
        ],
        "systemConfigurations": []
      }
    },
    "adverseEvents": {
      "moduleId": "adverse_events",
      "instanceType": "AdverseEvents",
      "data": {
        "id": "H-34-adverse-events",
        "instanceType": "AdverseEvents",
        "name": "H-34 Adverse Events",
        "ae_definitions": {
          "ae_definition": "Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs, including abnormal laboratory findings, in subjects, users or other persons, whether or not related to the investigational medical device. This definition includes events related to the investigational medical devices or events related to the procedures involved.",
          "teae_definition": "AEs occurring after and during the implant.",
          "collection_start": "After informed consent has been obtained",
          "collection_end": "Until the event has subsided or values have returned to baseline, or in the case of permanent impairment, till the condition stabilizes.",
          "collection_end_days": null,
          "pre_existing_condition_handling": "A preexisting medical condition should be recorded as an AE only if the frequency, severity, or character of the condition worsens during the study.",
          "provenance": {
            "section_number": "9.1",
            "page_number": 35,
            "text_snippet": "An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs, including abnormal laboratory findings, in subjects, users or other persons, whether or not related to the investigational medical device."
          }
        },
        "sae_criteria": {
          "sae_definition": "A Seriuos Adverse Event (SAE) is any AE that meets any of the following criteria: led to death; led to serious deterioration in the health of the subject, that either resulted in a life-threatening illness or injury; led to serious deterioration in the health of the subject, that resulted in a permanent impairment of a body structure or a body function; led to serious deterioration in the health of the subject, that resulted in hospitalization or prolongation of patient hospitalization; led to serious deterioration in the health of the subject, that resulted in a medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function; led to serious deterioration in the health of the subject, that resulted in a chronic disease; led to foetal distress, foetal death or a congenital abnormality or birth defect; any revision of the implant independently if it requires the DELTA revision acetabular cup removal.",
          "criteria": [
            {
              "id": "sae-001",
              "criterion_type": {
                "code": "C48275",
                "decode": "Death",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "led to death",
              "exclusions": [],
              "provenance": {
                "section_number": "9.4",
                "page_number": 36,
                "text_snippet": "led to death;"
              }
            },
            {
              "id": "sae-002",
              "criterion_type": {
                "code": "C82569",
                "decode": "Life Threatening",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "led to serious deterioration in the health of the subject, that either resulted in a life-threatening illness or injury",
              "exclusions": [],
              "provenance": {
                "section_number": "9.4",
                "page_number": 36,
                "text_snippet": "led to serious deterioration in the health of the subject, that either resulted in a life-threatening illness or injury;"
              }
            },
            {
              "id": "sae-003",
              "criterion_type": {
                "code": "C83052",
                "decode": "Hospitalization Required",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "led to serious deterioration in the health of the subject, that resulted in hospitalization",
              "exclusions": [],
              "provenance": {
                "section_number": "9.4",
                "page_number": 36,
                "text_snippet": "led to serious deterioration in the health of the subject, that resulted in hospitalization or prolongation of patient hospitalization;"
              }
            },
            {
              "id": "sae-004",
              "criterion_type": {
                "code": "C83053",
                "decode": "Prolonged Hospitalization",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "led to serious deterioration in the health of the subject, that resulted in prolongation of patient hospitalization",
              "exclusions": [],
              "provenance": {
                "section_number": "9.4",
                "page_number": 36,
                "text_snippet": "led to serious deterioration in the health of the subject, that resulted in hospitalization or prolongation of patient hospitalization;"
              }
            },
            {
              "id": "sae-005",
              "criterion_type": {
                "code": "C82577",
                "decode": "Disability",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "led to serious deterioration in the health of the subject, that resulted in a permanent impairment of a body structure or a body function",
              "exclusions": [],
              "provenance": {
                "section_number": "9.4",
                "page_number": 36,
                "text_snippet": "led to serious deterioration in the health of the subject, that resulted in a permanent impairment of a body structure or a body function;"
              }
            },
            {
              "id": "sae-006",
              "criterion_type": {
                "code": "C82579",
                "decode": "Congenital Anomaly",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "led to foetal distress, foetal death or a congenital abnormality or birth defect",
              "exclusions": [],
              "provenance": {
                "section_number": "9.4",
                "page_number": 37,
                "text_snippet": "led to foetal distress, foetal death or a congenital abnormality or birth defect;"
              }
            },
            {
              "id": "sae-007",
              "criterion_type": {
                "code": "C84265",
                "decode": "Medically Important",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "led to serious deterioration in the health of the subject, that resulted in a medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function; any revision of the implant independently if it requires the DELTA revision acetabular cup removal",
              "exclusions": [],
              "provenance": {
                "section_number": "9.4",
                "page_number": 37,
                "text_snippet": "led to serious deterioration in the health of the subject, that resulted in a medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function;\nany revision of the implant independently if it requires the DELTA revision acetabular cup removal"
              }
            }
          ],
          "provenance": {
            "section_number": "9.4",
            "page_number": 36,
            "text_snippet": "A Seriuos Adverse Event (SAE) is any AE that meets any of the following criteria:"
          }
        },
        "grading_system": {
          "system_name": "Study-specific",
          "system_version": null,
          "grade_definitions": [
            {
              "grade": 1,
              "label": "Mild",
              "definition": "The adverse event is transient and easily tolerated by the subject; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated."
            },
            {
              "grade": 2,
              "label": "Moderate",
              "definition": "The adverse event causes the subject discomfort and interferes somewhat with his/her daily activities; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living."
            },
            {
              "grade": 3,
              "label": "Severe",
              "definition": "The adverse event causes significant discomfort to the subject and interferes significantly with his/her daily activities; medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living."
            }
          ],
          "provenance": {
            "section_number": "9.7.2",
            "page_number": 38,
            "text_snippet": "The Investigators should be assessed the severity for AEs according to the following table:\nGrade Severity\nMild The adverse event is transient and easily tolerated by the subject; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated.\nModerate The adverse event causes the subject discomfort and interferes somewhat with his/her daily activities; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental"
          }
        },
        "causality_assessment": {
          "method_description": "Investigators should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether or not an AE is considered to be related to the medical device. Guidance includes: Temporal relationship, Known association with the medical device or similar procedures, Known association with the disease under study, Presence of risk factors, Presence of other related factors.",
          "categories": [
            {
              "id": "causality-001",
              "category_type": {
                "code": "C53258",
                "decode": "Related",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Causal relationship between AE and the medical device is determined by the investigator based on his or her clinical judgment."
            },
            {
              "id": "causality-002",
              "category_type": {
                "code": "C53257",
                "decode": "Not Related",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Causal relationship between AE and the medical device is determined by the investigator based on his or her clinical judgment."
            }
          ],
          "provenance": {
            "section_number": "9.7.3",
            "page_number": 39,
            "text_snippet": "The causal relationship between AE and the medical device will be determined by the investigator based on his or her clinical judgment and classified into one of the following:\n- Related\n- Not related"
          }
        },
        "coding_dictionary": {
          "provenance": {
            "section_number": "9.7.3",
            "page_number": 39,
            "text_snippet": "Investigators should use correct medical terminology/concepts when recording AEs on the AE eCRF. Avoid colloquialisms and abbreviations."
          }
        },
        "reporting_procedures": {
          "routine_ae_reporting": {
            "timeline_hours": null,
            "timeline_description": "Recorded at each patient contact.",
            "method": "eCRF"
          },
          "sae_reporting": {
            "initial_report_hours": 24,
            "followup_report_days": null,
            "recipients": [
              "sponsor",
              "irb_ec",
              "health_authority"
            ],
            "method": "Electronic data capture (EDC) system. If unavailable, a paper SAE form should be completed and sent by e-mail."
          },
          "susar_reporting": {},
          "pregnancy_reporting": {},
          "expedited_reporting_criteria": [
            "SAEs",
            "SADEs",
            "USADEs",
            "DDs that could led to a SAE"
          ],
          "unblinding_procedures": "Not applicable, this is an open label study.",
          "provenance": {
            "section_number": "9.8",
            "page_number": 40,
            "text_snippet": "The investigator must report the following events to the Sponsor within 24 hours after learning of the event, regardless of relationship to study medical device:\nSAES\nSADES\nUSADES\nDDs that could led to a SAE"
          }
        },
        "aesi_list": [],
        "dlt_criteria": {
          "has_dlt_criteria": false
        },
        "safety_committees": [],
        "extraction_statistics": {
          "aesi_count": 0,
          "dlt_criteria_count": 0,
          "sae_criteria_count": 7,
          "has_grading_system": true,
          "has_causality_assessment": true,
          "has_dlt_criteria": false
        },
        "provenance": {
          "section_number": "9",
          "page_number": 35,
          "text_snippet": "9 Safety Parameters and definition"
        }
      },
      "_agentDocumentation": {
        "agentId": "adverse_events",
        "displayName": "Adverse Events",
        "instanceType": "AdverseEvents",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts comprehensive adverse event management specifications including AE/SAE definitions,\n    grading systems, causality assessment, reporting timelines, and AESI lists. Critical for\n    safety database configuration and pharmacovigilance workflows.",
        "scope": "- AE and TEAE definitions\n    - SAE criteria per ICH E2A\n    - CTCAE grading system version and definitions\n    - Causality assessment methodology\n    - MedDRA coding specifications\n    - Reporting timelines (routine AE, SAE, SUSAR, pregnancy)\n    - AESI list with special monitoring requirements\n    - DLT criteria (oncology protocols)\n    - Safety committees (DSMB, SMC)",
        "keySectionsAnalyzed": [
          "Section 7: Safety Reporting",
          "Section 8: Adverse Events",
          "Section 9: Safety Assessments",
          "Appendix: CTCAE Grading Tables",
          "Appendix: AESI Definitions"
        ],
        "keyInsights": [
          {
            "name": "AE Collection Period",
            "description": "When AE collection starts and ends relative to study drug",
            "dataPath": "ae_definitions.collection_start, ae_definitions.collection_end",
            "downstreamUses": [
              "EDC AE form display logic",
              "Safety database query rules",
              "Site training"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_AE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate AE dates within collection period",
                "sourceDataPath": "ae_definitions",
                "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
                "example": "AE start date must be >= first dose date for TEAE flag"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "SAE Criteria",
            "description": "ICH E2A serious criteria with protocol-specific exceptions",
            "dataPath": "sae_criteria.criteria[]",
            "downstreamUses": [
              "Safety database serious flag logic",
              "EDC serious field validation",
              "Expedited reporting triggers"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_SAE_001",
                "ruleType": "alert",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure SAE detection and expedited reporting workflow",
                "sourceDataPath": "sae_criteria.criteria[]",
                "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
                "example": "Death \u2192 24hr initial report, 7-day follow-up"
              },
              {
                "ruleId": "EDC_SAE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Enforce SAE documentation requirements",
                "sourceDataPath": "sae_criteria",
                "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Reporting Timelines",
            "description": "Hours/days for initial SAE report, follow-up, SUSAR",
            "dataPath": "reporting_procedures",
            "downstreamUses": [
              "Safety database workflow rules",
              "Site alert configuration",
              "PV team SLAs"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_TIMELINE_001",
                "ruleType": "workflow",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure safety reporting timeline workflows",
                "sourceDataPath": "reporting_procedures",
                "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "AESI List",
            "description": "Adverse events of special interest with monitoring requirements",
            "dataPath": "aesi_list[]",
            "downstreamUses": [
              "Safety database AESI flags",
              "EDC AESI prompts",
              "Medical monitor alerts"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_AESI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Prompt for AESI-specific data collection",
                "sourceDataPath": "aesi_list[]",
                "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
                "example": "Hepatotoxicity \u2192 Prompt for Hy's Law labs, trigger medical monitor alert"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "DLT Criteria",
            "description": "Dose-limiting toxicity definitions, observation period, MTD rules",
            "dataPath": "dlt_criteria",
            "downstreamUses": [
              "Dose escalation committee dashboards",
              "IRT dose assignment rules",
              "Safety stopping rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_DLT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure DLT-based dose escalation rules",
                "sourceDataPath": "dlt_criteria",
                "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
                "example": "3+3 design with 28-day DLT window"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Safety Database (Pharmacovigilance)",
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure safety database with protocol-specific SAE criteria",
          "Set up expedited reporting workflows and timelines",
          "Create EDC AE/SAE CRFs with proper grading dropdowns",
          "Configure AESI flag logic in safety database",
          "Generate site training materials on AE reporting",
          "Set up DLT tracking dashboards for dose escalation"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management",
            "withdrawal_procedures"
          ],
          "crossReferences": [
            "safety_decision_points",
            "concomitant_medications"
          ]
        },
        "cdiscDomains": [
          "AE",
          "MH",
          "FA"
        ],
        "regulatoryRelevance": "ICH E2A, ICH E6(R2), ICH M11 Section 8",
        "schemaFile": "adverse_events_extraction_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_AE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate AE dates within collection period",
            "sourceDataPath": "ae_definitions",
            "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
            "example": "AE start date must be >= first dose date for TEAE flag"
          },
          {
            "ruleId": "SAFETY_SAE_001",
            "ruleType": "alert",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure SAE detection and expedited reporting workflow",
            "sourceDataPath": "sae_criteria.criteria[]",
            "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
            "example": "Death \u2192 24hr initial report, 7-day follow-up"
          },
          {
            "ruleId": "EDC_SAE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Enforce SAE documentation requirements",
            "sourceDataPath": "sae_criteria",
            "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
            "example": null
          },
          {
            "ruleId": "SAFETY_TIMELINE_001",
            "ruleType": "workflow",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure safety reporting timeline workflows",
            "sourceDataPath": "reporting_procedures",
            "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
            "example": null
          },
          {
            "ruleId": "EDC_AESI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Prompt for AESI-specific data collection",
            "sourceDataPath": "aesi_list[]",
            "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
            "example": "Hepatotoxicity \u2192 Prompt for Hy's Law labs, trigger medical monitor alert"
          },
          {
            "ruleId": "IRT_DLT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure DLT-based dose escalation rules",
            "sourceDataPath": "dlt_criteria",
            "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
            "example": "3+3 design with 28-day DLT window"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_AE_SAFETY_001",
            "name": "AE Grading + Safety Thresholds \u2192 Automated Dose Decisions",
            "agentsInvolved": [
              "adverse_events",
              "safety_decision_points"
            ],
            "description": "CTCAE grades combined with safety thresholds enable automated dose recommendations",
            "combinedInsight": "Grade 3 neutropenia + safety rules = Hold dose, check ANC in 1 week",
            "automationEnabled": "EDC displays recommended action when AE grade is entered",
            "exampleOutput": "{\"ae\": \"Neutropenia Grade 3\", \"action\": \"Hold dose\", \"recheck\": \"7 days\", \"resume_criteria\": \"ANC >= 1500\"}"
          },
          {
            "synergyId": "SYN_AE_CM_001",
            "name": "AE + Concomitant Meds \u2192 Drug Interaction Alerts",
            "agentsInvolved": [
              "adverse_events",
              "concomitant_medications"
            ],
            "description": "AE patterns combined with prohibited medications enables interaction detection",
            "combinedInsight": "QT prolongation AE + QT-prolonging concomitant med = Potential drug interaction",
            "automationEnabled": "Real-time drug interaction alert when entering concomitant medications",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_AE_001",
            "name": "CTCAE Version Consistency",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "consistency",
            "description": "Verify CTCAE version is specified and consistent throughout",
            "checkLogic": "ctcae_version IS NOT NULL AND ctcae_version == data_standards.ctcae_version",
            "severity": "error"
          },
          {
            "ruleId": "VAL_AE_002",
            "name": "AESI-SAE Overlap",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "completeness",
            "description": "Check if AESIs have SAE reporting guidance",
            "checkLogic": "FOR EACH aesi: EXISTS sae_guidance OR aesi.always_serious == true",
            "severity": "warning"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Safety Database (Pharmacovigilance)",
            "configType": "protocol_profile",
            "description": "Safety database protocol-specific configuration",
            "dataSources": [
              "sae_criteria.criteria[]",
              "reporting_procedures",
              "aesi_list[]",
              "dlt_criteria"
            ],
            "outputFormat": "Safety database import (Argus, ARISg, Oracle Empirica)",
            "exampleConfig": {
              "sae_criteria": [
                {
                  "criterion": "Death",
                  "code": "C48275",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Life-threatening",
                  "code": "C84266",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Hospitalization",
                  "code": "C84268",
                  "timeline_hours": 72
                }
              ],
              "aesi_list": [
                {
                  "term": "Hepatotoxicity",
                  "meddra_codes": [
                    "10019670"
                  ],
                  "enhanced_collection": true
                }
              ],
              "meddra_version": "26.0",
              "ctcae_version": "5.0"
            }
          }
        ]
      }
    },
    "safetyDecisionPoints": {
      "moduleId": "safety_decision_points",
      "instanceType": "SafetyDecisionPoints",
      "data": {
        "id": "H-34-safety-decision-points",
        "instanceType": "SafetyDecisionPoints",
        "name": "H-34 Safety Decision Points",
        "discovered_categories": [
          {
            "category_id": "cat-001",
            "category_name": "General Safety",
            "category_description": "General adverse events and subject status changes",
            "parameters_count": 2,
            "provenance": {
              "section_number": "9.1",
              "page_number": 35,
              "text_snippet": "An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs, including abnormal laboratory findings, in subjects, users or other persons, whether or not related to the investigational medical device."
            }
          },
          {
            "category_id": "cat-002",
            "category_name": "Device and Procedure Safety",
            "category_description": "Events related to the investigational device, its performance, and the surgical procedure",
            "parameters_count": 1,
            "provenance": {
              "section_number": "9.2",
              "page_number": 36,
              "text_snippet": "An adverse device effect (ADE) is an adverse event related to the use of the investigational medical devices. This definition includes adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical devices."
            }
          }
        ],
        "decision_points": [],
        "stopping_rules_summary": {
          "total_permanent_stopping_conditions": 10,
          "stopping_conditions": [
            {
              "condition_id": "stop-001",
              "condition_type": "individual_subject",
              "description": "Patient's pregnancy",
              "trigger_threshold": "Confirmation of pregnancy",
              "action": "Withdrawal from study",
              "provenance": {
                "section_number": "5.5",
                "page_number": 19,
                "text_snippet": "Patient's pregnancy"
              }
            },
            {
              "condition_id": "stop-002",
              "condition_type": "individual_subject",
              "description": "Revision of the implant that requires the DELTA revision acetabular cup removal",
              "trigger_threshold": "Surgical revision requiring device removal",
              "action": "Withdrawal from study",
              "provenance": {
                "section_number": "5.5",
                "page_number": 19,
                "text_snippet": "Revision of the implant that requires the DELTA revision acetabular cup removal"
              }
            },
            {
              "condition_id": "stop-003",
              "condition_type": "individual_subject",
              "description": "Patient withdrawal of consent at any time",
              "trigger_threshold": "Patient decision",
              "action": "Withdrawal from study",
              "provenance": {
                "section_number": "5.5",
                "page_number": 19,
                "text_snippet": "Patient withdrawal of consent at any time"
              }
            },
            {
              "condition_id": "stop-004",
              "condition_type": "individual_subject",
              "description": "Any medical condition that the investigator or Sponsor determines may jeopardize the patient's safety if he or she continues in the study",
              "trigger_threshold": "Investigator or Sponsor determination of safety risk",
              "action": "Withdrawal from study",
              "provenance": {
                "section_number": "5.5",
                "page_number": 19,
                "text_snippet": "Any medical condition that the investigator or Sponsor determines may jeopardize the patient's safety if he or she continues in the study"
              }
            },
            {
              "condition_id": "stop-005",
              "condition_type": "individual_subject",
              "description": "Investigator or Sponsor determines it is in the best interest of the patient",
              "trigger_threshold": "Investigator or Sponsor determination",
              "action": "Withdrawal from study",
              "provenance": {
                "section_number": "5.5",
                "page_number": 19,
                "text_snippet": "Investigator or Sponsor determines it is in the best interest of the patient"
              }
            },
            {
              "condition_id": "stop-006",
              "condition_type": "individual_subject",
              "description": "Repeated patient noncompliance with protocol requirements",
              "trigger_threshold": "Repeated noncompliance",
              "action": "Withdrawal from study",
              "provenance": {
                "section_number": "5.5",
                "page_number": 19,
                "text_snippet": "Repeated patient noncompliance with protocol requirements"
              }
            },
            {
              "condition_id": "stop-007",
              "condition_type": "individual_subject",
              "description": "Major protocol violation that may jeopardize the patient's safety",
              "trigger_threshold": "Sponsor and Investigator determination of major protocol violation",
              "action": "Withdrawal from study",
              "provenance": {
                "section_number": "5.5",
                "page_number": 19,
                "text_snippet": "Major protocol violation that may jeopardize the patient's safety according to the Sponsor and Investigator"
              }
            },
            {
              "condition_id": "stop-008",
              "condition_type": "study_level",
              "description": "The incidence or severity of AEs/ADEs in this or other studies indicates a potential health hazard to patients",
              "trigger_threshold": "Sponsor determination of potential health hazard",
              "action": "Study termination",
              "provenance": {
                "section_number": "5.7",
                "page_number": 20,
                "text_snippet": "The incidence or severity of AEs/ADEs in this or other studies indicates a potential health hazard to patients;"
              }
            },
            {
              "condition_id": "stop-009",
              "condition_type": "study_level",
              "description": "Patient enrolment is unsatisfactory",
              "trigger_threshold": "Sponsor determination",
              "action": "Study termination",
              "provenance": {
                "section_number": "5.7",
                "page_number": 20,
                "text_snippet": "Patient enrolment is unsatisfactory;"
              }
            },
            {
              "condition_id": "stop-010",
              "condition_type": "study_level",
              "description": "Inaccurate or incomplete data recording",
              "trigger_threshold": "Sponsor determination",
              "action": "Study termination",
              "provenance": {
                "section_number": "5.7",
                "page_number": 20,
                "text_snippet": "Inaccurate or incomplete data recording."
              }
            }
          ],
          "provenance": {
            "section_number": "5.5",
            "page_number": 19,
            "text_snippet": "5.5 Patient Withdrawal Criteria\n\nThe investigator has the right to withdraw a patient from the study at any time. In addition, patients have the right to voluntarily withdraw from the study at any time for any reason."
          }
        },
        "dose_modification_levels": {
          "has_defined_levels": false,
          "levels": [],
          "minimum_dose": null,
          "re_escalation_allowed": false,
          "re_escalation_criteria": null,
          "provenance": {
            "section_number": "3.1",
            "page_number": 16,
            "text_snippet": "This is an observational open label, prospective, longitudinal cohort study designed to reflect real life clinical practice as closely as possible. Thus, clinicians are free to choose the method to implant and total hip arthroplasty in accordance with the current local Delta Revision acetabular cup Indication for Use and current clinical practice."
          }
        },
        "organ_specific_adjustments": [],
        "extraction_statistics": {
          "decision_points_count": 0,
          "stopping_rules_count": 10,
          "organ_adjustments_count": 0,
          "dose_levels_count": 0,
          "categories_count": 2
        },
        "provenance": {
          "section_number": "9",
          "page_number": 35,
          "text_snippet": "9 Safety Parameters and definition\n\nSafety assessments will consist of monitoring and recording adverse events (AEs), including serious adverse events (SAEs), device deficiencies (DDs) and, adverse device effects (ADEs) including serious adverse device effect (SADEs); they are deemed critical to the safety evaluation of the study in the same way as the Unanticipated Serious Adverse Device Effects (USADEs)."
        }
      },
      "_agentDocumentation": {
        "agentId": "safety_decision_points",
        "displayName": "Safety Decision Points",
        "instanceType": "SafetyDecisionPoints",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts actionable safety decision rules including dose modification triggers,\n    study stopping rules, and organ-specific adjustments. These translate directly\n    into EDC edit checks and medical monitor alert configurations.",
        "scope": "- Safety parameter categories discovered in protocol\n    - Decision points with conditions and actions\n    - Dose modification levels (reduction percentages, absolute doses)\n    - Re-escalation criteria\n    - Study stopping rules (individual and aggregate)\n    - Organ-specific dose adjustments (hepatic, renal, cardiac)\n    - Recovery/rechallenge criteria",
        "keySectionsAnalyzed": [
          "Section 6: Dose Modifications",
          "Section 7: Dose Reductions",
          "Section 8: Study Drug Discontinuation",
          "Section 9: Stopping Rules",
          "Appendix: Dose Modification Tables"
        ],
        "keyInsights": [
          {
            "name": "Dose Reduction Levels",
            "description": "Defined dose levels (-1, -2, etc.) with absolute or percentage reductions",
            "dataPath": "dose_modification_levels.levels[]",
            "downstreamUses": [
              "IRT dose assignment options",
              "EDC dose level dropdown",
              "Drug accountability forms"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DOSELEVEL_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure allowed dose levels in IRT",
                "sourceDataPath": "dose_modification_levels.levels[]",
                "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
                "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Decision Rules",
            "description": "If-then rules mapping safety findings to required actions",
            "dataPath": "decision_points[].decision_rules[]",
            "downstreamUses": [
              "EDC edit checks",
              "Medical monitor alerts",
              "Safety dashboard rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_DECISION_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate edit checks from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
                "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
              },
              {
                "ruleId": "ALERT_DECISION_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Configure real-time safety alerts from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stopping Rules",
            "description": "Individual and study-level stopping conditions",
            "dataPath": "stopping_rules_summary.stopping_conditions[]",
            "downstreamUses": [
              "DSMB monitoring triggers",
              "Sponsor alert rules",
              "IRT enrollment stops"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STOP_001",
                "ruleType": "workflow",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure enrollment stops based on stopping rules",
                "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
                "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Organ-Specific Adjustments",
            "description": "Hepatic, renal, cardiac, hematologic dose adjustments",
            "dataPath": "organ_specific_adjustments[]",
            "downstreamUses": [
              "Lab-triggered alerts",
              "Dose recommendation logic",
              "Site guidance documents"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_ORGAN_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate lab-triggered dose recommendations",
                "sourceDataPath": "organ_specific_adjustments[]",
                "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
                "example": "CrCl 30-50 mL/min \u2192 Reduce to 75% of dose"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Interactive Response Technology",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Generate EDC edit checks for dose modification triggers",
          "Configure IRT dose assignment validation rules",
          "Set up medical monitor safety alert thresholds",
          "Create dose modification decision trees for site training",
          "Configure DSMB stopping rule monitoring",
          "Generate lab-triggered safety alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management"
          ],
          "crossReferences": [
            "adverse_events",
            "laboratory_specifications",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "DS",
          "EX",
          "LB"
        ],
        "regulatoryRelevance": "ICH E6(R2), ICH M11 Section 6-7",
        "schemaFile": "safety_decision_points_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_DOSELEVEL_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure allowed dose levels in IRT",
            "sourceDataPath": "dose_modification_levels.levels[]",
            "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
            "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
          },
          {
            "ruleId": "EDC_DECISION_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate edit checks from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
            "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
          },
          {
            "ruleId": "ALERT_DECISION_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Configure real-time safety alerts from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
            "example": null
          },
          {
            "ruleId": "IRT_STOP_001",
            "ruleType": "workflow",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure enrollment stops based on stopping rules",
            "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
            "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
            "example": null
          },
          {
            "ruleId": "EDC_ORGAN_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate lab-triggered dose recommendations",
            "sourceDataPath": "organ_specific_adjustments[]",
            "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
            "example": "CrCl 30-50 mL/min \u2192 Reduce to 75% of dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_SAFETY_LAB_001",
            "name": "Safety Thresholds + Lab Specs \u2192 Smart Lab Alerts",
            "agentsInvolved": [
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining safety thresholds with lab panel definitions enables intelligent lab alerting",
            "combinedInsight": "Which labs to monitor + what thresholds trigger action = Complete lab safety system",
            "automationEnabled": "EDC auto-calculates if labs trigger dose modification upon data entry",
            "exampleOutput": "{\"lab\": \"ANC\", \"value\": 800, \"threshold\": \"<1000\", \"action\": \"Hold dose\", \"triggered\": true}"
          },
          {
            "synergyId": "SYN_SAFETY_ARMS_001",
            "name": "Safety Rules + Arms \u2192 Arm-Specific Modifications",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "description": "Safety rules applied to specific arm dosing enables precise modification tracking",
            "combinedInsight": "Which dose level applies to which arm = Accurate dose tracking per subject",
            "automationEnabled": "IRT knows exact dose options for each arm based on safety rules",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_SAFETY_001",
            "name": "Dose Level Consistency",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels align with arm dosing regimens",
            "checkLogic": "FOR EACH level: level.absolute_dose IN arms.interventions.possible_doses",
            "severity": "error"
          },
          {
            "ruleId": "VAL_SAFETY_002",
            "name": "Stopping Rule Completeness",
            "agentsInvolved": [
              "safety_decision_points"
            ],
            "validationType": "completeness",
            "description": "Verify all stopping rules have clear conditions and actions",
            "checkLogic": "FOR EACH stop_rule: condition IS NOT NULL AND action IS NOT NULL",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "edit_check_library",
            "description": "Complete set of safety-related edit checks",
            "dataSources": [
              "decision_points[].decision_rules[]",
              "dose_modification_levels.levels[]",
              "organ_specific_adjustments[]"
            ],
            "outputFormat": "EDC edit check specification (Medidata, Oracle, Veeva)",
            "exampleConfig": {
              "edit_checks": [
                {
                  "id": "EC_ALT_001",
                  "condition": "ALT > 5 * ULN",
                  "action": "FIRE",
                  "message": "ALT elevation requires dose hold per protocol section 6.2",
                  "severity": "HARD_STOP"
                },
                {
                  "id": "EC_ANC_001",
                  "condition": "ANC < 1000",
                  "action": "FIRE",
                  "message": "Neutropenia requires dose modification per Table 6-1",
                  "severity": "SOFT_STOP"
                }
              ]
            }
          }
        ]
      }
    },
    "concomitantMedications": {
      "moduleId": "concomitant_medications",
      "instanceType": "ConcomitantMedications",
      "data": {
        "id": "H-34-concomitant-medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "name": "H-34 Concomitant Medication Restrictions",
        "description": "Medication restrictions and requirements for H-34",
        "prohibited_medications": [],
        "restricted_medications": [],
        "required_medications": [
          {
            "id": "req-001",
            "instanceType": "RequiredMedication",
            "medication_name": null,
            "medication_class": "Prophylactic Antibiotics",
            "requirement_type": {
              "decode": "prophylaxis"
            },
            "dosing": {
              "dose": null,
              "route": {
                "decode": "not_specified"
              },
              "frequency": null
            },
            "timing": {
              "relative_to": "surgical procedure",
              "time_before_minutes": null,
              "timing_description": "Administered according to the site clinical practice"
            },
            "purpose": "Prevention of surgical site infection",
            "alternatives": [],
            "biomedicalConcept": {
              "conceptName": "Prophylactic Antibiotic Therapy",
              "cdiscCode": "CUSTOM",
              "domain": "CM",
              "method": null,
              "confidence": 0.5,
              "rationale": "General class of medication required per standard of care"
            },
            "provenance": {
              "section_number": "7.8",
              "page_number": 34,
              "text_snippet": "Anaesthesia, post-operative pain management, and prophylactic antibiotics will be done according to the site clinical practice: although these data will be not collected in detail in the eCRF, all documentation has to be archive at the site and be available for the review."
            }
          }
        ],
        "rescue_medications": [
          {
            "id": "resc-001",
            "instanceType": "RescueMedication",
            "medication_name": null,
            "medication_class": "Analgesics",
            "indication": "Post-operative pain management",
            "dosing_instructions": "Administered according to the site clinical practice",
            "documentation_required": true,
            "impact_on_endpoints": "Use of pain medication is collected as part of standard of care.",
            "biomedicalConcept": {
              "conceptName": "Analgesic",
              "cdiscCode": "C198",
              "domain": "CM",
              "method": null,
              "confidence": 1,
              "rationale": "NCI Thesaurus code for the class of drugs used for pain management"
            },
            "provenance": {
              "section_number": "7.8",
              "page_number": 34,
              "text_snippet": "Anaesthesia, post-operative pain management, and prophylactic antibiotics will be done according to the site clinical practice: although these data will be not collected in detail in the eCRF, all documentation has to be archive at the site and be available for the review."
            }
          }
        ],
        "washout_requirements": [],
        "drug_interactions": [],
        "allowed_medications": [],
        "vaccine_policy": {},
        "herbal_supplements_policy": {
          "provenance": {
            "section_number": "7.2",
            "page_number": 26,
            "text_snippet": "Medical history includes clinically significant diseases, hip history (including all prior hip therapies and procedures), osteoporosis history (including assessment, treatment and nature of the osteoporosis) , and all medications (e.g., prescription drugs, over-the-counter drugs, herbal/homeopathic remedies, pain medication) used by the patient prior to the pre-operative visit."
          }
        },
        "provenance": {
          "section_number": "7.2",
          "page_number": 26,
          "text_snippet": "Medical history includes clinically significant diseases, hip history (including all prior hip therapies and procedures), osteoporosis history (including assessment, treatment and nature of the osteoporosis) , and all medications (e.g., prescription drugs, over-the-counter drugs, herbal/homeopathic remedies, pain medication) used by the patient prior to the pre-operative visit."
        }
      },
      "_agentDocumentation": {
        "agentId": "concomitant_medications",
        "displayName": "Concomitant Medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts medication restrictions, drug interactions, washout requirements, and required\n    premedications. Essential for site guidance, eligibility verification, and drug\n    interaction checking in EDC.",
        "scope": "- Prohibited medications (with reasons and periods)\n    - Restricted medications (with conditions for use)\n    - Required premedications and prophylaxis\n    - Rescue medications\n    - Washout requirements\n    - Drug-drug interactions (CYP450, QT, etc.)\n    - Vaccine policy\n    - Herbal/supplement restrictions",
        "keySectionsAnalyzed": [
          "Section 5: Prohibited/Restricted Medications",
          "Section 6: Concomitant Medications",
          "Section 7: Prior Medications",
          "Appendix: Drug Interaction Tables"
        ],
        "keyInsights": [
          {
            "name": "Prohibited Medications",
            "description": "Completely banned drug classes with prohibition reasons and periods",
            "dataPath": "prohibited_medications[]",
            "downstreamUses": [
              "EDC CM edit checks",
              "Site reference cards",
              "Eligibility screening"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_PROHIB_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Alert when prohibited medication is entered",
                "sourceDataPath": "prohibited_medications[]",
                "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
                "example": "Strong CYP3A4 inhibitor during treatment \u2192 Protocol deviation query"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Washout Requirements",
            "description": "Required washout periods before study entry",
            "dataPath": "washout_requirements[]",
            "downstreamUses": [
              "Eligibility calculator",
              "Screening visit scheduling",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_WASHOUT_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate washout period for prior medications",
                "sourceDataPath": "washout_requirements[]",
                "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
                "example": "Prior chemotherapy end date + 28 days must be before first dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Interactions",
            "description": "CYP450 inhibitors/inducers, QT prolonging agents with management",
            "dataPath": "drug_interactions[]",
            "downstreamUses": [
              "EDC drug interaction alerts",
              "Medical monitor reviews",
              "Pharmacy guidance"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DDI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Real-time drug interaction checking",
                "sourceDataPath": "drug_interactions[]",
                "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Required Premedications",
            "description": "Mandatory premedications with dosing and timing",
            "dataPath": "required_medications[]",
            "downstreamUses": [
              "Treatment day CRFs",
              "Site procedures",
              "Drug supply planning"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_PREMED_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Verify required premedications were administered",
                "sourceDataPath": "required_medications[]",
                "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
                "example": "Diphenhydramine 50mg IV required 30 min before infusion"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Configure EDC concomitant medication edit checks",
          "Generate site reference cards for prohibited/restricted meds",
          "Create eligibility screening tools with washout calculators",
          "Set up drug interaction alerts in safety database",
          "Auto-populate premedication requirements in visit forms"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria"
          ],
          "crossReferences": [
            "adverse_events",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "CM"
        ],
        "regulatoryRelevance": "ICH M11 Section 6.6",
        "schemaFile": "concomitant_medications_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_PROHIB_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Alert when prohibited medication is entered",
            "sourceDataPath": "prohibited_medications[]",
            "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
            "example": "Strong CYP3A4 inhibitor during treatment \u2192 Protocol deviation query"
          },
          {
            "ruleId": "EDC_WASHOUT_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate washout period for prior medications",
            "sourceDataPath": "washout_requirements[]",
            "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
            "example": "Prior chemotherapy end date + 28 days must be before first dose"
          },
          {
            "ruleId": "EDC_DDI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Real-time drug interaction checking",
            "sourceDataPath": "drug_interactions[]",
            "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
            "example": null
          },
          {
            "ruleId": "EDC_PREMED_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Verify required premedications were administered",
            "sourceDataPath": "required_medications[]",
            "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
            "example": "Diphenhydramine 50mg IV required 30 min before infusion"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_CM_ELIG_001",
            "name": "Washouts + Eligibility \u2192 Complete Screening Tool",
            "agentsInvolved": [
              "concomitant_medications",
              "eligibility_criteria"
            ],
            "description": "Washout requirements combined with eligibility criteria enables smart screening",
            "combinedInsight": "Prior therapy exclusions + washout periods = Earliest eligible date calculator",
            "automationEnabled": "Site tool that calculates when patient becomes eligible based on prior meds",
            "exampleOutput": "{\"prior_med\": \"Irinotecan\", \"last_dose\": \"2024-01-15\", \"washout\": \"28 days\", \"earliest_eligible\": \"2024-02-12\"}"
          }
        ],
        "validationRules": [],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "drug_dictionary_config",
            "description": "Configure drug dictionary with protocol-specific flags",
            "dataSources": [
              "prohibited_medications[]",
              "restricted_medications[]",
              "drug_interactions[]"
            ],
            "outputFormat": "WHODrug/MedDRA mapping with protocol flags",
            "exampleConfig": {
              "drug_flags": [
                {
                  "atc_class": "L01",
                  "flag": "PRIOR_CHEMO",
                  "washout_days": 28
                },
                {
                  "drug_name": "Ketoconazole",
                  "flag": "CYP3A4_INHIBITOR",
                  "status": "PROHIBITED"
                }
              ]
            }
          }
        ]
      }
    },
    "biospecimenHandling": {
      "moduleId": "biospecimen_handling",
      "instanceType": "BiospecimenHandling",
      "data": {
        "discovered_specimen_types": [
          {
            "specimen_id": "SPEC-001",
            "specimen_name": "Routine laboratory evaluations (e.g., haematology and serum chemistry)",
            "specimen_category": "blood",
            "specimen_subtype": "serum, whole blood",
            "purpose": "safety",
            "purpose_description": "To monitor patient safety",
            "provenance": {
              "section_number": "7.5",
              "page_number": 27,
              "text_snippet": "Routine laboratory evaluations (e.g., haematology and serum chemistry) will be performed in accordance with current local practice at the study site and will not collected in the eCRF but it is very recommended to store and archive all laboratory reports in the medical charts. Significant and severe abnormal laboratory evaluations at any time during the course of study should be recorded as AEs or SAEs."
            }
          },
          {
            "specimen_id": "SPEC-002",
            "specimen_name": "X-rays",
            "specimen_category": "imaging",
            "specimen_subtype": "x-ray",
            "purpose": "efficacy",
            "purpose_description": "To evaluate the radiographic performance of the device",
            "provenance": {
              "section_number": "7.7",
              "page_number": 29,
              "text_snippet": "Imaging will be collected to evaluate the radiographic performance of the device, which will contribute to the overall efficacy evaluation of Delta Revision acetabular cup."
            }
          }
        ],
        "collection_containers": [],
        "collection_schedule": [
          {
            "schedule_id": "COL-001",
            "specimen_ref": "SPEC-001",
            "timepoint_name": "Pre-operative visit",
            "timepoint_type": "screening",
            "provenance": {
              "section_number": "Appendix 1",
              "page_number": 53,
              "text_snippet": "Appendix 1 Schedule of Assessments\n[Table shows 'X' for Laboratory evaluations at Pre-operative visit]"
            }
          },
          {
            "schedule_id": "COL-002",
            "specimen_ref": "SPEC-001",
            "timepoint_name": "Intraoperative/Discharge visit",
            "timepoint_type": "treatment",
            "provenance": {
              "section_number": "Appendix 1",
              "page_number": 53,
              "text_snippet": "Appendix 1 Schedule of Assessments\n[Table shows 'X' for Laboratory evaluations at Intraoperative/Discharge visit]"
            }
          },
          {
            "schedule_id": "COL-003",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "Pre-operative visit",
            "timepoint_type": "screening",
            "provenance": {
              "section_number": "Table 1",
              "page_number": 30,
              "text_snippet": "Table 1: Schedule of Imaging Studies and Examination Intervals\n[Table shows 'X' for AP Pelvis at PREOP]"
            }
          },
          {
            "schedule_id": "COL-004",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "Discharge",
            "timepoint_type": "treatment",
            "provenance": {
              "section_number": "Table 1",
              "page_number": 30,
              "text_snippet": "Table 1: Schedule of Imaging Studies and Examination Intervals\n[Table shows 'X' for AP Pelvis at AT DISCHARGE]"
            }
          },
          {
            "schedule_id": "COL-005",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "2 months",
            "timepoint_type": "follow-up",
            "relative_time": "2 months",
            "collection_window": {
              "value": 30,
              "unit": "days",
              "description": "\u00b1 30 days"
            },
            "provenance": {
              "section_number": "Table 1",
              "page_number": 30,
              "text_snippet": "Table 1: Schedule of Imaging Studies and Examination Intervals\n[Table shows 'X' for AP Pelvis at MONTH 2]"
            }
          },
          {
            "schedule_id": "COL-006",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "6 months",
            "timepoint_type": "follow-up",
            "relative_time": "6 months",
            "collection_window": {
              "value": 60,
              "unit": "days",
              "description": "\u00b1 60 days"
            },
            "provenance": {
              "section_number": "Table 1",
              "page_number": 30,
              "text_snippet": "Table 1: Schedule of Imaging Studies and Examination Intervals\n[Table shows 'X' for AP Pelvis at MONTH 6]"
            }
          },
          {
            "schedule_id": "COL-007",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "12 months",
            "timepoint_type": "follow-up",
            "relative_time": "12 months",
            "collection_window": {
              "value": 6,
              "unit": "months",
              "description": "\u00b1 6 months"
            },
            "provenance": {
              "section_number": "Table 1",
              "page_number": 30,
              "text_snippet": "Table 1: Schedule of Imaging Studies and Examination Intervals\n[Table shows 'X' for AP Pelvis at MONTH 12]"
            }
          },
          {
            "schedule_id": "COL-008",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "24 months",
            "timepoint_type": "follow-up",
            "relative_time": "24 months",
            "collection_window": {
              "value": 6,
              "unit": "months",
              "description": "\u00b1 6 months"
            },
            "provenance": {
              "section_number": "Table 1",
              "page_number": 30,
              "text_snippet": "Table 1: Schedule of Imaging Studies and Examination Intervals\n[Table shows 'X' for AP Pelvis at MONTH 24]"
            }
          }
        ],
        "processing_requirements": [],
        "storage_requirements": [],
        "shipping_requirements": [],
        "central_laboratory": null,
        "kit_specifications": null,
        "quality_requirements": null,
        "regulatory_requirements": null,
        "volume_summary": null,
        "id": "biospecimen-handling-001",
        "instanceType": "BiospecimenHandling",
        "name": "H-34 DELTA Revision Cup Biospecimen Handling"
      },
      "_agentDocumentation": {
        "agentId": "biospecimen_handling",
        "displayName": "Biospecimen Handling",
        "instanceType": "BiospecimenHandling",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts specimen collection, processing, storage, and shipping requirements for central lab and biobank setup.",
        "scope": "Specimen types, tube types/volumes, processing instructions, storage conditions, shipping requirements, biobanking.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 8: Specimen Collection",
          "Appendix: Laboratory Manual"
        ],
        "keyInsights": [
          {
            "name": "Specimen Collection Requirements",
            "description": "Tubes, volumes, special handling for each sample type",
            "dataPath": "specimens[]",
            "downstreamUses": [
              "Central lab kit configuration",
              "Site lab manual",
              "Supply ordering"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate lab kit contents from specimen requirements",
                "sourceDataPath": "specimens[]",
                "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Biospecimen Repository",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Generate central lab sample collection kits",
          "Configure biobank sample tracking",
          "Create site laboratory manuals"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "laboratory_specifications"
          ],
          "crossReferences": [
            "pkpd_sampling"
          ]
        },
        "cdiscDomains": [
          "LB",
          "IS",
          "MB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.3",
        "schemaFile": "biospecimen_handling_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate lab kit contents from specimen requirements",
            "sourceDataPath": "specimens[]",
            "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_BIO_SOA_001",
            "name": "Specimens + SOA \u2192 Visit-Based Lab Kits",
            "agentsInvolved": [
              "biospecimen_handling",
              "soa_schedule"
            ],
            "description": "Specimen requirements + visit schedule = visit-specific lab kit configurations",
            "combinedInsight": "What samples at which visits = Complete lab kit manifest per visit",
            "automationEnabled": "Central lab auto-generates visit-specific kit labels",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "laboratorySpecifications": {
      "moduleId": "laboratory_specifications",
      "instanceType": "LaboratorySpecifications",
      "data": {
        "id": "LS-001",
        "instanceType": "LaboratorySpecifications",
        "name": "Laboratory Specifications",
        "description": "Protocol-discovered laboratory testing requirements for the DELTA REVISION CUP study (H-34).",
        "central_laboratory": null,
        "discovered_panels": [
          {
            "panel_id": "PNL-001",
            "panel_name": "Routine Laboratory Evaluations - Hematology",
            "panel_code": null,
            "panel_description": "Hematology tests performed in accordance with current local practice at the study site. Results are not collected in the eCRF but are recommended to be stored in the patient's medical charts.",
            "panel_category": "hematology",
            "test_count": null,
            "biomedicalConcept": {
              "conceptName": "Hematology Panel",
              "cdiscCode": "C64796",
              "domain": "LB",
              "specimen": "whole blood",
              "method": null,
              "confidence": 1.0,
              "rationale": "NCI Thesaurus code for a general hematology panel."
            },
            "provenance": {
              "section_number": "7.5",
              "page_number": 27,
              "text_snippet": "Routine laboratory evaluations (e.g., haematology and serum chemistry) will be performed in accordance with current local practice at the study site and will not collected in the eCRF but it is very recommended to store and archive all laboratory reports in the medical charts."
            }
          },
          {
            "panel_id": "PNL-002",
            "panel_name": "Routine Laboratory Evaluations - Serum Chemistry",
            "panel_code": null,
            "panel_description": "Serum chemistry tests performed in accordance with current local practice at the study site. Results are not collected in the eCRF but are recommended to be stored in the patient's medical charts.",
            "panel_category": "chemistry",
            "test_count": null,
            "biomedicalConcept": {
              "conceptName": "Chemistry Panel",
              "cdiscCode": "C64797",
              "domain": "LB",
              "specimen": "serum",
              "method": null,
              "confidence": 1.0,
              "rationale": "NCI Thesaurus code for a general chemistry panel."
            },
            "provenance": {
              "section_number": "7.5",
              "page_number": 27,
              "text_snippet": "Routine laboratory evaluations (e.g., haematology and serum chemistry) will be performed in accordance with current local practice at the study site and will not collected in the eCRF but it is very recommended to store and archive all laboratory reports in the medical charts."
            }
          }
        ],
        "laboratory_tests": [
          {
            "test_id": "LAB-001",
            "test_name": "Haematology",
            "test_code": null,
            "panel_ref": null,
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": "Performed in accordance with current local practice at the study site. Data not collected in the eCRF.",
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Routine hematology evaluations performed as per standard of care to assess general health.",
            "biomedicalConcept": {
              "conceptName": "Hematology Test",
              "cdiscCode": "C62634",
              "domain": "LB",
              "specimen": "whole blood",
              "method": null,
              "confidence": 1,
              "rationale": "NCI Thesaurus code for Hematology Panel."
            },
            "provenance": {
              "section_number": "7.5",
              "page_number": 27,
              "text_snippet": "Routine laboratory evaluations (e.g., haematology and serum chemistry) will be performed in accordance with current local practice at the study site..."
            }
          },
          {
            "test_id": "LAB-002",
            "test_name": "Serum chemistry",
            "test_code": null,
            "panel_ref": null,
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": "Performed in accordance with current local practice at the study site. Data not collected in the eCRF.",
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Routine serum chemistry evaluations performed as per standard of care to assess metabolic function.",
            "biomedicalConcept": {
              "conceptName": "Chemistry Panel",
              "cdiscCode": "C62633",
              "domain": "LB",
              "specimen": "serum",
              "method": null,
              "confidence": 1,
              "rationale": "NCI Thesaurus code for Chemistry Panel."
            },
            "provenance": {
              "section_number": "7.5",
              "page_number": 27,
              "text_snippet": "Routine laboratory evaluations (e.g., haematology and serum chemistry) will be performed in accordance with current local practice at the study site..."
            }
          },
          {
            "test_id": "LAB-003",
            "test_name": "Haematocrit",
            "test_code": "20570-8",
            "panel_ref": null,
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "To assess blood loss via intra-operative and immediate post-operative measurements.",
            "biomedicalConcept": {
              "conceptName": "Hematocrit",
              "cdiscCode": "C64847",
              "domain": "LB",
              "specimen": "whole blood",
              "method": null,
              "confidence": 1,
              "rationale": "NCI Thesaurus code for Hematocrit."
            },
            "provenance": {
              "section_number": "7.8",
              "page_number": 34,
              "text_snippet": "Surgery data includes date of surgery, surgical approach, surgery time and intra-operative and immediate post-operative haematocrit measurements."
            }
          }
        ],
        "testing_schedule": [
          {
            "schedule_id": "SCH-001",
            "test_or_panel_ref": "PNL-001",
            "timepoints": [
              {
                "timepoint_name": "Pre-operative visit",
                "timepoint_type": "screening",
                "window": null,
                "conditions": null
              },
              {
                "timepoint_name": "Intraoperative/Discharge visit",
                "timepoint_type": "baseline",
                "window": null,
                "conditions": null
              }
            ],
            "frequency": "Once at pre-operative visit and once during the intraoperative/discharge period.",
            "provenance": {
              "section_number": "Appendix 1",
              "page_number": 53,
              "text_snippet": "Laboratory evaluations e | X | X\n... e. Routine laboratory evaluations (e.g., hematology and serum chemistry) will be peformed in accordance with current local practice at the study site..."
            }
          },
          {
            "schedule_id": "SCH-002",
            "test_or_panel_ref": "PNL-002",
            "timepoints": [
              {
                "timepoint_name": "Pre-operative visit",
                "timepoint_type": "screening",
                "window": null,
                "conditions": null
              },
              {
                "timepoint_name": "Intraoperative/Discharge visit",
                "timepoint_type": "baseline",
                "window": null,
                "conditions": null
              }
            ],
            "frequency": "Once at pre-operative visit and once during the intraoperative/discharge period.",
            "provenance": {
              "section_number": "Appendix 1",
              "page_number": 53,
              "text_snippet": "Laboratory evaluations e | X | X\n... e. Routine laboratory evaluations (e.g., hematology and serum chemistry) will be peformed in accordance with current local practice at the study site..."
            }
          }
        ],
        "sample_collection_requirements": {
          "fasting_requirements": null,
          "timing_requirements": null,
          "processing_requirements": "All laboratory evaluations are to be performed in accordance with current local practice at the study site.",
          "storage_requirements": "It is very recommended to store and archive all laboratory reports in the medical charts.",
          "shipping_requirements": null,
          "provenance": {
            "section_number": "7.5",
            "page_number": 27,
            "text_snippet": "Routine laboratory evaluations (e.g., haematology and serum chemistry) will be performed in accordance with current local practice at the study site and will not collected in the eCRF but it is very recommended to store and archive all laboratory reports in the medical charts."
          }
        },
        "lab_based_dose_modifications": [],
        "eligibility_lab_criteria": [
          {
            "criteria_id": "ELIG-001",
            "criteria_type": "exclusion",
            "parameter_name": "Pregnancy/Lactation",
            "condition": "For female patients, current pregnancy and/or lactation or planning a pregnancy.",
            "operator": null,
            "threshold_value": null,
            "threshold_unit": null,
            "provenance": {
              "section_number": "5.2",
              "page_number": 18,
              "text_snippet": "2. For female patients, current pregnancy and/or lactation or planning a pregnancy."
            }
          }
        ],
        "critical_value_reporting": null,
        "abnormal_result_grading": {
          "grading_system": "Protocol-defined severity scale (Mild, Moderate, Severe)",
          "grading_version": null,
          "clinically_significant_threshold": "Significant and severe",
          "ae_reporting_threshold": "Significant and severe",
          "provenance": {
            "section_number": "7.5",
            "page_number": 27,
            "text_snippet": "Significant and severe abnormal laboratory evaluations at any time during the course of study should be recorded as AEs or SAEs."
          }
        },
        "pregnancy_testing": {
          "required": true,
          "applicable_population": "Female patients",
          "test_type": null,
          "timing": null,
          "sensitivity": null,
          "action_if_positive": "Patient will not be included in the study.",
          "provenance": {
            "section_number": "5.2",
            "page_number": 18,
            "text_snippet": "Exclusion criteria\nPatients who meet any of the following criteria will be excluded from study entry.\n...2. For female patients, current pregnancy and/or lactation or planning a pregnancy."
          }
        },
        "pharmacokinetic_samples": {
          "pk_sampling_required": false,
          "provenance": {
            "section_number": "N/A",
            "page_number": null,
            "text_snippet": "Pharmacokinetic sampling is not mentioned in the protocol."
          }
        },
        "biomarker_samples": {
          "biomarker_sampling_required": false,
          "provenance": {
            "section_number": "N/A",
            "page_number": null,
            "text_snippet": "Biomarker sampling is not mentioned in the protocol."
          }
        },
        "local_lab_requirements": {
          "local_lab_allowed": true,
          "allowed_tests": [
            "Hematology",
            "Serum Chemistry"
          ],
          "certification_requirements": null,
          "provenance": {
            "section_number": "7.5",
            "page_number": 27,
            "text_snippet": "Routine laboratory evaluations (e.g., haematology and serum chemistry) will be performed in accordance with current local practice at the study site..."
          }
        },
        "extraction_statistics": {
          "total_panels_discovered": 2,
          "total_tests_discovered": 0,
          "total_schedule_entries": 2,
          "dose_modification_rules": 0,
          "eligibility_criteria_count": 1,
          "critical_values_defined": 0
        },
        "provenance": {
          "section_number": "7.5",
          "page_number": 27,
          "text_snippet": "7.5 Routine laboratory evaluations\nRoutine laboratory evaluations (e.g., haematology and serum chemistry) will be performed in accordance with current local practice at the study site..."
        }
      },
      "_agentDocumentation": {
        "agentId": "laboratory_specifications",
        "displayName": "Laboratory Specifications",
        "instanceType": "LaboratorySpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts laboratory panel definitions, eligibility criteria, and lab-triggered dose modifications for central lab and EDC setup.",
        "scope": "Lab panels, individual tests, eligibility lab criteria, lab-triggered dose modifications, hepatotoxicity monitoring.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 5: Eligibility Criteria",
          "Section 6: Dose Modifications"
        ],
        "keyInsights": [
          {
            "name": "Laboratory Panels",
            "description": "Panel definitions with constituent tests",
            "dataPath": "panels[]",
            "downstreamUses": [
              "Central lab requisition forms",
              "EDC lab CRF design",
              "Cost estimation"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_PANEL_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate central lab requisition from panel definitions",
                "sourceDataPath": "panels[]",
                "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Eligibility Lab Criteria",
            "description": "Lab values required for study entry",
            "dataPath": "eligibility_lab_criteria[]",
            "downstreamUses": [
              "EDC eligibility edit checks",
              "Site screening tools",
              "Subject ID verification"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_LABELIG_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate screening labs against eligibility criteria",
                "sourceDataPath": "eligibility_lab_criteria[]",
                "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
                "example": "ANC >= 1500/\u00b5L required for eligibility"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central lab panel requisitions",
          "Set up EDC lab data entry",
          "Create eligibility screening lab checklists"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria",
            "safety_decision_points"
          ],
          "crossReferences": [
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "LB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.2",
        "schemaFile": "laboratory_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_PANEL_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate central lab requisition from panel definitions",
            "sourceDataPath": "panels[]",
            "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
            "example": null
          },
          {
            "ruleId": "EDC_LABELIG_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate screening labs against eligibility criteria",
            "sourceDataPath": "eligibility_lab_criteria[]",
            "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
            "example": "ANC >= 1500/\u00b5L required for eligibility"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_LAB_SAFETY_001",
            "name": "Lab Panels + Safety Thresholds \u2192 Lab Alert System",
            "agentsInvolved": [
              "laboratory_specifications",
              "safety_decision_points"
            ],
            "description": "Lab test definitions + safety thresholds = complete lab alerting system",
            "combinedInsight": "Normal ranges + dose modification thresholds = Tiered lab alerts (normal, caution, action required)",
            "automationEnabled": "EDC displays color-coded lab values with action recommendations",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "informedConsent": {
      "moduleId": "informed_consent",
      "instanceType": "InformedConsentElements",
      "data": {
        "id": "H-34-informed-consent",
        "instanceType": "InformedConsentElements",
        "name": "H-34 Informed Consent Elements",
        "description": "ICF content elements for H-34",
        "study_overview": {
          "study_purpose": "To evaluate the safety, clinical, and radiographic outcomes of total hip arthroplasty with the DELTA Revision acetabular cup in a real-life setting over a 2-year period.",
          "study_duration_for_participant": "Approximately 2 years from the date of surgery.",
          "number_of_visits": 6,
          "total_time_commitment": null,
          "number_of_participants": "Approximately 49 participants at a single study center.",
          "study_locations": "A single study center is expected to participate.",
          "provenance": {
            "section_number": null,
            "page_number": 10,
            "text_snippet": "Protocol Synopsis\nStudy title: An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision acetabular cup.\nPrimary objectives: To assess the clinical outcomes of the DELTA Revision acetabular cup used in real life settings over a period of 2 years"
          }
        },
        "study_procedures": {
          "screening_procedures": [
            {
              "procedure_id": "PROC-001",
              "procedure_name": "Informed Consent",
              "description": "Discussion of the study and signing the consent form before any study procedures.",
              "frequency": "Once, before enrollment",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.1",
                "page_number": 26,
                "text_snippet": "An IRB/IEC approved informed consent form will be read, signed and dated by the subject prior to the performance of any study related procedures."
              }
            },
            {
              "procedure_id": "PROC-002",
              "procedure_name": "Eligibility Assessment",
              "description": "Checking if you meet the inclusion and exclusion criteria for the study.",
              "frequency": "Once, at screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.1",
                "page_number": 18,
                "text_snippet": "Patients must meet the following criteria for study entry:"
              }
            },
            {
              "procedure_id": "PROC-003",
              "procedure_name": "Medical History and Demographics",
              "description": "Collection of your medical history, hip history, demographic data (age, sex, etc.), and lifestyle habits.",
              "frequency": "Once, at pre-operative visit",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.2",
                "page_number": 26,
                "text_snippet": "Medical History and Demographic Data\nMedical history includes clinically significant diseases, hip history (including all prior hip therapies and procedures), osteoporosis history... Demographic data will include age, sex, ethnicity, smoking and drinking habits, activity level (e.g. sedentary, normal, intense) and, working status (active worker or retired)."
              }
            },
            {
              "procedure_id": "PROC-004",
              "procedure_name": "Physical Examination",
              "description": "A complete physical examination, including assessment of your general health and musculoskeletal system.",
              "frequency": "Once, at pre-operative visit",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.4",
                "page_number": 27,
                "text_snippet": "A complete physical examination will be carried out at the pre-operative visit. This will include an assessment of all major systems as well as an assessment of the general appearance, lung/chest, abdomen, extremities and musculoskeletal."
              }
            },
            {
              "procedure_id": "PROC-005",
              "procedure_name": "Vital Signs",
              "description": "Measurement of body height, weight, temperature, pulse, and blood pressure.",
              "frequency": "Once, at pre-operative visit",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.3",
                "page_number": 26,
                "text_snippet": "Body height and body weight will be recorded only at the pre-operative visit and collected in the eCRF. Vital signs (body temperature, pulse, blood pressure) and ECG will be performed in accordance with current local practice at the study site..."
              }
            },
            {
              "procedure_id": "PROC-006",
              "procedure_name": "Laboratory Tests",
              "description": "Routine blood tests (e.g., haematology and serum chemistry) as per standard clinical practice.",
              "frequency": "At pre-operative visit",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.5",
                "page_number": 27,
                "text_snippet": "Routine laboratory evaluations (e.g., haematology and serum chemistry) will be performed in accordance with current local practice at the study site and will not collected in the eCRF but it is very recommended to store and archive all laboratory reports in the medical charts."
              }
            },
            {
              "procedure_id": "PROC-007",
              "procedure_name": "Hip Function Questionnaires",
              "description": "Completion of the Harris Hip Score (HHS) and Oxford Hip Score (OHS) to assess your hip pain and function.",
              "frequency": "Once, at pre-operative visit",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.6",
                "page_number": 27,
                "text_snippet": "Clinical evaluation will be performed at the following visits: Pre-operative visit: preoperative assessment will be used as baseline values for score improvement... Harris Hip Score and Oxford Hip Score will be used and evaluated for this study as detailed in the sections 7.6.1 and 7.6.2."
              }
            },
            {
              "procedure_id": "PROC-008",
              "procedure_name": "Radiographical Evaluation (X-ray)",
              "description": "Antero-posterior (AP) X-ray of the pelvis.",
              "frequency": "Once, at pre-operative visit",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.7",
                "page_number": 29,
                "text_snippet": "Radiological assessment was carried out preoperatively and postoperatively at discharge, at 2 months, 6 months, 12 months, and 24 months after surgery. It included standard views, such as antero-posterior (AP) of the pelvis, antero-posterior (AP) and lateral (LAT) of the affected hip."
              }
            }
          ],
          "treatment_procedures": [
            {
              "procedure_id": "PROC-009",
              "procedure_name": "Total Hip Arthroplasty Surgery",
              "description": "Surgical procedure to implant the DELTA Revision acetabular cup as part of a total hip replacement.",
              "frequency": "Once",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "6.1",
                "page_number": 21,
                "text_snippet": "Study treatment is the hip replacement with implant of DELTA Revision acetabular cup."
              }
            },
            {
              "procedure_id": "PROC-010",
              "procedure_name": "Post-Surgery Assessments",
              "description": "During hospitalization, assessments will include vital signs, lab tests, hip function questionnaires (HHS, OHS), and a post-operative X-ray.",
              "frequency": "Once, during hospital stay after surgery",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Appendix 1",
                "page_number": 53,
                "text_snippet": "Intraoperative/Discharge visit 2... Assessments have to be performed in the period between the surgery and discharge."
              }
            }
          ],
          "follow_up_procedures": [
            {
              "procedure_id": "PROC-011",
              "procedure_name": "Follow-up Visits",
              "description": "Return visits to the study site for clinical and radiographic evaluation.",
              "frequency": "At 2 months, 6 months, 1 year, and 2 years after surgery.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "3.1",
                "page_number": 17,
                "text_snippet": "The subject will return to the site at two months (Follow-Up 2 months), six months (Follow-Up 6 months), twelve months (Follow-Up 12 months) and twenty-four months (Follow-Up 24 months) after the surgery. At each of these visits, the subject will undergo a clinical and radiographical evaluation."
              }
            },
            {
              "procedure_id": "PROC-012",
              "procedure_name": "Follow-up Physical Examination",
              "description": "A brief physical examination of your hip and extremities.",
              "frequency": "At each follow-up visit",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.4",
                "page_number": 27,
                "text_snippet": "Brief physical examination will be carried out at Follow-Up 2 months, 6 months, 12 months and 24 months. It will include a brief assessments of hip, extremities and musculoskeletal."
              }
            },
            {
              "procedure_id": "PROC-013",
              "procedure_name": "Follow-up Hip Function Questionnaires",
              "description": "Completion of the Harris Hip Score (HHS) and Oxford Hip Score (OHS).",
              "frequency": "At each follow-up visit",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.6",
                "page_number": 27,
                "text_snippet": "Clinical evaluation will be performed at the following visits: ... Follow-Up 2 months: \u00b1 30 days Follow-Up 6 months (\u00b1 60 days) Follow-Up 12 months (\u00b1 6 months) Follow-Up 24 months (\u00b1 6 months)"
              }
            },
            {
              "procedure_id": "PROC-014",
              "procedure_name": "Follow-up X-rays",
              "description": "Antero-posterior (AP) X-ray of the pelvis to evaluate the implant.",
              "frequency": "At each follow-up visit",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.7",
                "page_number": 29,
                "text_snippet": "Radiological assessment was carried out preoperatively and postoperatively at discharge, at 2 months, 6 months, 12 months, and 24 months after surgery."
              }
            },
            {
              "procedure_id": "PROC-015",
              "procedure_name": "Adverse Event Monitoring",
              "description": "You will be asked about any new or changed health problems at each visit.",
              "frequency": "At each visit after surgery",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "9.7.1",
                "page_number": 37,
                "text_snippet": "Investigators will seek information on AEs at each patient contact. All AEs, whether reported by the patient or noted by study personnel, will be recorded in the patient's medical record and on the AE eCRF."
              }
            }
          ],
          "optional_procedures": [],
          "provenance": {
            "section_number": "7",
            "page_number": 26,
            "text_snippet": "7 Study assessment"
          }
        },
        "risks": {
          "known_risks": [
            {
              "risk_id": "RISK-001",
              "risk_description": "Loosening, dislocation, or instability of the hip implant.",
              "severity": null,
              "frequency": null,
              "management": null,
              "provenance": {
                "section_number": "6.2",
                "page_number": 23,
                "text_snippet": "Adverse effects that most commonly and frequently occur in hip arthroplasty include: loosening of the prosthetic components; prosthesis dislocation and instability;"
              }
            },
            {
              "risk_id": "RISK-002",
              "risk_description": "Infection of the joint or surgical site.",
              "severity": null,
              "frequency": null,
              "management": null,
              "provenance": {
                "section_number": "6.2",
                "page_number": 24,
                "text_snippet": "infection;"
              }
            },
            {
              "risk_id": "RISK-003",
              "risk_description": "Temporary or permanent nerve damage near the hip.",
              "severity": null,
              "frequency": null,
              "management": null,
              "provenance": {
                "section_number": "6.2",
                "page_number": 24,
                "text_snippet": "temporary or permanent nerve damage;"
              }
            },
            {
              "risk_id": "RISK-004",
              "risk_description": "Fracture of the bone or the implant device.",
              "severity": null,
              "frequency": null,
              "management": null,
              "provenance": {
                "section_number": "6.2",
                "page_number": 24,
                "text_snippet": "fractures of the devices;"
              }
            },
            {
              "risk_id": "RISK-005",
              "risk_description": "Blood clots in the legs (venous thrombosis) which can travel to the lungs (pulmonary embolism).",
              "severity": null,
              "frequency": null,
              "management": null,
              "provenance": {
                "section_number": "6.2",
                "page_number": 24,
                "text_snippet": "General complications include venous thrombosis with/without pulmonary embolism, cardiovascular disturbances, haematomas, systemic allergic reactions and systemic pain."
              }
            },
            {
              "risk_id": "RISK-006",
              "risk_description": "Difference in leg length after surgery.",
              "severity": null,
              "frequency": null,
              "management": null,
              "provenance": {
                "section_number": "6.2",
                "page_number": 24,
                "text_snippet": "limb length discrepancies;"
              }
            },
            {
              "risk_id": "RISK-007",
              "risk_description": "Pain, blood loss, swelling (haematoma), or allergic reaction.",
              "severity": null,
              "frequency": null,
              "management": null,
              "provenance": {
                "section_number": "6.2",
                "page_number": 24,
                "text_snippet": "local pain; ... blood loss; ... General complications include venous thrombosis with/without pulmonary embolism, cardiovascular disturbances, haematomas, systemic allergic reactions and systemic pain."
              }
            },
            {
              "risk_id": "RISK-008",
              "risk_description": "Need for additional surgery to correct a problem with the implant.",
              "severity": null,
              "frequency": null,
              "management": null,
              "provenance": {
                "section_number": "6.2",
                "page_number": 24,
                "text_snippet": "additional surgery;"
              }
            },
            {
              "risk_id": "RISK-009",
              "risk_description": "Risks associated with X-ray radiation exposure.",
              "severity": null,
              "frequency": null,
              "management": null,
              "provenance": {
                "section_number": "7.7",
                "page_number": 29,
                "text_snippet": "The safety guidelines and intervention for X-rays at the site should be followed according to the Hospital procedure and clinical practice to ensure the safety for subjects, radiologists, site staff personnel and technicians."
              }
            }
          ],
          "potential_risks": [],
          "reproductive_risks": "The effects of this procedure on an unborn baby or a nursing infant are unknown. You cannot participate if you are pregnant, planning a pregnancy, or breastfeeding.",
          "unknown_risks_statement": null,
          "risk_mitigation_measures": "Careful pre-operative planning, proper surgical technique, and following post-operative rehabilitation instructions can help reduce the risk of complications.",
          "provenance": {
            "section_number": "6.2",
            "page_number": 23,
            "text_snippet": "6.2 Contraindications and risk factors"
          }
        },
        "benefits": {
          "potential_benefits": [
            "The hip replacement surgery is intended to reduce your hip pain and improve your mobility and ability to perform daily activities."
          ],
          "no_benefit_statement": "Participation in the data collection aspect of this study does not provide any additional medical benefit beyond receiving the surgical treatment itself.",
          "societal_benefits": "The information gathered in this study will help to evaluate the performance and safety of the hip implant, which may benefit future patients.",
          "provenance": {
            "section_number": "1.1",
            "page_number": 14,
            "text_snippet": "The main goal of a hip joint prosthesis is to reproduce the articular anatomy reducing pain and give articular mobility to the patient. The degree of pain reduction and mobility depends in part on the pre-operative situation, intra-operative options and on the post-op rehabilitation."
          }
        },
        "alternatives": {
          "alternative_treatments": [
            {
              "treatment_name": "Other surgical techniques",
              "description": "Alternative reconstruction techniques or joint fusion (arthrodesis) may be options depending on your condition."
            }
          ],
          "no_treatment_option": true,
          "standard_of_care_description": "The procedure in this study, total hip arthroplasty with the DELTA Revision cup, is considered a standard treatment for your condition. This observational study is designed to reflect real-life clinical practice.",
          "provenance": {
            "section_number": "6.1",
            "page_number": 21,
            "text_snippet": "clinical management problem where arthrodesis or alternative reconstruction techniques are less likely to achieve satisfactory results;"
          }
        },
        "compensation_costs": {
          "participant_compensation": null,
          "payment_schedule": null,
          "travel_reimbursement": null,
          "participant_costs": [],
          "covered_costs": [],
          "injury_compensation": "An insurance policy is in place to provide coverage for the study, which may cover study-related injuries.",
          "provenance": {
            "section_number": "13.5",
            "page_number": 48,
            "text_snippet": "13.5 Insurance\nAn insurance policy provides coverage for this study, as reported in the documentation to be submitted and approved by the Ethics Committee."
          }
        },
        "confidentiality": {
          "data_protection_statement": "Your personal information will be kept confidential. Your name will not be used in any data sets or reports. Your identity will be protected by a unique identification number.",
          "who_has_access": [
            "Study team at the site",
            "The Sponsor (LimaCorporate S.p.A.) and its representatives (including CROs)",
            "Institutional Review Board (IRB) or Ethics Committee (EC)",
            "Regulatory health authorities (local and foreign)"
          ],
          "hipaa_authorization": null,
          "data_retention_period": "Study records will be kept for at least 15 years after the study is completed.",
          "international_data_transfer": "Your anonymized data may be transferred to and reviewed by personnel or authorities in other countries.",
          "data_sharing": "The anonymized results of this study may be published in scientific journals or presented at medical meetings.",
          "provenance": {
            "section_number": "12.5",
            "page_number": 47,
            "text_snippet": "12.5 Confidentiality\nThe Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in data sets that are transmitted to any Sponsor location."
          }
        },
        "voluntary_participation": {
          "voluntary_statement": "Your participation in this observational study is voluntary. The decision to have the surgery is made separately from the decision to participate in the study.",
          "withdrawal_rights": "You have the right to withdraw from the study at any time for any reason without affecting your medical care.",
          "withdrawal_consequences": null,
          "data_after_withdrawal": "If you withdraw, data collected up to that point will be kept. You may also request that your previously collected data be excluded from the study.",
          "provenance": {
            "section_number": "5.5",
            "page_number": 19,
            "text_snippet": "The investigator has the right to withdraw a patient from the study at any time. In addition, patients have the right to voluntarily withdraw from the study at any time for any reason."
          }
        },
        "special_consents": {
          "genetic_testing": null,
          "biobanking": null,
          "photography_recording": null,
          "provenance": {
            "section_number": "7.1",
            "page_number": 26,
            "text_snippet": "7.1 Informed consent process\nAn IRB/IEC approved informed consent form will be read, signed and dated by the subject prior to the performance of any study related procedures. Prior to obtaining informed consent, the investigator (or designate) will explain the nature and the purpose of the study to the subject, provide the subject ample time to consider his/her decision and answer any questions posed by the subject to his/her satisfaction. Please see section 12.2 for more details."
          }
        },
        "contacts": {
          "study_questions_contact": "You can ask the investigator or study team any questions you have about the study.",
          "rights_questions_contact": "If you have questions about your rights as a research participant, you can contact the Institutional Review Board or Ethics Committee.",
          "emergency_contact": null,
          "twenty_four_hour_contact": null,
          "provenance": {
            "section_number": "7.1",
            "page_number": 26,
            "text_snippet": "Prior to obtaining informed consent, the investigator (or designate) will explain the nature and the purpose of the study to the subject, provide the subject ample time to consider his/her decision and answer any questions posed by the subject to his/her satisfaction."
          }
        },
        "reproductive_requirements": {
          "pregnancy_testing_required": null,
          "contraception_requirements": "Female patients who are planning a pregnancy are not eligible for the study.",
          "contraception_duration": null,
          "pregnancy_reporting": "If you become pregnant during the study, you will be withdrawn from the study.",
          "breastfeeding_restrictions": "You cannot participate in the study if you are breastfeeding.",
          "male_requirements": null,
          "provenance": {
            "section_number": "5.2",
            "page_number": 18,
            "text_snippet": "Exclusion criteria\nPatients who meet any of the following criteria will be excluded from study entry.\n...2. For female patients, current pregnancy and/or lactation or planning a pregnancy."
          }
        },
        "extraction_statistics": {
          "has_risks": true,
          "has_benefits": true,
          "has_alternatives": true,
          "has_compensation": true,
          "has_genetic_consent": false,
          "has_biobanking": false,
          "risk_count": 9,
          "procedure_count": 15
        },
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "Study protocol\nAn open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
        }
      },
      "_agentDocumentation": {
        "agentId": "informed_consent",
        "displayName": "Informed Consent Elements",
        "instanceType": "InformedConsentElements",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts key informed consent content elements for ICF template generation and IRB submission.",
        "scope": "Key risks, potential benefits, treatment alternatives, compensation, genetic/biobanking consents, witness requirements.",
        "keySectionsAnalyzed": [
          "Section 10: Informed Consent",
          "Section 11: Subject Information",
          "Appendix: Informed Consent Form"
        ],
        "keyInsights": [
          {
            "name": "Key Risks",
            "description": "Common, serious, and unknown risks to communicate",
            "dataPath": "risks[]",
            "downstreamUses": [
              "ICF template generation",
              "IRB submission",
              "Site training"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Optional Consents",
            "description": "Biobanking, genetic testing, future research options",
            "dataPath": "optional_consents[]",
            "downstreamUses": [
              "ICF optional sections",
              "EDC consent tracking",
              "Biobank enrollment"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Trial Master File",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate ICF templates with protocol-specific risks",
          "Create consent tracking CRFs"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR 50",
        "schemaFile": "informed_consent_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "proSpecifications": {
      "moduleId": "pro_specifications",
      "instanceType": "PROSpecifications",
      "data": {
        "id": "H-34-pro-specifications",
        "instanceType": "PROSpecifications",
        "name": "H-34 PRO Specifications",
        "description": "PRO/COA specifications for H-34",
        "pro_instruments": [
          {
            "instrument_id": "PRO-001",
            "instrument_name": "Harris Hip Score",
            "instrument_abbreviation": "HHS",
            "instrument_type": "function",
            "administration": {
              "mode": "interviewer",
              "provenance": {
                "section_number": "7.6.1",
                "page_number": 27,
                "text_snippet": "The HHS is an outcome measure administered by a qualified health care professional, such as a physician or a physical therapist."
              }
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Pre-operative",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "Intra-operative/Discharge",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "2 months",
                  "window_before_days": 0,
                  "window_after_days": 30,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "6 months",
                  "window_before_days": 0,
                  "window_after_days": 60,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-005",
                  "timepoint_name": "1 year",
                  "window_before_days": 0,
                  "window_after_days": 180,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-006",
                  "timepoint_name": "2 years",
                  "window_before_days": 0,
                  "window_after_days": 180,
                  "is_required": true
                }
              ],
              "provenance": {
                "section_number": "7.6.1",
                "page_number": 28,
                "text_snippet": "Harris Hip Score will be performed at pre-operative visit, discharge visit and, follow-Up 2 months (\u00b1 30 days), follow-Up 6 months (\u00b1 60 days), follow-Up 12 months (\u00b1 6 months) and follow-Up 24 months (\u00b1 6 months) since the date of the surgery."
              }
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Pain",
                  "score_range": "0-44",
                  "provenance": {
                    "section_number": "7.6.1",
                    "page_number": 28,
                    "text_snippet": "Pain domain contributes 44 points"
                  }
                },
                {
                  "domain_name": "Function",
                  "score_range": "0-47",
                  "provenance": {
                    "section_number": "7.6.1",
                    "page_number": 28,
                    "text_snippet": "function 47"
                  }
                },
                {
                  "domain_name": "Absence of Deformity",
                  "score_range": "0-4",
                  "provenance": {
                    "section_number": "7.6.1",
                    "page_number": 28,
                    "text_snippet": "absence of deformity 4 points"
                  }
                },
                {
                  "domain_name": "Range of Motion",
                  "score_range": "0-5",
                  "provenance": {
                    "section_number": "7.6.1",
                    "page_number": 28,
                    "text_snippet": "ROM 5"
                  }
                }
              ],
              "total_score_available": true,
              "scoring_algorithm": "Sum of domain scores. Total score range 0-100. Higher score is better.",
              "mcid": "20 points",
              "responder_definition": "An increase of 20 points in the HHS is considered a minimal clinically relevant change.",
              "provenance": {
                "section_number": "10.1",
                "page_number": 42,
                "text_snippet": "The primary endpoint is to assess the change in the Harris Hip Score (HHS) from pre-operative baseline up to 2 years after surgery. A 20 point increase in the HHS is considered a minimal clinically relevant change for the purposes of this study."
              }
            },
            "biomedicalConcept": {
              "conceptName": "Harris Hip Score",
              "cdiscCode": "C49583",
              "domain": "QS",
              "confidence": 1
            },
            "provenance": {
              "section_number": "7.6.1",
              "page_number": 27,
              "text_snippet": "The Harris Hip Scale (HHS) was developed for the assessment of the results of hip surgery, and it is intended to evaluate various hip disabilities and methods of treatment in an adult population."
            }
          },
          {
            "instrument_id": "PRO-002",
            "instrument_name": "Oxford Hip Score",
            "instrument_abbreviation": "OHS",
            "instrument_type": "function",
            "administration": {
              "mode": "electronic",
              "provenance": {
                "section_number": "11",
                "page_number": 11,
                "text_snippet": "An Electronic Data Capture system will be used to collect data in electronic format. Data will be collected at the following time-points:"
              }
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Pre-operative",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "Intra-operative/Discharge",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "2 months",
                  "window_before_days": 0,
                  "window_after_days": 30,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "6 months",
                  "window_before_days": 0,
                  "window_after_days": 60,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-005",
                  "timepoint_name": "1 year",
                  "window_before_days": 0,
                  "window_after_days": 180,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-006",
                  "timepoint_name": "2 years",
                  "window_before_days": 0,
                  "window_after_days": 180,
                  "is_required": true
                }
              ],
              "recall_period": "past 4 weeks",
              "provenance": {
                "section_number": "7.6.2",
                "page_number": 29,
                "text_snippet": "Oxford Hip Score will be performed at pre-operative visit, discharge visit and, follow-Up 2 months (\u00b1 30 days), follow-Up 6 months (\u00b1 60 days), follow-Up 12 months (\u00b1 6 months) and follow-Up 24 months (\u00b1 6 months) since the date of the surgery."
              }
            },
            "scoring": {
              "total_score_available": true,
              "scoring_algorithm": "12 items, each scored 0-4. Total score range 0-48. Higher score is better outcome.",
              "provenance": {
                "section_number": "7.6.2",
                "page_number": 28,
                "text_snippet": "The OHS is a short 12-item survey that can be done with pen and paper. Patients are asked to reflect on their pain and functional ability over the previous weeks. There are two domains (pain and function) with six items or questions in each, using the following scoring: each question has been scored between 0 and 4, with 4 being the best outcome, producing overall scores running from 0 to 48, with 48 being the best outcome."
              }
            },
            "biomedicalConcept": {
              "conceptName": "Oxford Hip Score",
              "cdiscCode": "C103274",
              "domain": "QS",
              "confidence": 1
            },
            "provenance": {
              "section_number": "7.6.2",
              "page_number": 28,
              "text_snippet": "The Oxford Hip Score (OHS) is a joint-specific, patient-reported outcome (PRO) measure, or PROM, designed to assess disability in patients undergoing total hip replacement (THR) [10]."
            }
          }
        ],
        "epro_system": {
          "vendor_name": "LimaCorporate",
          "platform_name": "Sponsor-designated EDC system",
          "integration_with_edc": true,
          "provenance": {
            "section_number": "11.3",
            "page_number": 44,
            "text_snippet": "All data required in this study is collected on a proper eCRF provided by LimaCorporate. All data documented for each patient is associated to a study ID code composed by study centre code and patient number.\neCRFs are to be completed using a Sponsor-designated EDC system."
          }
        },
        "clinro_instruments": [
          {
            "instrument_id": "CLINRO-001",
            "instrument_name": "Range of Motion",
            "instrument_abbreviation": "ROM",
            "assessor": "investigator",
            "schedule": [
              "Pre-operative",
              "Intra-operative/Discharge",
              "2 months",
              "6 months",
              "1 year",
              "2 years"
            ],
            "biomedicalConcept": {
              "conceptName": "Range of Motion",
              "cdiscCode": "C25233",
              "domain": "QS",
              "confidence": 1
            },
            "provenance": {
              "section_number": null,
              "page_number": 10,
              "text_snippet": "Secondary endpoints:\n- Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;"
            }
          },
          {
            "instrument_id": "CLINRO-002",
            "instrument_name": "Radiographic Implant Evaluation",
            "assessor": "investigator",
            "schedule": [
              "Discharge",
              "2 months",
              "6 months",
              "1 year",
              "2 years"
            ],
            "biomedicalConcept": {
              "conceptName": "Radiography",
              "cdiscCode": "C16955",
              "domain": "QS",
              "confidence": 1
            },
            "provenance": {
              "section_number": null,
              "page_number": 10,
              "text_snippet": "Radiographic implant evaluation and stability assessment of the DELTA Revision acetabular cup at the following timepoints: at discharge, 2 months, 6 months, 1 year, and 2 years after the implant"
            }
          }
        ],
        "obsro_instruments": [],
        "perfo_instruments": [],
        "daily_diary": null,
        "analysis_specifications": {
          "primary_pro_endpoint": "Evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant.",
          "secondary_pro_endpoints": [
            "Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant",
            "Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant",
            "Survivorship of the implant (Kaplan-Meier estimate) at 2 years of follow-up after surgery",
            "Radiographic implant evaluation and stability assessment of the DELTA Revision acetabular cup at discharge, 2 months, 6 months, 1 year, and 2 years after the implant"
          ],
          "analysis_population": "All enrolled subjects",
          "statistical_methods": [
            "Standard one-sided paired T-test for the primary endpoint (HHS change from baseline)",
            "Descriptive statistics for secondary endpoints (ROM, OHS, radiographic evaluation)",
            "Kaplan-Meier methods for survival of the implant"
          ],
          "responder_analysis_planned": true,
          "time_to_event_analysis_planned": true,
          "provenance": {
            "section_number": null,
            "page_number": 10,
            "text_snippet": "Primary endpoints:\nThe evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant.\n\nSecondary endpoints:\n- Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;\n- Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;"
          }
        },
        "extraction_statistics": {
          "pro_instrument_count": 2,
          "clinro_count": 2,
          "obsro_count": 0,
          "perfo_count": 0,
          "has_epro": true,
          "has_daily_diary": false,
          "total_assessment_timepoints": 6
        },
        "provenance": {
          "section_number": "7",
          "page_number": 26,
          "text_snippet": "7 Study assessment"
        }
      },
      "_agentDocumentation": {
        "agentId": "pro_specifications",
        "displayName": "PRO/eCOA Specifications",
        "instanceType": "PROSpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts patient-reported outcome specifications for ePRO/eCOA vendor configuration.",
        "scope": "PRO instruments, ePRO system config, ClinRO/ObsRO/PerfO instruments, daily diaries, compliance thresholds.",
        "keySectionsAnalyzed": [
          "Section 7: Efficacy Assessments",
          "Section 8: Patient-Reported Outcomes",
          "Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "PRO Instruments",
            "description": "Questionnaires with administration mode, timing, scoring",
            "dataPath": "pro_instruments[]",
            "downstreamUses": [
              "ePRO vendor setup",
              "Site training",
              "Compliance monitoring"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EPRO_CONFIG_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Patient-Reported Outcomes",
                "description": "Generate ePRO vendor configuration from PRO specifications",
                "sourceDataPath": "pro_instruments[]",
                "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Patient-Reported Outcomes",
          "Electronic Clinical Outcome Assessment",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure ePRO/eCOA vendor systems",
          "Set up compliance monitoring and alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "endpoints_estimands_sap"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "QS",
          "RS"
        ],
        "regulatoryRelevance": "FDA PRO Guidance, ICH M11 Section 7.4",
        "schemaFile": "pro_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "EPRO_CONFIG_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Patient-Reported Outcomes",
            "description": "Generate ePRO vendor configuration from PRO specifications",
            "sourceDataPath": "pro_instruments[]",
            "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_PRO_SOA_001",
            "name": "PRO + SOA \u2192 Complete ePRO Schedule",
            "agentsInvolved": [
              "pro_specifications",
              "soa_schedule"
            ],
            "description": "PRO instruments + visit timing = exact ePRO administration schedule",
            "combinedInsight": "Which PRO at which visit with what window = Complete ePRO schedule",
            "automationEnabled": "ePRO system auto-schedules assessments based on subject visit dates",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "dataManagement": {
      "moduleId": "data_management",
      "instanceType": "DataManagement",
      "data": {
        "id": "H-34-data-management",
        "instanceType": "DataManagementPlan",
        "name": "H-34 Data Management Plan",
        "edc_specifications": {
          "instanceType": "EDCSpecifications",
          "vendor_name": "LimaCorporate Designated EDC",
          "system_capabilities": [
            "imaging_upload",
            "audit_trail"
          ],
          "integration_systems": [],
          "language_requirements": [
            "English"
          ],
          "crf_modules": [
            {
              "id": "crf-001",
              "module_name": "Screening & Enrollment",
              "forms": [
                "Informed Consent",
                "Inclusion/Exclusion Criteria"
              ],
              "visit_schedule": [
                "Pre-operative Visit"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Appendix 1",
                "page_number": 53,
                "text_snippet": "Informed Consent a X\nInclusion/exclusion criteria X"
              }
            },
            {
              "id": "crf-002",
              "module_name": "Baseline Characteristics",
              "forms": [
                "Demographics",
                "Medical History",
                "Vital Signs"
              ],
              "visit_schedule": [
                "Pre-operative Visit"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Appendix 1",
                "page_number": 53,
                "text_snippet": "Demographics b X\nMedical history c X\nVital signs d X"
              }
            },
            {
              "id": "crf-003",
              "module_name": "Surgical & Implant Data",
              "forms": [
                "Surgical Procedures",
                "Implant Details"
              ],
              "visit_schedule": [
                "Intra-operative/Discharge visit"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Appendix 1",
                "page_number": 53,
                "text_snippet": "Surgery and Implant data f X"
              }
            },
            {
              "id": "crf-004",
              "module_name": "Clinical & Functional Assessments",
              "forms": [
                "Harris Hip Score (HHS)",
                "Range of Motion (ROM)",
                "Oxford Hip Score (OHS)",
                "Physical Examination"
              ],
              "visit_schedule": [
                "Pre-operative Visit",
                "Intra-operative/Discharge visit",
                "Follow-up"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Appendix 1",
                "page_number": 53,
                "text_snippet": "Physical examination X X X\nHaris Hip Score (HHS) and Range of motion (ROM) X X X\nOxford Hip Score (OHS) X X X"
              }
            },
            {
              "id": "crf-005",
              "module_name": "Radiographical Evaluation",
              "forms": [
                "X-Ray Image Upload",
                "Radiographic Assessments"
              ],
              "visit_schedule": [
                "Intra-operative/Discharge visit",
                "Follow-up"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Appendix 1",
                "page_number": 53,
                "text_snippet": "Radiographical evaluation X X X"
              }
            },
            {
              "id": "crf-006",
              "module_name": "Safety Reporting",
              "forms": [
                "Adverse Events",
                "Serious Adverse Events"
              ],
              "visit_schedule": [
                "Intra-operative/Discharge visit",
                "Follow-up"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Appendix 1",
                "page_number": 53,
                "text_snippet": "AE reporting h X X X"
              }
            },
            {
              "id": "crf-007",
              "module_name": "Medications",
              "forms": [
                "Concomitant Medications"
              ],
              "visit_schedule": [
                "Pre-operative Visit",
                "Intra-operative/Discharge visit",
                "Follow-up"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Appendix 1",
                "page_number": 53,
                "text_snippet": "Medications g X X X"
              }
            }
          ],
          "provenance": {
            "section_number": "11.3",
            "page_number": 44,
            "text_snippet": "All data required in this study is collected on a proper eCRF provided by LimaCorporate. All data documented for each patient is associated to a study ID code composed by study centre code and patient number. eCRFs are to be completed using a Sponsor-designated EDC system."
          }
        },
        "data_standards": {
          "instanceType": "DataStandards",
          "sdtm_version": null,
          "sdtm_ig_version": null,
          "adam_version": null,
          "controlled_terminology": {
            "cdisc_ct_version": null,
            "meddra_version": null,
            "whodrug_version": null,
            "snomed_version": null
          },
          "define_xml_required": false,
          "define_xml_version": null,
          "adrg_required": false,
          "sdrg_required": false,
          "provenance": {
            "section_number": "11",
            "page_number": 43,
            "text_snippet": "11 Data collection and management"
          }
        },
        "data_quality": {
          "instanceType": "DataQuality",
          "edit_checks": {
            "standard_checks": [
              "consistency_checks",
              "required_fields"
            ],
            "protocol_specific_checks": [],
            "auto_query_enabled": false
          },
          "sdv_strategy": {
            "approach": "targeted",
            "sdv_percentage": null,
            "critical_data_points": [
              "critical protocol data"
            ],
            "sdv_timing": "hybrid"
          },
          "query_management": {
            "resolution_target_days": null,
            "escalation_threshold_days": null,
            "auto_query_triggers": []
          },
          "data_review": {
            "medical_review_frequency": null,
            "statistical_review_frequency": null,
            "data_review_committee": false
          },
          "provenance": {
            "section_number": "11.4",
            "page_number": 45,
            "text_snippet": "Study monitors will perform ongoing SDV to confirm that critical protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, complete, and verifiable from source documents."
          }
        },
        "database_management": {
          "instanceType": "DatabaseManagement",
          "database_design": {
            "external_data_sources": [
              "imaging"
            ],
            "calculated_fields": [
              "BMI"
            ],
            "derived_variables": [
              "Time to Event"
            ]
          },
          "interim_locks": [],
          "final_database_lock": {
            "trigger_event": null,
            "timeline_days_from_lplv": null,
            "prerequisites": [
              "All CRF pages completed",
              "All queries resolved"
            ],
            "signoff_required": [],
            "provenance": {
              "section_number": "11.2",
              "page_number": 44,
              "text_snippet": "At the end of the trial, the Principal Investigator should confirm that the data in CRF are reliable, accurate and complete."
            }
          },
          "provenance": {
            "section_number": "11.2",
            "page_number": 44,
            "text_snippet": "The eCRFs and patient's questionnaires data transferred/sent from the investigational site to the Sponsor and/or Sponsor- assigned CRO and directed by the Sponsor will be reviewed for completeness, consistency, legibility and protocol compliance."
          }
        },
        "data_transfers": {
          "instanceType": "DataTransfers",
          "central_lab": null,
          "imaging": {
            "vendor_name": null,
            "data_collected": [
              "X-rays"
            ],
            "transfer_method": null
          },
          "epro": null,
          "external_adjudication": null,
          "dsmb_exports": null,
          "provenance": {
            "section_number": "7.7",
            "page_number": 29,
            "text_snippet": "The anonymized X-rays data have to be uploaded directly in the eCRF."
          }
        },
        "data_archival": {
          "instanceType": "DataArchival",
          "retention_period_years": 15,
          "retention_basis": "EN ISO 14155:2020",
          "archival_format": [
            "electronic"
          ],
          "archival_location": "sponsor",
          "destruction_policy": "Documents may be destroyed after retention period with written approval of the Sponsor, subject to local regulations.",
          "provenance": {
            "section_number": "11.5",
            "page_number": 45,
            "text_snippet": "Records and documents pertaining to the conduct of this study, including eCRFs, patient's questionnaires and scores, Informed Consent Forms, laboratory test results, and implant records, must be retained by the Principal Investigator for at least 15 years after completion of the study, or for the length of time required by relevant national or local health authorities, whichever is longer in a secure place. After that period of time, the documents may be destroyed, subject to local regulations."
          }
        },
        "extraction_statistics": {
          "has_edc_specifications": true,
          "has_data_standards": false,
          "has_sdv_strategy": true,
          "has_database_lock_plan": false,
          "integration_count": 0,
          "crf_module_count": 7
        },
        "provenance": {
          "section_number": "11",
          "page_number": 43,
          "text_snippet": "11 Data collection and management"
        }
      },
      "_agentDocumentation": {
        "agentId": "data_management",
        "displayName": "Data Management",
        "instanceType": "DataManagement",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts data management specifications for EDC setup and data management planning.",
        "scope": "EDC requirements, CDISC standards versions, data entry timelines, query management, database lock procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Data Management",
          "Section 11: Quality Assurance",
          "Appendix: Data Management Plan"
        ],
        "keyInsights": [
          {
            "name": "CDISC Standards",
            "description": "Required CDASH, SDTM, ADaM versions",
            "dataPath": "cdisc_standards",
            "downstreamUses": [
              "CRF standards library selection",
              "SDTM mapping",
              "ADaM specifications"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure EDC data entry timelines",
          "Set up CDISC standards compliance checks"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "All"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR Part 11",
        "schemaFile": "data_management_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "siteOperationsLogistics": {
      "moduleId": "site_operations_logistics",
      "instanceType": "SiteOperationsLogistics",
      "data": {
        "id": "H-34-site-operations-logistics",
        "instanceType": "SiteOperationsLogistics",
        "name": "H-34 Site Operations & Logistics",
        "site_selection": {
          "instanceType": "SiteSelectionCriteria",
          "required_criteria": [
            {
              "id": "REQ-001",
              "criterion": "Sufficient patient volume",
              "description": "Site must have a sufficient number of patients who will receive total hip arthroplasty with the DELTA Revision acetabular cup per year.",
              "assessment_method": "Review of site's patient volume data.",
              "minimum_requirement": "Not specified",
              "provenance": {
                "section_number": null,
                "page_number": 11,
                "text_snippet": "Centres will be selected based on the number of patients who will receive total hip arthroplasty with DELTA Revision acetabular cup per year."
              }
            }
          ],
          "preferred_criteria": [],
          "exclusionary_criteria": [],
          "geographic_requirements": {
            "countries": [],
            "regions": [],
            "site_count_target": 1,
            "language_requirements": [],
            "provenance": {
              "section_number": null,
              "page_number": 11,
              "text_snippet": "Expected number of study centres: 1"
            }
          },
          "facility_requirements": {
            "patient_population_access": null,
            "equipment_required": [
              "Surgical facilities for total hip arthroplasty",
              "X-ray equipment for AP and lateral hip views"
            ],
            "laboratory_capabilities": [],
            "pharmacy_capabilities": null,
            "storage_capabilities": "Controlled rooms for sterile device storage at ambient temperature (0-50\u00b0 C).",
            "provenance": {
              "section_number": "6.1.1",
              "page_number": 22,
              "text_snippet": "Delta Revision acetabular cups are provided sterile and should be stored at ambient temperature (indicative range 0-50\u00b0 C / 32-122\u00b0F) in their protective closed packaging in controlled rooms, protected from exposure to light, heat and sudden changes in temperature."
            }
          },
          "experience_requirements": {
            "therapeutic_area_experience": "Orthopaedic surgery, specifically joint replacement procedures.",
            "phase_experience": "Post-market observational study experience.",
            "enrollment_history": null,
            "gcp_compliance_record": "Must be able to conduct the study in full conformance with EN ISO 14155:2020.",
            "provenance": {
              "section_number": "12.1",
              "page_number": 45,
              "text_snippet": "This study will be conducted in full conformance with the EN ISO 14155:2020 Clinical investigations of medical devices for human subjects \u2013 Good Clinical Practice and the principles of the Declaration of Helsinki, 2008"
            }
          },
          "provenance": {
            "section_number": null,
            "page_number": 11,
            "text_snippet": "Study sites no."
          }
        },
        "regulatory_ethics": {
          "instanceType": "RegulatoryEthics",
          "regulatory_authorities": [
            {
              "id": "AUTH-001",
              "authority_name": "Applicable Local Health Authorities",
              "country_region": "Site-specific",
              "submission_type": "Clinical Investigation Notification/Approval",
              "submission_number": null,
              "approval_status": "required_prior_to_initiation",
              "approval_date": null,
              "special_designations": [],
              "provenance": {
                "section_number": "12.4",
                "page_number": 47,
                "text_snippet": "As required by applicable local regulations, the Sponsor will ensure all legal regulatory aspects are covered, and obtain approval of the appropriate regulatory bodies, prior to study initiation in regions where an approval is required."
              }
            }
          ],
          "ethics_committees": [
            {
              "id": "EC-001",
              "committee_type": "IRB/EC",
              "centralized_or_local": "local",
              "approval_requirements": "Approval of protocol, informed consent form, and any patient-facing materials is required before study initiation.",
              "approval_timeline": null,
              "continuing_review_frequency": "annual",
              "provenance": {
                "section_number": "12.3",
                "page_number": 46,
                "text_snippet": "This protocol, the Informed Consent Forms, any information to be given to the patient, and relevant supporting information must be submitted to the IRB/EC by the Principal Investigator and Sponsor and reviewed and approved by the IRB/EC before the study is initiated... The Principal Investigator is responsible for providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the"
              }
            }
          ],
          "informed_consent": {
            "consent_type": "written",
            "languages_required": [
              "Local language, readily understood by the patient"
            ],
            "reconsent_triggers": [
              "protocol_amendment",
              "availability of important new information"
            ],
            "assent_required": false,
            "electronic_consent_allowed": false,
            "provenance": {
              "section_number": "12.2",
              "page_number": 46,
              "text_snippet": "The patient will be required to provide written informed consent to confirm that they allow their medical data to be collected and analysed... The sponsor will provide a sample informed consent form, in language readily understood by the patient... If during the study important new information becomes available, the consent form will be revised."
            }
          },
          "data_privacy": {
            "applicable_regulations": [
              "Local data privacy laws"
            ],
            "data_transfer_requirements": "Patient data will be anonymized and identified by a patient number for transmission to the sponsor.",
            "anonymization_requirements": "Patient names are not included in data sets transmitted to the Sponsor. Data is coded with a unique patient identification number.",
            "provenance": {
              "section_number": "12.5",
              "page_number": 47,
              "text_snippet": "The Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in data sets that are transmitted to any Sponsor location."
            }
          },
          "provenance": {
            "section_number": "12",
            "page_number": 45,
            "text_snippet": "Ethical Consideration"
          }
        },
        "site_personnel": {
          "instanceType": "SitePersonnel",
          "principal_investigator": {
            "qualifications_required": [
              "Orthopaedic surgeon",
              "Good knowledge of the specific operative technique for the study device"
            ],
            "responsibilities": [
              "Overall study conduct",
              "Obtaining informed consent",
              "Data collection and recording",
              "AE/SAE reporting",
              "Maintaining study documentation",
              "Ensuring compliance with protocol and regulations"
            ],
            "delegation_restrictions": [],
            "time_commitment": null,
            "provenance": {
              "section_number": null,
              "page_number": 3,
              "text_snippet": "I agree to conduct this clinical study in accordance with the design and specific provisions of this protocol; modifications to the study or protocol are acceptable only with a mutually agreed upon protocol amendment. I agree to await Ethics Committee approval for the protocol and informed consent before initiating the study, to obtain informed consent from subjects prior to their enrolment in the study, to collect and record data as required by this protocol and case report forms, to prepare"
            }
          },
          "sub_investigators": {
            "provenance": {
              "section_number": null,
              "page_number": 3,
              "text_snippet": "Investigator's Statement and Signature"
            }
          },
          "coordinators": {
            "provenance": {
              "section_number": null,
              "page_number": 3,
              "text_snippet": "Investigator's Statement and Signature"
            }
          },
          "other_personnel": [
            {
              "id": "PERS-001",
              "role": "Designated site staff",
              "responsibilities": [
                "eCRF completion"
              ],
              "qualifications": [
                "Trained on the EDC system"
              ],
              "provenance": {
                "section_number": "11.3",
                "page_number": 44,
                "text_snippet": "eCRFs are to be completed using a Sponsor-designated EDC system. Sites will receive training and have access to a manual for appropriate eCRF completion. ... All eCRFs should be completed by designated, trained site staff."
              }
            }
          ],
          "provenance": {
            "section_number": null,
            "page_number": 3,
            "text_snippet": "Investigator's Statement and Signature"
          }
        },
        "training_requirements": {
          "instanceType": "TrainingRequirements",
          "protocol_training": {
            "required_for": [
              "PI",
              "Surgeons"
            ],
            "format": null,
            "duration": null,
            "assessment_required": false,
            "completion_deadline": "before_performing_procedure",
            "provenance": {
              "section_number": "6.1",
              "page_number": 21,
              "text_snippet": "The Delta System must be used exclusively by orthopaedic surgeons having a good knowledge of the specific surgical techniques: it is indicated for use in total hip arthroplasty."
            }
          },
          "gcp_training": {
            "required": true,
            "frequency": null,
            "certification_required": false,
            "accepted_providers": [],
            "provenance": {
              "section_number": "12.1",
              "page_number": 45,
              "text_snippet": "This study will be conducted in full conformance with the EN ISO 14155:2020 Clinical investigations of medical devices for human subjects \u2013 Good Clinical Practice"
            }
          },
          "specialized_training": [
            {
              "id": "TRAIN-001",
              "training_name": "EDC System Training",
              "required_for": [
                "Site personnel responsible for data entry"
              ],
              "certification_required": false,
              "renewal_period": null,
              "provenance": {
                "section_number": "11.3",
                "page_number": 44,
                "text_snippet": "eCRFs are to be completed using a Sponsor-designated EDC system. Sites will receive training and have access to a manual for appropriate eCRF completion. The site personnel, once the training is completed, will receive personal password to not share with other staff members."
              }
            },
            {
              "id": "TRAIN-002",
              "training_name": "Surgical Technique for DELTA Revision Acetabular Cup",
              "required_for": [
                "Surgeons implanting the device"
              ],
              "certification_required": false,
              "renewal_period": null,
              "provenance": {
                "section_number": "6.1",
                "page_number": 21,
                "text_snippet": "The Delta System must be used exclusively by orthopaedic surgeons having a good knowledge of the specific surgical techniques: it is indicated for use in total hip arthroplasty."
              }
            }
          ],
          "training_documentation": {},
          "provenance": {
            "section_number": "11.3",
            "page_number": 44,
            "text_snippet": "eCRFs are to be completed using a Sponsor-designated EDC system. Sites will receive training and have access to a manual for appropriate eCRF completion."
          }
        },
        "monitoring_plan": {
          "instanceType": "MonitoringPlan",
          "monitoring_approach": "traditional",
          "site_initiation_visit": {
            "provenance": {
              "section_number": "13.3",
              "page_number": 48,
              "text_snippet": "13.3 Monitoring procedures"
            }
          },
          "routine_monitoring": {
            "frequency": null,
            "visit_type": "on_site",
            "sdv_percentage": 100,
            "sdv_scope": [
              "Critical protocol data"
            ],
            "remote_monitoring_activities": [
              "Review of eCRF data"
            ],
            "provenance": {
              "section_number": "11.4",
              "page_number": 45,
              "text_snippet": "Study monitors will perform ongoing SDV to confirm that critical protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, complete, and verifiable from source documents."
            }
          },
          "triggered_monitoring": {
            "provenance": {
              "section_number": "13.3",
              "page_number": 48,
              "text_snippet": "13.3 Monitoring procedures"
            }
          },
          "close_out_visit": {
            "provenance": {
              "section_number": "13.3",
              "page_number": 48,
              "text_snippet": "13.3 Monitoring procedures"
            }
          },
          "provenance": {
            "section_number": "13.3",
            "page_number": 48,
            "text_snippet": "The investigator is responsible for the validity of all data collected at the site. The Sponsor is responsible for collecting these data and verifying that the study is conducted in compliance with the protocol, EN ISO 14155:2020 Clinical investigations of medical devices for human subjects \u2013 Good Clinical Practice and regulatory requirements.\nSponsor assigned monitors may conduct site visits."
          }
        },
        "site_activation_timeline": {
          "instanceType": "SiteActivationTimeline",
          "site_selection_phase": null,
          "feasibility_assessment": null,
          "contract_negotiation": null,
          "regulatory_submission": null,
          "ethics_approval": null,
          "site_training": null,
          "site_initiation_visit": null,
          "first_patient_ready": null,
          "critical_path_items": [
            "Ethics Committee approval",
            "Regulatory approval (if required)"
          ],
          "provenance": {
            "section_number": null,
            "page_number": 3,
            "text_snippet": "I agree to await Ethics Committee approval for the protocol and informed consent before initiating the study"
          }
        },
        "drug_supply_logistics": {
          "instanceType": "DrugSupplyLogistics",
          "packaging_labeling": {
            "blinding_requirements": "open_label",
            "label_languages": [],
            "temperature_indicators": false,
            "tamper_evident": false,
            "kit_design": "Device is provided sterile in protective closed packaging with labels.",
            "provenance": {
              "section_number": "6.1.1",
              "page_number": 22,
              "text_snippet": "Delta Revision acetabular cups are provided sterile and should be stored at ambient temperature (indicative range 0-50\u00b0 C / 32-122\u00b0F) in their protective closed packaging in controlled rooms... Once the package is opened, ensure that both the model and size of the implant correspond to the description printed on the labels."
            }
          },
          "storage_distribution": {
            "storage_temperature": "0-50\u00b0C",
            "distribution_model": "direct_to_site",
            "cold_chain_required": false,
            "shelf_life_months": null,
            "shipping_conditions": "Protected from light, heat, and sudden temperature changes.",
            "provenance": {
              "section_number": "6.1.1",
              "page_number": 22,
              "text_snippet": "Delta Revision acetabular cups are provided sterile and should be stored at ambient temperature (indicative range 0-50\u00b0 C / 32-122\u00b0F) in their protective closed packaging in controlled rooms, protected from exposure to light, heat and sudden changes in temperature."
            }
          },
          "inventory_management": {
            "iwrs_rtsm_system": null,
            "kit_design": "It is recommended that additional implants of different sizes be available during surgery.",
            "resupply_triggers": null,
            "resupply_threshold_days": null,
            "expiry_management": "Do not use implants after the expiration date printed on the label.",
            "provenance": {
              "section_number": "6.1.2",
              "page_number": 23,
              "text_snippet": "Do not use implants after the expiration date printed on the label."
            }
          },
          "dispensing_schedule": [],
          "drug_accountability": {
            "accountability_frequency": "At time of implant",
            "accountability_method": "Device code and lot number recorded in patient's case history.",
            "documentation_requirements": "Record device details (type, size, material, batch number, expire date) in eCRF and source documents.",
            "discrepancy_handling": null,
            "provenance": {
              "section_number": "7.8",
              "page_number": 34,
              "text_snippet": "Implant data for Delta Revision acetabular cup include the type, size, material, batch number and expire date: the label of acetabular cup implanted has to be archived also in the source documents. All above mentioned data for surgery and device have to be collected in the eCRF."
            }
          },
          "drug_return_destruction": {
            "return_required": false,
            "return_timing": null,
            "destruction_method": "Disposal of medical devices is to be performed by the hospitals in conformity with applicable laws.",
            "destruction_documentation": null,
            "environmental_requirements": null,
            "provenance": {
              "section_number": "6.1.1",
              "page_number": 22,
              "text_snippet": "The disposal of medical devices is to be performed by the hospitals in conformity with applicable laws."
            }
          },
          "dosing_error_handling": {},
          "comparator_medications": [],
          "emergency_unblinding": {},
          "provenance": {
            "section_number": "6",
            "page_number": 20,
            "text_snippet": "Study device and surgical procedures"
          }
        },
        "technology_systems": {
          "instanceType": "TechnologySystems",
          "edc_system": {
            "vendor_name": "Sponsor-designated EDC system provided by LimaCorporate",
            "system_capabilities": [
              "audit_trail"
            ],
            "integration_requirements": [],
            "language_requirements": [],
            "provenance": {
              "section_number": "11.3",
              "page_number": 44,
              "text_snippet": "All data required in this study is collected on a proper eCRF provided by LimaCorporate. ... eCRFs are to be completed using a Sponsor-designated EDC system."
            }
          },
          "iwrs_rtsm": {
            "provenance": {
              "section_number": "11",
              "page_number": 43,
              "text_snippet": "11 Data collection and management"
            }
          },
          "epro_devices": {
            "provenance": {
              "section_number": "11",
              "page_number": 43,
              "text_snippet": "11 Data collection and management"
            }
          },
          "central_services": [],
          "provenance": {
            "section_number": "11",
            "page_number": 43,
            "text_snippet": "11 Data collection and management"
          }
        },
        "equipment_facilities": {
          "instanceType": "EquipmentFacilities",
          "specialized_equipment": [
            {
              "id": "EQUIP-001",
              "equipment": "Reusable surgical instruments for Delta System",
              "required_or_preferred": "required",
              "specifications": "Must be instruments specifically designed for use with the implants being used.",
              "calibration_frequency": null,
              "provenance": {
                "section_number": "6.1.1",
                "page_number": 22,
                "text_snippet": "The Instruments used for implantation of the Delta System are reusable surgical instruments."
              }
            },
            {
              "id": "EQUIP-002",
              "equipment": "X-ray equipment",
              "required_or_preferred": "required",
              "specifications": "Capable of performing AP pelvis, AP hip, and lateral hip views.",
              "calibration_frequency": null,
              "provenance": {
                "section_number": "7.7",
                "page_number": 29,
                "text_snippet": "Radiological assessment was carried out preoperatively and postoperatively at discharge, at 2 months, 6 months, 12 months, and 24 months after surgery. It included standard views, such as antero-posterior (AP) of the pelvis, antero-posterior (AP) and lateral (LAT) of the affected hip."
              }
            }
          ],
          "facility_requirements": {
            "patient_space": "Orthopaedic surgery operating room.",
            "storage_space": "Controlled rooms for sterile device storage.",
            "safety_equipment": [],
            "provenance": {
              "section_number": "6.1.1",
              "page_number": 22,
              "text_snippet": "Delta Revision acetabular cups are provided sterile and should be stored at ambient temperature (indicative range 0-50\u00b0 C / 32-122\u00b0F) in their protective closed packaging in controlled rooms"
            }
          },
          "provenance": {
            "section_number": "6",
            "page_number": 20,
            "text_snippet": "6 Study device and surgical procedures"
          }
        },
        "vendor_coordination": [
          {
            "id": "VENDOR-001",
            "vendor_type": "CRO",
            "vendor_name": "External contract research organisation",
            "services_provided": [
              "Statistical analyses",
              "Data management",
              "Study conduct support"
            ],
            "site_interface_required": true,
            "training_required": false,
            "contact_info": null,
            "provenance": {
              "section_number": "10.4",
              "page_number": 42,
              "text_snippet": "Statistical analyses will be performed by an external contract research organisation (CRO) and/or consultant, managed by the Sponsor."
            }
          }
        ],
        "extraction_statistics": {
          "has_site_selection_criteria": true,
          "has_regulatory_info": true,
          "has_personnel_requirements": true,
          "has_training_requirements": true,
          "has_monitoring_plan": true,
          "has_activation_timeline": true,
          "has_drug_supply_info": true,
          "has_technology_systems": true,
          "has_dispensing_schedule": false,
          "has_drug_accountability": true,
          "has_emergency_unblinding": false,
          "site_count_target": 1,
          "country_count": 0,
          "vendor_count": 1,
          "comparator_medication_count": 0
        },
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "Study protocol\n\nAn open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
        }
      },
      "_agentDocumentation": {
        "agentId": "site_operations_logistics",
        "displayName": "Site Operations & Logistics",
        "instanceType": "SiteOperationsLogistics",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts site operational requirements for site initiation planning and CTMS configuration.",
        "scope": "Site equipment, training requirements, drug storage, IP accountability, vendor coordination.",
        "keySectionsAnalyzed": [
          "Section 9: Study Procedures",
          "Section 10: Drug Supply",
          "Appendix: Site Requirements"
        ],
        "keyInsights": [
          {
            "name": "Equipment Requirements",
            "description": "Site equipment needs for assessments",
            "dataPath": "equipment_requirements[]",
            "downstreamUses": [
              "Site feasibility",
              "Site initiation checklist",
              "Budget planning"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Trial Master File"
        ],
        "automationUseCases": [
          "Generate site initiation checklists",
          "Configure LMS training assignments"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "arms_design",
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "site_operations_logistics_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "qualityManagement": {
      "moduleId": "quality_management",
      "instanceType": "QualityManagement",
      "data": {
        "id": "H-34-quality-management",
        "instanceType": "QualityManagement",
        "name": "H-34 Quality Management",
        "ich_m11_section": "6.3",
        "monitoring": {
          "monitoring_approach": {
            "instanceType": "MonitoringApproach",
            "strategy": "hybrid",
            "rationale": "A hybrid approach combining on-site visits with remote data review is employed to ensure compliance with EN ISO 14155:2020 and focus on critical data and processes in this post-market observational study.",
            "regulatory_framework": [
              "ICH_E6_R2"
            ],
            "adaptive_monitoring": true,
            "centralized_monitoring_enabled": true,
            "centralized_monitoring_tools": [
              "statistical_monitoring",
              "KRI_dashboard"
            ],
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The strategy is derived as 'hybrid' because the protocol mentions both on-site visits and remote review. The rationale and other elements are inferred from standard practices for a post-market study compliant with ISO 14155, as the protocol lacks a detailed monitoring plan.",
                "supporting_context": [
                  "Section 13.3: 'Sponsor assigned monitors may conduct site visits.'",
                  "Section 13.3: '...to allow review by the study monitor, both remotely via the internet and during site visits.'",
                  "Section 13.3: '...verifying that the study is conducted in compliance with the protocol, EN ISO 14155:2020...'"
                ],
                "confidence": "medium"
              }
            }
          },
          "sdv_strategy": {
            "instanceType": "SDVStrategy",
            "overall_approach": "risk_based",
            "default_sdv_percentage": 30,
            "critical_data_100_percent": [
              "informed_consent",
              "eligibility_criteria",
              "primary_endpoint",
              "SAEs",
              "withdrawal_reason"
            ],
            "sdv_reduction_criteria": {
              "enabled": false,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not mention criteria for reducing SDV. This is inferred as not enabled based on the absence of a detailed risk-based monitoring plan.",
                  "supporting_context": [
                    "Section 11.4 mentions SDV but provides no details on reduction strategies."
                  ],
                  "confidence": "medium"
                }
              }
            },
            "sdv_escalation_criteria": {
              "error_rate_threshold_percent": 5,
              "escalated_sdv_percentage": 100,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not specify SDV escalation criteria. These values represent common industry standards for a risk-based approach, which is not detailed in the protocol.",
                  "supporting_context": [
                    "Section 11.4: 'Study monitors will perform ongoing SDV to confirm that critical protocol data... are accurate, complete, and verifiable...'"
                  ],
                  "confidence": "low"
                }
              }
            },
            "remote_sdv_enabled": true,
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The SDV strategy is derived based on standard clinical practice. The protocol confirms SDV will occur but does not specify the approach (e.g., risk-based) or percentages. Critical data points are inferred from the study's primary objectives and safety parameters.",
                "supporting_context": [
                  "Section 11.4: 'Study monitors will perform ongoing SDV to confirm that critical protocol data... are accurate, complete, and verifiable from source documents.'"
                ],
                "confidence": "medium"
              }
            }
          },
          "monitoring_visits": {
            "instanceType": "MonitoringVisits",
            "site_initiation_visit": {
              "required": true,
              "timing": "Before first subject enrolled",
              "format": "on_site",
              "key_activities": [
                "protocol_training",
                "EDC_training",
                "safety_reporting_procedures_review"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "A Site Initiation Visit is a standard requirement for Good Clinical Practice but is not explicitly described in the protocol. The timing, format, and activities are based on industry standards.",
                  "supporting_context": [
                    "General GCP principles implied by compliance with EN ISO 14155:2020 (Section 13.3)."
                  ],
                  "confidence": "high"
                }
              }
            },
            "routine_monitoring": {
              "on_site_visit_frequency": "risk_based_adaptive",
              "remote_monitoring_frequency": "monthly",
              "on_site_activities": [
                "ICF_review",
                "source_data_verification",
                "AE_SAE_review",
                "essential_document_collection"
              ],
              "remote_activities": [
                "data_listing_review",
                "KRI_monitoring",
                "query_management_review"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol confirms monitoring visits will occur but does not specify the frequency or a detailed list of activities. The listed activities and frequencies are derived from standard monitoring practices for a hybrid approach.",
                  "supporting_context": [
                    "Section 13.3: 'Sponsor assigned monitors may conduct site visits.'",
                    "Section 13.3: '...allow review by the study monitor, both remotely via the internet and during site visits.'"
                  ],
                  "confidence": "medium"
                }
              }
            },
            "triggered_visits": [
              {
                "id": "trigger-001",
                "trigger_type": "SAE_occurrence",
                "response_timeline_hours": 48,
                "actions": [
                  "phone_call_with_PI",
                  "review_source_documents_remotely"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not mention triggered visits. This trigger is inferred as a standard response to a critical safety event like an SAE, aligning with the 24-hour reporting requirement.",
                    "supporting_context": [
                      "Section 9.8: 'The investigator must report the following events to the Sponsor within 24 hours after learning of the event... SAEs'"
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "id": "trigger-002",
                "trigger_type": "KRI_threshold_breach",
                "response_timeline_hours": 72,
                "actions": [
                  "centralized_data_review",
                  "root_cause_analysis",
                  "determine_need_for_on-site_visit"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not mention triggered visits or KRIs. This is a standard component of a risk-based quality management system, which is not detailed in this protocol.",
                    "supporting_context": [
                      "General principles of risk-based monitoring."
                    ],
                    "confidence": "low"
                  }
                }
              }
            ],
            "close_out_visit": {
              "timing": "after_LPLV",
              "timing_days_after_event": 60,
              "format": "on_site",
              "activities": [
                "final_SDV",
                "essential_document_collection",
                "device_accountability_reconciliation"
              ],
              "site_release_criteria": [
                "all_CRFs_complete",
                "all_queries_resolved",
                "final_report_signed_by_PI"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "A Close-Out Visit is a standard requirement for Good Clinical Practice but is not explicitly described in the protocol. The timing, format, and activities are based on industry standards for study closure.",
                  "supporting_context": [
                    "Section 11.5: 'Records and documents pertaining to the conduct of this study... must be retained by the Principal Investigator for at least 15 years after completion of the study...'"
                  ],
                  "confidence": "high"
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The overall visit structure is derived from standard clinical trial practice. The protocol confirms 'site visits' will occur but does not specify the types, timing, or activities for each visit.",
                "supporting_context": [
                  "Section 13.3: 'Sponsor assigned monitors may conduct site visits.'"
                ],
                "confidence": "medium"
              }
            }
          },
          "key_risk_indicators": [
            {
              "id": "KRI-001",
              "instanceType": "KeyRiskIndicator",
              "name": "Informed Consent Compliance",
              "category": "protocol_compliance",
              "metric": "Percentage of subjects with a valid, dated informed consent form signed prior to any study procedures.",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "100%",
              "threshold_amber": "N/A",
              "threshold_red": "<100%",
              "action_amber": "N/A",
              "action_red": "Immediate site contact, root cause analysis, CAPA initiation.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is derived from the critical requirement to obtain informed consent before any study procedures. The protocol mandates this process, but does not define it as a KRI. The thresholds are binary because 100% compliance is required.",
                  "supporting_context": [
                    "Section 12.2: 'Prior to participation of a patient in this study, the investigator... will explain the nature and purpose of the data collection... The patient will be required to provide written informed consent... This must be obtained prior to enrolment and any data being entered in the study database.'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "KRI-002",
              "instanceType": "KeyRiskIndicator",
              "name": "Primary Endpoint Data Timeliness",
              "category": "data_integrity",
              "metric": "Percentage of Harris Hip Score (HHS) assessments entered into EDC more than 10 working days after the visit date.",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "<5%",
              "threshold_amber": "5-10%",
              "threshold_red": ">10%",
              "action_amber": "Notify site of data entry backlog and monitor progress.",
              "action_red": "Site call to address backlog, identify root cause (e.g., staffing), and agree on a resolution plan.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is derived from the protocol's requirement for timely eCRF data entry. The 10-day window is explicitly stated. The percentage thresholds and actions are based on standard industry practice for monitoring data quality, as they are not specified in the protocol.",
                  "supporting_context": [
                    "Section 13.3: 'The site must complete the eCRFs within 10 working days of the patient's visit...'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "KRI-003",
              "instanceType": "KeyRiskIndicator",
              "name": "SAE Reporting Timeliness",
              "category": "patient_safety",
              "metric": "Number of SAEs not reported to the sponsor within 24 hours of site awareness.",
              "data_source": "EDC",
              "review_frequency": "weekly",
              "threshold_green": "0",
              "threshold_amber": "N/A",
              "threshold_red": "\u22651",
              "action_amber": "N/A",
              "action_red": "Immediate follow-up with site to complete report, conduct root cause analysis, and provide retraining on safety reporting.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is directly derived from the protocol's explicit 24-hour reporting requirement for SAEs. The protocol mandates the timeline, but does not frame it as a KRI. The thresholds are binary because any late report is a significant issue.",
                  "supporting_context": [
                    "Section 9.8: 'The investigator must report the following events to the Sponsor within 24 hours after learning of the event... SAEs'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "KRI-004",
              "instanceType": "KeyRiskIndicator",
              "name": "Major Protocol Deviation Rate",
              "category": "protocol_compliance",
              "metric": "Rate of major protocol deviations per subject enrolled.",
              "data_source": "CTMS",
              "review_frequency": "monthly",
              "threshold_green": "<0.05",
              "threshold_amber": "0.05-0.10",
              "threshold_red": ">0.10",
              "action_amber": "Review deviation trends and discuss with site.",
              "action_red": "Investigate root cause of deviations, provide retraining, and consider a triggered monitoring visit.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not define protocol deviations or a KRI to monitor them. This KRI and its associated thresholds are derived from standard RBQM practices for maintaining study integrity.",
                  "supporting_context": [
                    "Section 5.5 lists 'Major protocol violation' as a reason for patient withdrawal, implying a process for their identification exists."
                  ],
                  "confidence": "low"
                }
              }
            },
            {
              "id": "KRI-05",
              "instanceType": "KeyRiskIndicator",
              "name": "Visit Compliance Rate",
              "category": "protocol_compliance",
              "metric": "Percentage of scheduled follow-up visits missed or outside the protocol-defined window.",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "<5%",
              "threshold_amber": "5-15%",
              "threshold_red": ">15%",
              "action_amber": "Discuss patient retention strategies with the site.",
              "action_red": "Implement patient retention plan, investigate reasons for missed visits, assess impact on data evaluability.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is derived from the visit schedule and windows defined in the protocol. Monitoring visit compliance is critical for data completeness, especially given the high assumed lost-to-follow-up rate. Thresholds are based on standard practice.",
                  "supporting_context": [
                    "Section 7: 'Follow-Up 2 months: \u00b1 30 days Follow-Up 6 months: \u00b1 60 days Follow-Up 12 months: \u00b1 6 months Follow-Up 24 months: \u00b1 6 months'"
                  ],
                  "confidence": "medium"
                }
              }
            }
          ],
          "quality_tolerance_limits": [
            {
              "id": "QTL-001",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Enrollment of subjects without valid informed consent",
              "category": "informed_consent",
              "acceptable_limit": "0 subjects",
              "acceptable_limit_numeric": 0,
              "alert_threshold": "N/A",
              "alert_threshold_numeric": null,
              "action_threshold": "1 subject",
              "action_threshold_numeric": 1,
              "predefined_actions": [
                "Halt enrollment",
                "Conduct root cause analysis of consent process",
                "Initiate CAPA",
                "Retrain site staff",
                "Notify IRB/EC"
              ],
              "escalation_path": [
                "project_manager",
                "sponsor_QA",
                "head_of_clinical_operations"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the absolute ethical and regulatory requirement for informed consent. The protocol mandates consent but does not define a QTL. The acceptable limit is zero, making any occurrence a breach of this critical tolerance limit.",
                  "supporting_context": [
                    "Section 12.2: 'The patient will be required to provide written informed consent to confirm that they allow their medical data to be collected and analysed. This must be obtained prior to enrolment...'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "QTL-002",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Percentage of subjects with one or more major protocol deviations impacting primary endpoint data",
              "category": "protocol_compliance",
              "acceptable_limit": "< 5% of total enrolled subjects",
              "acceptable_limit_numeric": 0.05,
              "alert_threshold": "3% of subjects",
              "alert_threshold_numeric": 0.03,
              "action_threshold": "5% of subjects",
              "action_threshold_numeric": 0.05,
              "predefined_actions": [
                "Review all deviations to identify trends",
                "Conduct root cause analysis",
                "Implement corrective actions (e.g., protocol clarification, site retraining)",
                "Assess impact on study analysis"
              ],
              "escalation_path": [
                "project_manager",
                "medical_monitor",
                "sponsor_QA"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not define QTLs or major deviations. This QTL is derived from standard RBQM practice (ICH E6 R2) to protect the integrity of the primary endpoint analysis. The thresholds are industry-standard values.",
                  "supporting_context": [
                    "Section 4.1 defines the primary endpoint (Harris Hip Score), which this QTL is designed to protect."
                  ],
                  "confidence": "low"
                }
              }
            },
            {
              "id": "QTL-003",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Lost to follow-up rate at the 2-year primary endpoint visit",
              "category": "data_integrity",
              "acceptable_limit": "< 20% of total enrolled subjects",
              "acceptable_limit_numeric": 0.2,
              "alert_threshold": "10% of subjects",
              "alert_threshold_numeric": 0.1,
              "action_threshold": "20% of subjects",
              "action_threshold_numeric": 0.2,
              "predefined_actions": [
                "Evaluate and enhance patient retention strategies",
                "Conduct analysis of reasons for withdrawal",
                "Consult with statisticians on impact to study power and analysis plan",
                "Document actions in study file"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the sample size calculation, which assumes a 40% loss to follow-up. A QTL is established at a lower threshold (20%) to provide an early warning and trigger action before the rate approaches the level that threatens study validity. The protocol does not define this as a QTL.",
                  "supporting_context": [
                    "Section 10.3: 'Assuming a 40% loss to follow-up, total enrolment for this study is set at 49 subjects.'"
                  ],
                  "confidence": "medium"
                }
              }
            }
          ],
          "findings_management": {
            "instanceType": "FindingsManagement",
            "finding_categories": [
              {
                "id": "finding-cat-001",
                "category": "critical",
                "definition": "A finding that directly impacts subject safety, well-being, or the integrity/interpretability of critical study data (e.g., failure to report an SAE, consent violation).",
                "response_timeline_days": 1,
                "requires_capa": true,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not define finding categories. This is derived from standard quality management systems, where issues impacting safety or primary data are considered critical.",
                    "supporting_context": [
                      "General principles of GCP and quality management."
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "id": "finding-cat-002",
                "category": "major",
                "definition": "A finding that could potentially impact subject safety or data integrity, or indicates a systemic issue (e.g., repeated minor deviations, incorrect procedure).",
                "response_timeline_days": 15,
                "requires_capa": true,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not define finding categories. This is derived from standard quality management systems.",
                    "supporting_context": [
                      "General principles of GCP and quality management."
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "id": "finding-cat-003",
                "category": "minor",
                "definition": "A finding that does not impact subject safety or data integrity but represents a departure from the protocol or SOPs (e.g., isolated documentation error).",
                "response_timeline_days": 30,
                "requires_capa": false,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not define finding categories. This is derived from standard quality management systems.",
                    "supporting_context": [
                      "General principles of GCP and quality management."
                    ],
                    "confidence": "medium"
                  }
                }
              }
            ],
            "capa_process": {
              "capa_triggers": [
                "critical_finding",
                "repeated_major_finding",
                "QTL_breach",
                "systemic_issue_identified"
              ],
              "response_timeline_days": 30,
              "verification_required": true,
              "tracking_system": "CTMS",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not describe a Corrective and Preventive Action (CAPA) process. This entire section is derived from standard quality management system requirements in a regulated clinical trial environment.",
                  "supporting_context": [
                    "General principles of GCP and quality management."
                  ],
                  "confidence": "low"
                }
              }
            },
            "protocol_deviation_management": {
              "deviation_categories": [
                "major",
                "minor"
              ],
              "internal_reporting_timeline_days": 5,
              "irb_reporting_required": true,
              "irb_reporting_timeline_days": 15,
              "root_cause_analysis_required": true,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol mentions 'Major protocol violation' as a reason for withdrawal but does not detail a management process. This framework is derived from standard clinical operations procedures for handling protocol deviations.",
                  "supporting_context": [
                    "Section 5.5: 'Major protocol violation that may jeopardize the patient's safety according to the Sponsor and Investigator'"
                  ],
                  "confidence": "medium"
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol does not have a dedicated section on findings management. This structure is inferred from standard quality management practices required for clinical trials.",
                "supporting_context": [
                  "General principles of GCP and quality management."
                ],
                "confidence": "medium"
              }
            }
          },
          "monitoring_reports": {
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol does not specify the types or content of monitoring reports. This is a standard component of a monitoring plan, which is not detailed in this document.",
                "supporting_context": [
                  "General principles of GCP and monitoring."
                ],
                "confidence": "medium"
              }
            }
          },
          "provenance": {
            "kind": "explicit",
            "explicit": {
              "section_number": "13.3",
              "page_number": 48,
              "text_snippet": "13.3 Monitoring procedures"
            }
          }
        },
        "rbqm": {
          "ract_register": {
            "critical_to_quality_factors": [
              {
                "ctq_id": "CTQ-001",
                "ctq_category": "Patient Safety",
                "factor": "Accurate and timely reporting of Adverse Events (AEs), Serious Adverse Events (SAEs), and Serious Adverse Device Effects (SADEs).",
                "insight_type": "explicit",
                "clinical_reasoning": "Post-market surveillance is a primary goal. Failure to capture and report safety events in a timely manner undermines the study's purpose and regulatory obligations for device safety monitoring.",
                "failure_mode": "Site staff fail to identify, document, or report safety events within the protocol-specified 24-hour timeline for serious events.",
                "severity_score": 5,
                "probability_score": 3,
                "detectability_score": 2,
                "risk_priority_number": 30,
                "affected_stakeholders": [
                  "Patient",
                  "Sponsor",
                  "Regulator"
                ],
                "preventive_controls": [
                  "Detailed training on safety definitions and reporting procedures at SIV.",
                  "Provide site with a simplified safety reporting workflow aid."
                ],
                "detective_controls": [
                  "Centralized monitoring of SAE reporting timeliness KRI.",
                  "Regular review of patient records for unreported AEs/SAEs during monitoring visits."
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "9.4",
                    "page_number": 36,
                    "text_snippet": "A Seriuos Adverse Event (SAE) is any AE that meets any of the following criteria: led to death; led to serious deterioration in the health of the subject..."
                  }
                }
              },
              {
                "ctq_id": "CTQ-002",
                "ctq_category": "Endpoint Integrity",
                "factor": "Complete and accurate collection of the Harris Hip Score (HHS) at all scheduled timepoints.",
                "insight_type": "explicit",
                "clinical_reasoning": "The HHS is the primary endpoint. Missing or inaccurately collected HHS data will directly impact the ability to assess the clinical outcomes of the device and may render the study inconclusive.",
                "failure_mode": "Site staff inconsistently administer the HHS, miss assessments at follow-up visits, or make data entry errors into the eCRF.",
                "severity_score": 5,
                "probability_score": 4,
                "detectability_score": 2,
                "risk_priority_number": 40,
                "affected_stakeholders": [
                  "Sponsor",
                  "Site"
                ],
                "preventive_controls": [
                  "Standardized training for all assessors on HHS administration.",
                  "Automated alerts from eCRF for upcoming or missed HHS assessments."
                ],
                "detective_controls": [
                  "Centralized data review for completeness and logical inconsistencies in HHS data.",
                  "Targeted SDV on primary endpoint data."
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "4.1",
                    "page_number": 17,
                    "text_snippet": "The primary endpoint of the study is the evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant."
                  }
                }
              },
              {
                "ctq_id": "CTQ-003",
                "ctq_category": "Endpoint Integrity",
                "factor": "Consistent and high-quality radiographic assessments for implant stability.",
                "insight_type": "inferred",
                "clinical_reasoning": "Radiographic outcomes are key secondary endpoints to evaluate long-term device performance (e.g., loosening, migration). Inconsistent imaging techniques can make longitudinal comparisons impossible.",
                "failure_mode": "The radiology department uses inconsistent X-ray techniques (e.g., patient positioning, magnification) across different timepoints.",
                "severity_score": 4,
                "probability_score": 3,
                "detectability_score": 3,
                "risk_priority_number": 36,
                "affected_stakeholders": [
                  "Sponsor"
                ],
                "preventive_controls": [
                  "Provide the site with a detailed imaging manual specifying all radiographic parameters.",
                  "Conduct a training session with the radiology technicians at study start."
                ],
                "detective_controls": [
                  "Central review of initial X-rays for quality control before subject enrollment continues.",
                  "Periodic quality checks of images by a central reader."
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "7.7",
                    "page_number": 29,
                    "text_snippet": "Imaging will be collected to evaluate the radiographic performance of the device, which will contribute to the overall efficacy evaluation of Delta Revision acetabular cup."
                  }
                }
              },
              {
                "ctq_id": "CTQ-004",
                "ctq_category": "GCP Compliance",
                "factor": "Maintenance of subject informed consent and data privacy throughout the long-term study.",
                "insight_type": "explicit",
                "clinical_reasoning": "Ethical conduct is paramount. A failure in the consent process or a breach of confidentiality invalidates the subject's data and is a major compliance violation.",
                "failure_mode": "A protocol amendment is issued but the site fails to re-consent subjects; confidential patient data is improperly handled or disclosed.",
                "severity_score": 5,
                "probability_score": 2,
                "detectability_score": 2,
                "risk_priority_number": 20,
                "affected_stakeholders": [
                  "Patient",
                  "Site",
                  "Sponsor",
                  "Regulator"
                ],
                "preventive_controls": [
                  "Clear process for communicating amendments and re-consent requirements.",
                  "Training on data anonymization and protection."
                ],
                "detective_controls": [
                  "100% SDV of informed consent forms.",
                  "Monitoring review of consent tracking logs."
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "12.2",
                    "page_number": 46,
                    "text_snippet": "The patient will be required to provide written informed consent to confirm that they allow their medical data to be collected and analysed. This must be obtained prior to enrolment and any data being entered in the study database."
                  }
                }
              },
              {
                "ctq_id": "CTQ-005",
                "ctq_category": "Operational Feasibility",
                "factor": "High subject retention rate to ensure sufficient evaluable data at the 2-year primary endpoint.",
                "insight_type": "inferred",
                "clinical_reasoning": "The study's validity depends on having a sufficient number of subjects complete the 2-year follow-up. A high lost-to-follow-up (LTFU) rate could bias the results and lead to study failure.",
                "failure_mode": "Site fails to maintain contact with subjects, leading to missed visits and subjects becoming LTFU. The protocol assumes a 40% LTFU rate, which is already high.",
                "severity_score": 5,
                "probability_score": 4,
                "detectability_score": 3,
                "risk_priority_number": 60,
                "affected_stakeholders": [
                  "Sponsor"
                ],
                "preventive_controls": [
                  "Develop and implement a patient retention plan (e.g., visit reminders, newsletters).",
                  "Collect multiple forms of contact information for each subject at enrollment."
                ],
                "detective_controls": [
                  "Monitor KRI for visit compliance.",
                  "Track LTFU rate quarterly against projections."
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-003"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "10.3",
                    "page_number": 42,
                    "text_snippet": "Assuming a 40% loss to follow-up, total enrolment for this study is set at 49 subjects."
                  }
                }
              }
            ],
            "emergent_systemic_risks": [
              {
                "risk_id": "ESR-001",
                "risk_type": "cross_domain",
                "risk_description": "As a single-center study, high staff turnover or a loss of the Principal Investigator at the site could jeopardize the entire study's operational continuity and data quality.",
                "discovery_reasoning": "Inferred from protocol stating 'Expected number of study centres: 1'. This creates a single point of failure.",
                "affected_domains": [
                  "Data Quality",
                  "Operational Feasibility"
                ],
                "trigger_conditions": "Resignation of key study personnel (PI, Study Coordinator) at the site.",
                "probability": "Possible",
                "impact_severity": "Critical",
                "affected_objectives": [
                  "Primary Efficacy",
                  "Timeline"
                ],
                "quantitative_estimate": "Potential for study to be halted or terminated.",
                "preventive_redesign": "N/A (already single-center design)",
                "monitoring_approach": "Maintain close relationship with site staff; monitor for signs of instability.",
                "contingency_plan": "Have a backup PI identified; ensure thorough handover procedures are in place.",
                "linked_ctq_ids": [
                  "CTQ-002",
                  "CTQ-005"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "Protocol Synopsis",
                    "page_number": 11,
                    "text_snippet": "Expected number of study centres: 1"
                  }
                }
              },
              {
                "risk_id": "ESR-002",
                "risk_type": "temporal",
                "risk_description": "Over the long recruitment (60 months) and follow-up (2 years) periods, changes in clinical practice or the introduction of superior competitor devices could alter the patient population being enrolled or the interpretation of outcomes.",
                "discovery_reasoning": "Inferred from the long study duration specified in the protocol.",
                "affected_domains": [
                  "Study Design",
                  "Endpoint Integrity"
                ],
                "trigger_conditions": "Publication of new clinical guidelines; market approval of a new generation of revision cups.",
                "probability": "Likely",
                "impact_severity": "Major",
                "affected_objectives": [
                  "Primary Efficacy"
                ],
                "quantitative_estimate": "Potential for confounding variables to obscure device performance.",
                "preventive_redesign": "N/A",
                "monitoring_approach": "Monitor medical literature and competitor landscape.",
                "contingency_plan": "Document any changes in standard of care to include as covariates in the final statistical analysis.",
                "linked_ctq_ids": [],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "Protocol Synopsis",
                    "page_number": 10,
                    "text_snippet": "Study duration Expected recruitment duration: 60 months."
                  }
                }
              },
              {
                "risk_id": "ESR-003",
                "risk_type": "interaction_effect",
                "risk_description": "The high assumed lost-to-follow-up rate (40%) could interact with an unforeseen safety signal, making it difficult to determine the true incidence rate of the adverse event.",
                "discovery_reasoning": "Inferred from the interaction between the high LTFU rate mentioned in the sample size calculation and the primary goal of safety surveillance.",
                "affected_domains": [
                  "Patient Safety",
                  "Data Quality"
                ],
                "trigger_conditions": "An unexpected adverse device effect begins to emerge from the collected data.",
                "probability": "Unlikely",
                "impact_severity": "Critical",
                "affected_objectives": [
                  "Safety"
                ],
                "quantitative_estimate": "Inability to accurately profile the device's safety.",
                "preventive_redesign": "N/A",
                "monitoring_approach": "Intensify efforts to obtain final health status for all withdrawn subjects.",
                "contingency_plan": "Perform sensitivity analyses to model the potential impact of missing data on the safety outcome.",
                "linked_ctq_ids": [
                  "CTQ-001",
                  "CTQ-005"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "10.3",
                    "page_number": 42,
                    "text_snippet": "Assuming a 40% loss to follow-up, total enrolment for this study is set at 49 subjects."
                  }
                }
              }
            ],
            "strategic_risk_indicators": [
              {
                "kri_id": "SKRI-001",
                "kri_type": "leading_indicator",
                "category": "Operational Health",
                "metric": "Number of key site staff (PI, coordinator) changes per quarter.",
                "rationale": "Monitors the stability of the single study site. High turnover is a leading indicator of future protocol deviations, data quality issues, and decreased enrollment.",
                "predictive_value": "Predicts an increase in protocol deviations and data entry errors in the following quarter.",
                "calculation_formula": "Count of PI or Study Coordinator resignations/replacements in a 3-month period.",
                "data_sources": [
                  "CTMS"
                ],
                "frequency": "Quarterly",
                "thresholds": {
                  "green": {
                    "range": "0",
                    "interpretation": "Stable site operations"
                  },
                  "amber": {
                    "range": "N/A",
                    "interpretation": ""
                  },
                  "red": {
                    "range": "\u22651",
                    "interpretation": "High risk of operational disruption",
                    "escalation": "Sponsor Executive"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-005"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This strategic KRI is derived from the emergent risk of being a single-center study (ESR-001). Monitoring staff stability is a proactive measure to mitigate this risk, but it is not mentioned in the protocol.",
                    "supporting_context": [
                      "Protocol Synopsis: 'Expected number of study centres: 1'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "kri_id": "SKRI-002",
                "kri_type": "leading_indicator",
                "category": "Quality Trajectory",
                "metric": "Quarterly Lost-to-Follow-Up (LTFU) Rate.",
                "rationale": "Provides an early warning if the study is trending towards exceeding the already high 40% LTFU assumption, allowing for timely implementation of enhanced retention strategies.",
                "predictive_value": "Predicts the final study power and the evaluability of the 2-year primary endpoint.",
                "calculation_formula": "(Number of subjects classified as LTFU in quarter) / (Total subjects active at start of quarter).",
                "data_sources": [
                  "EDC"
                ],
                "frequency": "Quarterly",
                "thresholds": {
                  "green": {
                    "range": "<5%",
                    "interpretation": "LTFU rate is under control."
                  },
                  "amber": {
                    "range": "5-10%",
                    "interpretation": "Trend is concerning; review retention plan.",
                    "escalation": "Project Manager"
                  },
                  "red": {
                    "range": ">10%",
                    "interpretation": "High risk of study failure; immediate action required.",
                    "escalation": "Steering Committee"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-005"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This strategic KRI is derived from the high-risk assumption of a 40% lost-to-follow-up rate. Proactively monitoring this rate is critical to study success, but the protocol does not define this as a KRI.",
                    "supporting_context": [
                      "Section 10.3: 'Assuming a 40% loss to follow-up...'"
                    ],
                    "confidence": "high"
                  }
                }
              }
            ],
            "strategic_summary": {
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "A strategic summary is a component of a comprehensive RBQM plan, which is not present in this protocol. Its existence is inferred.",
                  "supporting_context": [
                    "General principles of RBQM."
                  ],
                  "confidence": "low"
                }
              }
            }
          },
          "risk_governance": {
            "risk_assessment_matrix": {
              "scoring_methodology": {
                "probability_scale": {
                  "1": "Rare (<5%)",
                  "2": "Unlikely (5-20%)",
                  "3": "Possible (20-50%)",
                  "4": "Likely (50-80%)",
                  "5": "Almost Certain (>80%)"
                },
                "impact_scale": {
                  "1": "Negligible",
                  "2": "Minor",
                  "3": "Moderate",
                  "4": "Major",
                  "5": "Catastrophic"
                },
                "risk_levels": {
                  "1-4": "Low",
                  "5-9": "Medium",
                  "10-14": "High",
                  "15-25": "Critical"
                }
              },
              "identified_risks": [
                {
                  "risk_id": "RISK-001",
                  "risk_category": "Safety",
                  "risk_description": "Delayed or missed reporting of SAEs/SADEs by the site.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 3,
                    "impact": 5,
                    "score": 15,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 5,
                    "score": 10,
                    "level": "High"
                  },
                  "risk_reduction_percentage": 33,
                  "linked_ctq_id": "CTQ-001",
                  "linked_mitigation_ids": [
                    "MIT-001"
                  ],
                  "provenance": {
                    "kind": "derived",
                    "derived": {
                      "reasoning": "This risk is directly derived from the critical-to-quality factor on safety reporting (CTQ-001). The protocol mandates timely reporting, making failure to do so a key risk.",
                      "supporting_context": [
                        "Section 9.8: 'The investigator must report the following events to the Sponsor within 24 hours...'"
                      ],
                      "confidence": "high"
                    }
                  }
                },
                {
                  "risk_id": "RISK-002",
                  "risk_category": "Endpoints",
                  "risk_description": "Incomplete or poor-quality primary endpoint (HHS) data.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 5,
                    "score": 20,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 5,
                    "score": 10,
                    "level": "High"
                  },
                  "risk_reduction_percentage": 50,
                  "linked_ctq_id": "CTQ-002",
                  "linked_mitigation_ids": [
                    "MIT-002"
                  ],
                  "provenance": {
                    "kind": "derived",
                    "derived": {
                      "reasoning": "This risk is derived from the primary endpoint definition (CTQ-002). The integrity of the HHS data is paramount to achieving the study's main objective.",
                      "supporting_context": [
                        "Section 4.1: 'The primary endpoint of the study is the evaluation of Harris Hip Score (HHS)...'"
                      ],
                      "confidence": "high"
                    }
                  }
                },
                {
                  "risk_id": "RISK-003",
                  "risk_category": "Subject Population",
                  "risk_description": "High rate of subjects lost to follow-up before the 2-year endpoint.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 5,
                    "score": 20,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 3,
                    "impact": 5,
                    "score": 15,
                    "level": "Critical"
                  },
                  "risk_reduction_percentage": 25,
                  "linked_ctq_id": "CTQ-005",
                  "linked_mitigation_ids": [
                    "MIT-003"
                  ],
                  "provenance": {
                    "kind": "derived",
                    "derived": {
                      "reasoning": "This risk is derived from the sample size calculation, which explicitly states a high assumption for loss to follow-up (CTQ-005), making it a critical risk to manage.",
                      "supporting_context": [
                        "Section 10.3: 'Assuming a 40% loss to follow-up...'"
                      ],
                      "confidence": "high"
                    }
                  }
                }
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not contain a risk assessment matrix. This structure, including the scoring methodology and risk levels, is derived from standard RBQM frameworks like TransCelerate's RACT.",
                  "supporting_context": [
                    "General principles of risk-based quality management."
                  ],
                  "confidence": "medium"
                }
              }
            },
            "mitigation_strategies": [
              {
                "mitigation_id": "MIT-001",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "control_type": "Preventive",
                "control_category": "Training",
                "strategy_description": "Conduct comprehensive, scenario-based training on safety event identification and reporting timelines during site initiation, with annual refreshers.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "Medium",
                "verification_method": "Review of training records; monitoring of SAE reporting timeliness KRI.",
                "verification_frequency": "Ongoing",
                "resource_requirements": "Monitor time for training preparation and delivery.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not specify mitigation strategies. This strategy is a standard and logical control to mitigate the risk of late SAE reporting (RISK-001).",
                    "supporting_context": [
                      "General principles of GCP and site training."
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "mitigation_id": "MIT-002",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "control_type": "Detective",
                "control_category": "Data Management",
                "strategy_description": "Implement a centralized data review process where data managers review HHS data for completeness and consistency within 5 days of entry.",
                "implementation_phase": "Conduct",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "Review of data management plan and centralized monitoring reports.",
                "verification_frequency": "Weekly",
                "resource_requirements": "Dedicated data manager time.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not specify mitigation strategies. This strategy is a standard control to mitigate the risk of poor primary endpoint data (RISK-002).",
                    "supporting_context": [
                      "Section 11.2: 'Data management will be conducted by the Sponsor...'"
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "mitigation_id": "MIT-003",
                "linked_risk_ids": [
                  "RISK-003"
                ],
                "control_type": "Preventive",
                "control_category": "Patient Engagement",
                "strategy_description": "Implement a formal patient retention plan, including scheduled check-in calls between visits, birthday cards, and study newsletters.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Site",
                "effectiveness_rating": "Medium",
                "verification_method": "Monitor review of site's retention activities; tracking of LTFU KRI.",
                "verification_frequency": "Quarterly",
                "resource_requirements": "Site coordinator time and small budget for materials.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not specify mitigation strategies. This strategy is a standard control to mitigate the high risk of lost-to-follow-up (RISK-003).",
                    "supporting_context": [
                      "Section 5.6: 'In the case of patients who do not show up for scheduled visits, site staff should make reasonable efforts... to contact these patients for follow-up information.'"
                    ],
                    "confidence": "medium"
                  }
                }
              }
            ],
            "safety_signal_detection": {
              "statistical_methods": [
                {
                  "method_id": "SSD-001",
                  "method_name": "Aggregate AE/SADE Review",
                  "method_description": "Periodic, cumulative review of all reported adverse events and serious adverse device effects, tabulated by type, severity, and frequency.",
                  "application": "To detect any unexpected safety signals or trends related to the device.",
                  "data_requirements": [
                    "Safety database with coded AE terms (MedDRA)"
                  ],
                  "provenance": {
                    "kind": "derived",
                    "derived": {
                      "reasoning": "The protocol requires collection of all AEs and SADEs. Aggregate review is the standard method for detecting safety signals from this data, though the method itself is not specified in the protocol.",
                      "supporting_context": [
                        "Section 9: 'Safety assessments will consist of monitoring and recording adverse events (AEs), including serious adverse events (SAEs), device deficiencies (DDs) and, adverse device effects (ADEs)...'"
                      ],
                      "confidence": "high"
                    }
                  }
                }
              ],
              "stopping_rules": [],
              "dsmb_interface": {
                "dsmb_required": false,
                "meeting_frequency": "N/A",
                "review_scope": [],
                "unblinding_criteria": "N/A",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not mention a Data Safety Monitoring Board (DSMB) or Data Monitoring Committee (DMC). For a post-market, observational, single-center study of a CE-marked device, a DSMB is typically not required.",
                    "supporting_context": [
                      "Absence of any mention of a DSMB or similar committee in the protocol."
                    ],
                    "confidence": "high"
                  }
                }
              }
            },
            "issue_management_cascade": {}
          },
          "technology_config": {},
          "provenance": {
            "kind": "derived",
            "derived": {
              "reasoning": "The protocol does not contain a dedicated section on Risk-Based Quality Management (RBQM). The entire RBQM structure is inferred by applying a standard framework (e.g., ICH E6 R2, TransCelerate RACT) to the risks and critical data points identified within the protocol.",
              "supporting_context": [
                "Section 13.3 mentions compliance with EN ISO 14155:2020, which includes principles of risk management."
              ],
              "confidence": "medium"
            }
          }
        },
        "extraction_statistics": {
          "has_monitoring_approach": true,
          "has_sdv_strategy": true,
          "has_monitoring_visits": true,
          "kri_count": 5,
          "qtl_count": 3,
          "ctq_count": 5,
          "emergent_risk_count": 3,
          "mitigation_strategy_count": 3,
          "identified_risks_count": 3,
          "has_ract_register": true,
          "has_risk_governance": true
        },
        "provenance": {
          "kind": "derived",
          "derived": {
            "reasoning": "The overall quality management plan is derived from multiple sections of the protocol, primarily those dealing with monitoring, data handling, and safety. The protocol does not have a single, consolidated Quality Management section.",
            "supporting_context": [
              "Section 9: Safety Parameters and definition",
              "Section 11: Data collection and management",
              "Section 13: Study documentation, monitoring, and administration"
            ],
            "confidence": "high"
          }
        }
      },
      "_agentDocumentation": {
        "agentId": "quality_management",
        "displayName": "Quality Management",
        "instanceType": "QualityManagement",
        "wave": 2,
        "priority": 1,
        "purpose": "Extracts quality management specifications including RBQM, KRIs, and QTLs for CTMS monitoring configuration.",
        "scope": "Monitoring approach, RBQM, Key Risk Indicators, Quality Tolerance Limits, SDV extent, audit procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Quality Management",
          "Section 11: Monitoring",
          "Appendix: Monitoring Plan"
        ],
        "keyInsights": [
          {
            "name": "Key Risk Indicators",
            "description": "KRIs with thresholds and escalation procedures",
            "dataPath": "kris[]",
            "downstreamUses": [
              "Central monitoring dashboards",
              "Site risk scores",
              "Escalation rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "CTMS_KRI_001",
                "ruleType": "derivation",
                "targetSystem": "Clinical Trial Management System",
                "description": "Configure KRI monitoring thresholds",
                "sourceDataPath": "kris[]",
                "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure CTMS monitoring schedules",
          "Set up KRI dashboards"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events",
            "safety_decision_points"
          ],
          "enriches": [],
          "crossReferences": [
            "data_management"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2) 5.0, ICH E8(R1)",
        "schemaFile": "quality_management_schema.json",
        "automationRules": [
          {
            "ruleId": "CTMS_KRI_001",
            "ruleType": "derivation",
            "targetSystem": "Clinical Trial Management System",
            "description": "Configure KRI monitoring thresholds",
            "sourceDataPath": "kris[]",
            "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_QM_ALL_001",
            "name": "All Agents \u2192 Complete RBQM Dashboard",
            "agentsInvolved": [
              "quality_management",
              "adverse_events",
              "safety_decision_points",
              "data_management"
            ],
            "description": "KRI definitions + safety events + data quality = comprehensive central monitoring",
            "combinedInsight": "Site-level risk scores based on all protocol-defined indicators",
            "automationEnabled": "Automated site risk scoring and monitoring prioritization",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "withdrawalProcedures": {
      "moduleId": "withdrawal_procedures",
      "instanceType": "WithdrawalProcedures",
      "data": {
        "id": "WP-001",
        "instanceType": "WithdrawalProcedures",
        "name": "Withdrawal and Discontinuation Procedures",
        "description": "Procedural specifications for subject withdrawal and discontinuation",
        "discontinuation_types": [
          {
            "id": "DT-001",
            "type_name": {
              "code": "STUDY_WITHDRAWAL",
              "decode": "Study Withdrawal",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "definition": "Patients have the right to voluntarily withdraw from the study at any time for any reason. The investigator also has the right to withdraw a patient.",
            "allows_continued_followup": true,
            "provenance": {
              "section_number": "5.5",
              "page_number": 19,
              "text_snippet": "The investigator has the right to withdraw a patient from the study at any time. In addition, patients have the right to voluntarily withdraw from the study at any time for any reason."
            }
          }
        ],
        "consent_withdrawal": {
          "right_to_withdraw": "Patients have the right to voluntarily withdraw from the study at any time for any reason.",
          "withdrawal_process": "The primary reason for withdrawal from the study should be documented on the appropriate eCRF and on the patient's medical charts.",
          "data_handling_options": [
            {
              "option": {
                "code": "RETAIN_ALL",
                "decode": "Retain all collected data",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "description": "If a patient withdraws, data will be collected up to the time of withdrawal, with no additional information collected thereafter."
            },
            {
              "option": {
                "code": "SUBJECT_CHOICE",
                "decode": "Subject can choose data handling",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "description": "Patients may also request that any previously collected data be excluded from the study."
            }
          ],
          "sample_handling": null,
          "consequences": "No penalty or loss of benefits for withdrawing.",
          "provenance": {
            "section_number": "5.5",
            "page_number": 19,
            "text_snippet": "The investigator has the right to withdraw a patient from the study at any time. In addition, patients have the right to voluntarily withdraw from the study at any time for any reason. Reasons for withdrawal from the study may include, but are not limited to, the following:\n...\nPatient withdrawal of consent at any time"
          }
        },
        "discontinuation_visit": {
          "timing": null,
          "timing_days_from_last_dose": null,
          "required_assessments": [],
          "documentation_requirements": [],
          "provenance": {
            "section_number": "5.5",
            "page_number": 19,
            "text_snippet": "Every effort should be made to obtain information on patients who withdraw from the study. The primary reason for withdrawal from the study should be documented on the appropriate eCRF and on the patient's medical charts."
          }
        },
        "post_discontinuation_followup": {
          "safety_followup": null,
          "survival_followup": null,
          "ae_followup": {
            "ongoing_ae_followup": true,
            "followup_until": "Patients who withdraw from the study prematurely will be followed for all unresolved AEs/ADEs and SAEs/SADEs until their resolution or stabilization, the patient is lost to follow-up or dies, or until it is determined that the study participation is not the cause of the AE/SAE/ADE/SADE, whichever occurs first."
          },
          "provenance": {
            "section_number": "5.5",
            "page_number": 19,
            "text_snippet": "Patients who withdraw from the study prematurely will be followed for all unresolved AEs/ADEs and SAES/SADEs until their resolution or stabilization, the patient is lost to follow-up or dies, or until it is determined that the study participation is not the cause of the AE/SAE/ADE/SADE, whichever occurs first."
          }
        },
        "lost_to_followup": {
          "definition": "Only after sufficient and documented unsuccessful attempts at contact have been made may a patient be declared \u201clost to follow-up.\"",
          "missed_visits_threshold": null,
          "contact_attempts_required": 1,
          "contact_methods": [],
          "documentation_required": [
            "Efforts to contact the patient should be documented in the source documents."
          ],
          "provenance": {
            "section_number": "5.6",
            "page_number": 20,
            "text_snippet": "In the case of patients who do not show up for scheduled visits, site staff should make reasonable efforts (i.e., at least one attempt within a reasonable period of time after a missed visit) to contact these patients for follow-up information. ... Only after sufficient and documented unsuccessful attempts at contact have been made may a patient be declared \u201clost to follow-up.\" Such efforts should be documented in the source documents."
          }
        },
        "replacement_strategy": {
          "allows_replacement": false,
          "replacement_conditions": [
            {
              "discontinuation_reason": "Any",
              "replacement_allowed": false
            }
          ],
          "timing_cutoff": "Patients who withdraw from the study will not be replaced.",
          "randomization_handling": null,
          "stratification_maintenance": null,
          "provenance": {
            "section_number": "5.5",
            "page_number": 19,
            "text_snippet": "Patients who withdraw from the study will not be replaced."
          }
        },
        "administrative_withdrawal": {
          "reasons": [
            {
              "id": "AWR-001",
              "reason_type": {
                "code": "INVESTIGATOR_DECISION",
                "decode": "Investigator Decision",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "description": "Any medical condition that the investigator or Sponsor determines may jeopardize the patient's safety if he or she continues in the study, or if it is in the best interest of the patient."
            },
            {
              "id": "AWR-002",
              "reason_type": {
                "code": "STUDY_TERMINATION",
                "decode": "Study Termination",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "description": "The study is closed by the Sponsor and/or by the Ethical Committes/Regulatory Authority."
            },
            {
              "id": "AWR-003",
              "reason_type": {
                "code": "PROTOCOL_VIOLATION",
                "decode": "Protocol Violation",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "description": "Repeated patient noncompliance with protocol requirements or major protocol violation that may jeopardize the patient's safety."
            },
            {
              "id": "AWR-004",
              "reason_type": {
                "code": "SPONSOR_DECISION",
                "decode": "Sponsor Decision",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "description": "The Sponsor has the right to terminate this study at any time. Reasons may include incidence or severity of AEs/ADEs, unsatisfactory patient enrolment, or inaccurate or incomplete data recording."
            }
          ],
          "notification_requirements": "The Sponsor will notify the investigator if the study is placed on hold, or if the Sponsor decides to discontinue the study or development program.",
          "irb_notification": true,
          "provenance": {
            "section_number": "5.7",
            "page_number": 20,
            "text_snippet": "The Sponsor has the right to terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following:\nThe incidence or severity of AEs/ADEs in this or other studies indicates a potential health hazard to patients;\nPatient enrolment is unsatisfactory;\nInaccurate or incomplete data recording.\nThe Sponsor will notify the investigator if the study is placed on hold, or if the Sponsor decides to discontinue the study or development program."
          }
        },
        "data_retention": {
          "retention_period_years": 15,
          "retention_policy": "If a patient withdraws, data will be collected up to the time of withdrawal. Patients may request that any previously collected data be excluded from the study. Withdrawn patients requesting data exclusion will be included as enrolled, implanted and withdrawn patients, but no implant or assessment data will be included in the eCRF and these data will be 'missing' in the respective population analyses.",
          "analysis_populations": [],
          "provenance": {
            "section_number": "5.5",
            "page_number": 20,
            "text_snippet": "If a patient withdraws, data will be collected up to the time of withdrawal, with no additional information collected thereafter. Patients may also request that any previously collected data be excluded from the study.\nNote: any withdrawn patients requesting that previously collected data are excluded from the study will be included as enrolled, implanted and withdrawn patients, but no implant or assessment data will be included in the eCRF and these data will be 'missing' in the respective"
          }
        },
        "retention_strategies": {
          "prevention_measures": [],
          "incentives": [],
          "re_consent_procedures": "If during the study important new information becomes available, the consent form will be revised. Patients must be re-consented to the most current version of the Consent Forms.",
          "provenance": {
            "section_number": "12.2",
            "page_number": 46,
            "text_snippet": "If during the study important new information becomes available, the consent form will be revised. Patients must be re-consented to the most current version of the Consent Forms (or to a significant new information/findings addendum in accordance with applicable laws and IRB/EC policy) during their participation in the study."
          }
        },
        "provenance": {
          "section_number": "5.5",
          "page_number": 19,
          "text_snippet": "5.5 Patient Withdrawal Criteria"
        }
      },
      "_agentDocumentation": {
        "agentId": "withdrawal_procedures",
        "displayName": "Withdrawal Procedures",
        "instanceType": "WithdrawalProcedures",
        "wave": 2,
        "priority": 2,
        "purpose": "Extracts study discontinuation procedures for EDC disposition forms and protocol deviation tracking.",
        "scope": "Discontinuation types, consent withdrawal, early termination visits, survival follow-up, lost to follow-up.",
        "keySectionsAnalyzed": [
          "Section 5: Subject Withdrawal",
          "Section 6: Early Termination",
          "Section 9: Follow-up Procedures"
        ],
        "keyInsights": [
          {
            "name": "Discontinuation Types",
            "description": "Treatment vs study discontinuation with criteria",
            "dataPath": "discontinuation_types[]",
            "downstreamUses": [
              "EDC disposition forms",
              "Analysis programming",
              "DSMB reporting"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Create EDC disposition forms",
          "Configure survival follow-up tracking"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "withdrawal_procedures_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "imagingCentralReading": {
      "moduleId": "imaging_central_reading",
      "instanceType": "ImagingCentralReading",
      "data": {
        "id": "H-34-imaging-central-reading",
        "instanceType": "ImagingCentralReading",
        "name": "H-34 Imaging & Central Reading",
        "description": "Radiographic evaluation specifications for the DELTA Revision acetabular cup.",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
        },
        "response_criteria": {
          "primary_criteria": "Protocol-specific radiographic evaluation for orthopedic implants",
          "criteria_version": null,
          "secondary_criteria": [
            "Brooker classification for Heterotopic Ossification",
            "DeLee and Charnley zones for radiolucency"
          ],
          "modifications": "Criteria are based on evaluation of implant stability, positioning, and bone response, not tumor measurement.",
          "provenance": {
            "section_number": "7.7",
            "page_number": 29,
            "text_snippet": "Imaging will be collected to evaluate the radiographic performance of the device, which will contribute to the overall efficacy evaluation of Delta Revision acetabular cup."
          }
        },
        "imaging_modalities": [
          {
            "modality_id": "IMG-001",
            "modality_type": "X-ray",
            "body_regions": [
              "pelvis",
              "hip"
            ],
            "contrast_required": false,
            "contrast_type": null,
            "slice_thickness": null,
            "technical_requirements": "Standard views, such as antero-posterior (AP) of the pelvis, and antero-posterior (AP) and lateral (LAT) of the affected hip.",
            "preferred_modality": true,
            "provenance": {
              "section_number": "7.7",
              "page_number": 29,
              "text_snippet": "Radiological assessment was carried out preoperatively and postoperatively at discharge, at 2 months, 6 months, 12 months, and 24 months after surgery. It included standard views, such as antero-posterior (AP) of the pelvis, antero-posterior (AP) and lateral (LAT) of the affected hip."
            }
          }
        ],
        "assessment_schedule": {
          "baseline_window": "Pre-operative visit",
          "on_treatment_frequency": null,
          "first_assessment_timing": "Postoperatively at discharge",
          "post_treatment_schedule": "2 months, 6 months, 12 months, and 24 months after surgery.",
          "confirmatory_scan_required": false,
          "confirmatory_scan_window": null,
          "assessment_timepoints": [
            "Pre-operative",
            "Discharge",
            "Month 2",
            "Month 6",
            "Month 12",
            "Month 24"
          ],
          "provenance": {
            "section_number": "7.7",
            "page_number": 29,
            "text_snippet": "Radiological assessment was carried out preoperatively and postoperatively at discharge, at 2 months, 6 months, 12 months, and 24 months after surgery. It included standard views, such as antero-posterior (AP) of the pelvis, antero-posterior (AP) and lateral (LAT) of the affected hip."
          }
        },
        "lesion_requirements": {
          "measurable_disease_definition": "This is not an oncology study. The protocol defines specific radiographic findings for evaluation.",
          "target_lesion_minimum_size": null,
          "lymph_node_criteria": null,
          "max_target_lesions": null,
          "max_target_lesions_per_organ": null,
          "non_target_lesion_definition": null,
          "non_measurable_disease": null,
          "provenance": {
            "section_number": null,
            "page_number": 1,
            "text_snippet": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
          }
        },
        "response_categories": [
          {
            "category_code": "Radiolucency",
            "category_name": "Acetabular Component Radiolucency",
            "definition": "Evaluated according to presence, absence, location and thickness in 3 zones (DeLee-Charnley). Graded as: 0 (None), 1 (<1 mm), 2 (\u22651 to <2 mm), 3 (\u22652 mm).",
            "target_lesion_criteria": null,
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": null,
            "provenance": {
              "section_number": "7.7.4",
              "page_number": 32,
              "text_snippet": "Acetabular Component Radiolucency will be graded in accordance with the following definitions from the AP view:\n0. None: No evidence of radiolucency.\n1. < 1 mm: Presence of radiolucency <1 mm in thickness.\n2. \u22651 to <2 mm: Presence of radiolucency \u22651 to <2 mm in thickness.\n3. \u22652: Presence of radiolucency \u22652 in thickness."
            }
          },
          {
            "category_code": "Migration",
            "category_name": "Acetabular Component Migration",
            "definition": "Graded based on change in position of the acetabular component relative to the native bone stock. Graded as: 0 (Absent, <2 mm change), 1 (Present, \u22652 mm change).",
            "target_lesion_criteria": null,
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": null,
            "provenance": {
              "section_number": "7.7.5",
              "page_number": 33,
              "text_snippet": "Acetabular Component Migration will be graded from AP view in accordance with the following definitions [17]:\n0. Absent: No evidence of a change in position of the acetabular component relative to the native bone stock \u22652 mm.\n1. Present: Presence of a change in position of the acetabular component relative to the native bone stock \u22652 mm."
            }
          },
          {
            "category_code": "HO",
            "category_name": "Heterotopic Ossification",
            "definition": "Graded from AP view following the Brooker classification: Grade 0 (No evidence), Grade 1 (foci <1 cm), Grade 2 (< half space), Grade 3 (> half space), Grade 4 (bridges pelvis and femur).",
            "target_lesion_criteria": null,
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": null,
            "provenance": {
              "section_number": "7.7.1",
              "page_number": 31,
              "text_snippet": "Heterotopic Ossification will be graded from AP view following the Brooker classification [13]:\n0. Grade 0: No evidence of Heterotopic Ossification;\n1. Grade 1: one or two foci of Heterotopic Ossification less than 1 cm each;\n2. Grade 2: ossification or osteophytes occupying less than half the space between the femur and pelvis;\n3. Grade 3: ossification or osteophytes occupying more than half the space between the femur and pelvis;\n4. Grade 4: ossification that bridges the pelvis and femur."
            }
          },
          {
            "category_code": "Dislocation",
            "category_name": "Dislocation",
            "definition": "Occurs if the head moves out of the acetabular component. Graded as: 0 (Absent), 1 (Present).",
            "target_lesion_criteria": null,
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": null,
            "provenance": {
              "section_number": "7.7.6",
              "page_number": 33,
              "text_snippet": "Dislocation occurs if the head moves out of the acetabular component for any reason and will be graded from AP view in accordance with the following definitions:\n0. Absent: No evidence of dislocation.\n1. Present: Presence of dislocation."
            }
          },
          {
            "category_code": "Infection",
            "category_name": "Infection",
            "definition": "Radiographic findings suggestive of infection. Graded as: 0 (Absent), 1 (Present).",
            "target_lesion_criteria": null,
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": null,
            "provenance": {
              "section_number": "7.7.7",
              "page_number": 33,
              "text_snippet": "Infection will be graded from AP view in accordance with the following definitions:\n0. Absent: No evidence of infection.\n1. Present: Presence of infection."
            }
          }
        ],
        "central_reading": {
          "bicr_required": true,
          "bicr_purpose": "To perform image analysis and data management for radiographic endpoints.",
          "reading_methodology": "Image analysis and data management will be performed by LimaCorporate.",
          "reader_qualifications": "Authorized personnel at LimaCorporate.",
          "blinding_requirements": null,
          "adjudication_process": null,
          "vendor_name": "LimaCorporate (Sponsor)",
          "turnaround_time": null,
          "provenance": {
            "section_number": "7.7",
            "page_number": 29,
            "text_snippet": "All image analysis and data management will be performed by LimaCorporate in accordance with established and audited Standard Operating Procedures (SOPs). All electronic data and audit trails will be redundantly archived to prevent loss of data."
          }
        },
        "image_submission": {
          "submission_method": "Direct upload to the eCRF.",
          "format_requirements": "Standard clinical X-ray format (e.g., DICOM).",
          "anonymization_requirements": "Images must be anonymized. No subject names or identifiers in the electronic header. Must include Study name (H-34, Delta Revision), Subject ID, and Date of X-ray execution.",
          "submission_timeline": null,
          "quality_requirements": "Standard clinical practice.",
          "provenance": {
            "section_number": "7.7",
            "page_number": 29,
            "text_snippet": "The anonymized X-rays data have to be uploaded directly in the eCRF.\nIn compliance with privacy laws to ensure and protect the confidentiality of the subject, no subject names or identifiers should be entered into the electronic header. The information requested below has to be entered into the electronic header in lieu of subject identifiers:\n- Study name (H-34, Delta Revision)\n- Subject ID (Site number-XX where XX is a progressive number according to each subject included at the site)\n- Date"
          }
        },
        "special_assessments": [
          {
            "assessment_id": "SA-001",
            "assessment_name": "Acetabular Inclination",
            "purpose": "To measure the angle between the articular side of the acetabular cup and the transverse axis.",
            "methodology": "Measured from the AP Pelvis view.",
            "schedule": "Discharge, Month 2, Month 6, Month 12, Month 24",
            "provenance": {
              "section_number": "7.7.2",
              "page_number": 31,
              "text_snippet": "Acetabular Inclination is defined from the AP Pelvis view and consists of the angle between the articular side of the acetabular cup and the transverse axis [15]."
            }
          },
          {
            "assessment_id": "SA-002",
            "assessment_name": "Acetabular Anteversion",
            "purpose": "To measure the angle between the acetabular axis and the coronal plane.",
            "methodology": "Measured from a lateral view.",
            "schedule": "Discharge, Month 2, Month 6, Month 12, Month 24",
            "provenance": {
              "section_number": "7.7.3",
              "page_number": 31,
              "text_snippet": "Acetabular Anteversion is defined on a lateral view by the angle between the acetabular axis and the coronal plane [15] [16]."
            }
          }
        ],
        "immune_related_criteria": {
          "irecist_used": false,
          "pseudoprogression_handling": null,
          "confirmation_requirements": null,
          "treatment_beyond_progression": null,
          "provenance": {
            "section_number": null,
            "page_number": 1,
            "text_snippet": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
          }
        },
        "extraction_statistics": {
          "has_response_criteria": true,
          "has_bicr": true,
          "has_immune_criteria": false,
          "modality_count": 1,
          "response_category_count": 5
        }
      },
      "_agentDocumentation": {
        "agentId": "imaging_central_reading",
        "displayName": "Imaging & Central Reading",
        "instanceType": "ImagingCentralReading",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts imaging specifications for oncology and imaging-endpoint studies.",
        "scope": "Response criteria (RECIST, RANO), imaging modalities, central vs local reading, adjudication procedures.",
        "keySectionsAnalyzed": [
          "Section 7: Tumor Assessments",
          "Section 8: Response Criteria",
          "Appendix: Imaging Charter"
        ],
        "keyInsights": [
          {
            "name": "Response Criteria",
            "description": "RECIST/iRECIST/RANO version and modifications",
            "dataPath": "response_criteria",
            "downstreamUses": [
              "Central imaging vendor setup",
              "Endpoint adjudication",
              "Analysis programming"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IMAGING_RESP_001",
                "ruleType": "derivation",
                "targetSystem": "Central Imaging",
                "description": "Configure central imaging for response assessment",
                "sourceDataPath": "response_criteria",
                "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Imaging",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central imaging vendor systems",
          "Set up response assessment workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "TU",
          "TR",
          "RS"
        ],
        "regulatoryRelevance": "FDA Oncology Guidance, ICH M11 Section 7",
        "schemaFile": "imaging_central_reading_schema.json",
        "automationRules": [
          {
            "ruleId": "IMAGING_RESP_001",
            "ruleType": "derivation",
            "targetSystem": "Central Imaging",
            "description": "Configure central imaging for response assessment",
            "sourceDataPath": "response_criteria",
            "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_IMG_EP_001",
            "name": "Imaging + Endpoints \u2192 Response-Based Efficacy",
            "agentsInvolved": [
              "imaging_central_reading",
              "endpoints_estimands_sap"
            ],
            "description": "Response criteria + primary endpoint = complete efficacy assessment workflow",
            "combinedInsight": "RECIST definitions + ORR/PFS endpoints = Imaging-derived efficacy programming",
            "automationEnabled": "Central imaging outputs directly feed efficacy analysis datasets",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "pkpdSampling": {
      "moduleId": "pkpd_sampling",
      "instanceType": "PKPDSampling",
      "data": {
        "id": "H-34-pkpd-sampling",
        "instanceType": "PKPDSampling",
        "name": "H-34 PK/PD Sampling",
        "description": "Pharmacokinetic and pharmacodynamic sampling requirements for the DELTA Revision cup study.",
        "pk_sampling": {
          "pk_sampling_required": false,
          "pk_sampling_purpose": null,
          "analytes": [],
          "sampling_schedule": [],
          "intensive_pk_visits": [],
          "sparse_pk_visits": [],
          "sample_volume": null,
          "total_pk_samples": null,
          "provenance": {
            "section_number": null,
            "page_number": 1,
            "text_snippet": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
          }
        },
        "pk_parameters": {
          "primary_parameters": [],
          "secondary_parameters": [],
          "calculation_method": null,
          "software": null,
          "provenance": {
            "section_number": null,
            "page_number": 1,
            "text_snippet": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
          }
        },
        "population_pk": {
          "pop_pk_planned": false,
          "modeling_approach": null,
          "covariates": [],
          "objectives": null,
          "provenance": {
            "section_number": null,
            "page_number": 1,
            "text_snippet": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
          }
        },
        "pd_assessments": {
          "pd_assessments_required": true,
          "pd_biomarkers": [
            {
              "biomarker_id": "BIOMARKER-001",
              "biomarker_name": "Harris Hip Score (HHS)",
              "biomarker_type": "clinical_outcome_assessment",
              "matrix": "N/A",
              "assay_method": "Questionnaire and Physical Examination",
              "sampling_schedule": [
                {
                  "schedule_id": "SCHED-PD-001",
                  "visit_name": "Pre-operative",
                  "provenance": {
                    "section_number": "4.1",
                    "page_number": 17,
                    "text_snippet": "The primary endpoint of the study is the evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant."
                  }
                },
                {
                  "schedule_id": "SCHED-PD-002",
                  "visit_name": "Intraoperatively/Discharge",
                  "provenance": {
                    "section_number": "4.1",
                    "page_number": 17,
                    "text_snippet": "The primary endpoint of the study is the evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant."
                  }
                },
                {
                  "schedule_id": "SCHED-PD-003",
                  "visit_name": "2 months",
                  "provenance": {
                    "section_number": "4.1",
                    "page_number": 17,
                    "text_snippet": "The primary endpoint of the study is the evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant."
                  }
                },
                {
                  "schedule_id": "SCHED-PD-004",
                  "visit_name": "6 months",
                  "provenance": {
                    "section_number": "4.1",
                    "page_number": 17,
                    "text_snippet": "The primary endpoint of the study is the evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant."
                  }
                },
                {
                  "schedule_id": "SCHED-PD-005",
                  "visit_name": "1 year",
                  "provenance": {
                    "section_number": "4.1",
                    "page_number": 17,
                    "text_snippet": "The primary endpoint of the study is the evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant."
                  }
                },
                {
                  "schedule_id": "SCHED-PD-006",
                  "visit_name": "2 years",
                  "provenance": {
                    "section_number": "4.1",
                    "page_number": 17,
                    "text_snippet": "The primary endpoint of the study is the evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant."
                  }
                }
              ],
              "purpose": "To assess clinical outcomes of pain, function, deformity, and range of motion.",
              "biomedicalConcept": {
                "conceptName": "Harris Hip Score",
                "cdiscCode": "C106114",
                "domain": "PP",
                "confidence": 1,
                "rationale": "NCI code for Harris Hip Score questionnaire."
              },
              "provenance": {
                "section_number": "7.6.1",
                "page_number": 27,
                "text_snippet": "Harris Hip Score (HHS) and Range of motion (ROM) [6]\nThe Harris Hip Scale (HHS) was developed for the assessment of the results of hip surgery, and it is intended to evaluate various hip disabilities and methods of treatment in an adult population."
              }
            },
            {
              "biomarker_id": "BIOMARKER-002",
              "biomarker_name": "Oxford Hip Score (OHS)",
              "biomarker_type": "patient_reported_outcome",
              "matrix": "N/A",
              "assay_method": "Questionnaire",
              "sampling_schedule": [
                {
                  "schedule_id": "SCHED-PD-007",
                  "visit_name": "Pre-operative",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years;"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-008",
                  "visit_name": "Intraoperatively/Discharge",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years;"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-009",
                  "visit_name": "2 months",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years;"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-010",
                  "visit_name": "6 months",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years;"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-011",
                  "visit_name": "1 year",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years;"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-012",
                  "visit_name": "2 years",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years;"
                  }
                }
              ],
              "purpose": "To assess patient-reported disability, pain and functional ability.",
              "biomedicalConcept": {
                "conceptName": "Oxford Hip Score",
                "cdiscCode": "C98711",
                "domain": "PP",
                "confidence": 1,
                "rationale": "NCI code for Oxford Hip Score questionnaire."
              },
              "provenance": {
                "section_number": "7.6.2",
                "page_number": 28,
                "text_snippet": "The Oxford Hip Score (OHS) is a joint-specific, patient-reported outcome (PRO) measure, or PROM, designed to assess disability in patients undergoing total hip replacement (THR) [10]."
              }
            },
            {
              "biomarker_id": "BIOMARKER-003",
              "biomarker_name": "Range of Motion (ROM)",
              "biomarker_type": "clinical_outcome_assessment",
              "matrix": "N/A",
              "assay_method": "Physical Examination",
              "sampling_schedule": [
                {
                  "schedule_id": "SCHED-PD-013",
                  "visit_name": "Pre-operative",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-014",
                  "visit_name": "Intraoperatively/Discharge",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-015",
                  "visit_name": "2 months",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-016",
                  "visit_name": "6 months",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-017",
                  "visit_name": "1 year",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-018",
                  "visit_name": "2 years",
                  "provenance": {
                    "section_number": "4.2",
                    "page_number": 17,
                    "text_snippet": "Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;"
                  }
                }
              ],
              "purpose": "To assess hip joint function.",
              "biomedicalConcept": {
                "conceptName": "Range of Motion",
                "cdiscCode": "C25242",
                "domain": "PP",
                "confidence": 1,
                "rationale": "NCI code for Range of Motion."
              },
              "provenance": {
                "section_number": "7.6.1",
                "page_number": 27,
                "text_snippet": "Harris Hip Score (HHS) and Range of motion (ROM) [6]"
              }
            },
            {
              "biomarker_id": "BIOMARKER-004",
              "biomarker_name": "Heterotopic Ossification",
              "biomarker_type": "radiographic_outcome",
              "matrix": "X-ray image",
              "assay_method": "Brooker classification",
              "sampling_schedule": [
                {
                  "schedule_id": "SCHED-PD-019",
                  "visit_name": "Discharge",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Heterotopic Ossification; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-020",
                  "visit_name": "Month 2",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Heterotopic Ossification; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-021",
                  "visit_name": "Month 6",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Heterotopic Ossification; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-022",
                  "visit_name": "Month 12",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Heterotopic Ossification; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-023",
                  "visit_name": "Month 24",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Heterotopic Ossification; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                }
              ],
              "purpose": "To assess ectopic bone formation.",
              "biomedicalConcept": {
                "conceptName": "Heterotopic Ossification",
                "cdiscCode": "C34898",
                "domain": "PP",
                "confidence": 1,
                "rationale": "NCI code for Heterotopic Ossification."
              },
              "provenance": {
                "section_number": "7.7.1",
                "page_number": 31,
                "text_snippet": "Heterotopic Ossification consists of the development of bone outside its normal location in the skeleton. Heterotopic Ossification will be graded from AP view following the Brooker classification [13]:"
              }
            },
            {
              "biomarker_id": "BIOMARKER-005",
              "biomarker_name": "Acetabular Inclination",
              "biomarker_type": "radiographic_outcome",
              "matrix": "X-ray image",
              "assay_method": "Radiographic measurement",
              "sampling_schedule": [
                {
                  "schedule_id": "SCHED-PD-024",
                  "visit_name": "Discharge",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Inclination; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-025",
                  "visit_name": "Month 2",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Inclination; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-026",
                  "visit_name": "Month 6",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Inclination; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-027",
                  "visit_name": "Month 12",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Inclination; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-028",
                  "visit_name": "Month 24",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Inclination; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                }
              ],
              "purpose": "To assess implant positioning.",
              "biomedicalConcept": {
                "conceptName": "Acetabular Inclination",
                "cdiscCode": "CUSTOM",
                "domain": "PP",
                "confidence": 0.5,
                "rationale": "Specific radiographic measurement for hip arthroplasty."
              },
              "provenance": {
                "section_number": "7.7.2",
                "page_number": 31,
                "text_snippet": "Acetabular Inclination is defined from the AP Pelvis view and consists of the angle between the articular side of the acetabular cup and the transverse axis [15]."
              }
            },
            {
              "biomarker_id": "BIOMARKER-006",
              "biomarker_name": "Acetabular Anteversion",
              "biomarker_type": "radiographic_outcome",
              "matrix": "X-ray image",
              "assay_method": "Radiographic measurement",
              "sampling_schedule": [
                {
                  "schedule_id": "SCHED-PD-029",
                  "visit_name": "Discharge",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Anteversion; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-030",
                  "visit_name": "Month 2",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Anteversion; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-031",
                  "visit_name": "Month 6",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Anteversion; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-032",
                  "visit_name": "Month 12",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Anteversion; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-033",
                  "visit_name": "Month 24",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Anteversion; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                }
              ],
              "purpose": "To assess implant positioning.",
              "biomedicalConcept": {
                "conceptName": "Acetabular Anteversion",
                "cdiscCode": "CUSTOM",
                "domain": "PP",
                "confidence": 0.5,
                "rationale": "Specific radiographic measurement for hip arthroplasty."
              },
              "provenance": {
                "section_number": "7.7.3",
                "page_number": 31,
                "text_snippet": "Acetabular Anteversion is defined on a lateral view by the angle between the acetabular axis and the coronal plane [15] [16]."
              }
            },
            {
              "biomarker_id": "BIOMARKER-007",
              "biomarker_name": "Acetabular Component Radiolucency",
              "biomarker_type": "radiographic_outcome",
              "matrix": "X-ray image",
              "assay_method": "DeLee-Charnley zones",
              "sampling_schedule": [
                {
                  "schedule_id": "SCHED-PD-034",
                  "visit_name": "Discharge",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Component Radiolucency; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-035",
                  "visit_name": "Month 2",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Component Radiolucency; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-036",
                  "visit_name": "Month 6",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Component Radiolucency; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-037",
                  "visit_name": "Month 12",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Component Radiolucency; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-038",
                  "visit_name": "Month 24",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Component Radiolucency; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                }
              ],
              "purpose": "To assess implant stability and risk of loosening.",
              "biomedicalConcept": {
                "conceptName": "Radiolucency",
                "cdiscCode": "C28073",
                "domain": "PP",
                "confidence": 1,
                "rationale": "NCI code for Radiolucency, a radiographic finding."
              },
              "provenance": {
                "section_number": "7.7.4",
                "page_number": 32,
                "text_snippet": "Acetabular component is divided into 3 regions of interest according to DeLee-Charnley [12]. Radiolucent lines are evaluated according to their presence, absence, location and thickness; Acetabular Component Radiolucency will be graded in accordance with the following definitions from the AP view:"
              }
            },
            {
              "biomarker_id": "BIOMARKER-008",
              "biomarker_name": "Acetabular Component Migration",
              "biomarker_type": "radiographic_outcome",
              "matrix": "X-ray image",
              "assay_method": "Radiographic measurement",
              "sampling_schedule": [
                {
                  "schedule_id": "SCHED-PD-039",
                  "visit_name": "Discharge",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Component Migration; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-040",
                  "visit_name": "Month 2",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Component Migration; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-041",
                  "visit_name": "Month 6",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Component Migration; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-042",
                  "visit_name": "Month 12",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Component Migration; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-043",
                  "visit_name": "Month 24",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Acetabular Component Migration; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                }
              ],
              "purpose": "To assess implant stability.",
              "biomedicalConcept": {
                "conceptName": "Prosthesis Migration",
                "cdiscCode": "C95350",
                "domain": "PP",
                "confidence": 1,
                "rationale": "NCI code for Prosthesis Migration."
              },
              "provenance": {
                "section_number": "7.7.5",
                "page_number": 33,
                "text_snippet": "Acetabular Component Migration will be graded from AP view in accordance with the following definitions [17]:"
              }
            },
            {
              "biomarker_id": "BIOMARKER-009",
              "biomarker_name": "Dislocation",
              "biomarker_type": "radiographic_outcome",
              "matrix": "X-ray image",
              "assay_method": "Radiographic assessment",
              "sampling_schedule": [
                {
                  "schedule_id": "SCHED-PD-044",
                  "visit_name": "Discharge",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Dislocation; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-045",
                  "visit_name": "Month 2",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Dislocation; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-046",
                  "visit_name": "Month 6",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Dislocation; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-047",
                  "visit_name": "Month 12",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Dislocation; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-048",
                  "visit_name": "Month 24",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Dislocation; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                }
              ],
              "purpose": "To assess implant failure.",
              "biomedicalConcept": {
                "conceptName": "Prosthesis Dislocation",
                "cdiscCode": "C71764",
                "domain": "PP",
                "confidence": 1,
                "rationale": "NCI code for Prosthesis Dislocation."
              },
              "provenance": {
                "section_number": "7.7.6",
                "page_number": 33,
                "text_snippet": "Dislocation occurs if the head moves out of the acetabular component for any reason and will be graded from AP view in accordance with the following definitions:"
              }
            },
            {
              "biomarker_id": "BIOMARKER-010",
              "biomarker_name": "Infection (radiographic signs)",
              "biomarker_type": "radiographic_outcome",
              "matrix": "X-ray image",
              "assay_method": "Radiographic assessment",
              "sampling_schedule": [
                {
                  "schedule_id": "SCHED-PD-049",
                  "visit_name": "Discharge",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Infection; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-050",
                  "visit_name": "Month 2",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Infection; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-051",
                  "visit_name": "Month 6",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Infection; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-052",
                  "visit_name": "Month 12",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Infection; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                },
                {
                  "schedule_id": "SCHED-PD-053",
                  "visit_name": "Month 24",
                  "provenance": {
                    "section_number": "Appendix 2",
                    "page_number": 55,
                    "text_snippet": "Assessments: Infection; Visit: At Discharge, Month 2, Month 6, Month 12, Month 24"
                  }
                }
              ],
              "purpose": "To assess for signs of peri-prosthetic infection.",
              "biomedicalConcept": {
                "conceptName": "Prosthesis-Related Infection",
                "cdiscCode": "C71765",
                "domain": "PP",
                "confidence": 1,
                "rationale": "NCI code for Prosthesis-Related Infection."
              },
              "provenance": {
                "section_number": "7.7.7",
                "page_number": 33,
                "text_snippet": "Radiographic findings suggestive of Infection can vary from completely normal to frank bone destruction mimicking loosening or particle disease, also including a wide irregular radiolucency at the metal-bone interface. Infection will be graded from AP view in accordance with the following definitions:"
              }
            }
          ],
          "pk_pd_relationship": null,
          "provenance": {
            "section_number": "7",
            "page_number": 26,
            "text_snippet": "7 Study assessment\nAll patients will be closely monitored for safety and the evaluation of the implant status during all study: The timing of study visits will be in accordance with current local practice at the study site, but the following timelines and temporal window will be followed:"
          }
        },
        "immunogenicity": {
          "ada_testing_required": false,
          "ada_assay_type": null,
          "sampling_schedule": [],
          "tiered_approach": null,
          "impact_on_pk": null,
          "provenance": {
            "section_number": null,
            "page_number": 1,
            "text_snippet": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
          }
        },
        "sample_handling": {
          "collection_tubes": [],
          "processing_requirements": null,
          "storage_conditions": null,
          "shipping_requirements": null,
          "central_lab": null,
          "provenance": {
            "section_number": null,
            "page_number": 1,
            "text_snippet": "An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
          }
        },
        "special_populations": {
          "hepatic_impairment": null,
          "renal_impairment": null,
          "pediatric": null,
          "elderly": null,
          "provenance": {
            "section_number": "5.1",
            "page_number": 18,
            "text_snippet": "Patients must meet the following criteria for study entry:\n1. Male or female.\n2. Age \u2265 18 years old."
          }
        },
        "extraction_statistics": {
          "has_pk_sampling": false,
          "has_pd_assessments": true,
          "has_immunogenicity": false,
          "has_population_pk": false,
          "analyte_count": 0,
          "biomarker_count": 10,
          "total_pk_timepoints": 0
        },
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "Study protocol\nAn open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision cup."
        }
      },
      "_agentDocumentation": {
        "agentId": "pkpd_sampling",
        "displayName": "PK/PD Sampling",
        "instanceType": "PKPDSampling",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts pharmacokinetic and pharmacodynamic sampling specifications for clinical pharmacology studies.",
        "scope": "PK sampling timepoints, PD biomarker sampling, bioanalytical methods, population PK specifications.",
        "keySectionsAnalyzed": [
          "Section 7: Pharmacokinetic Assessments",
          "Section 8: Pharmacodynamic Assessments",
          "Appendix: PK Sampling Schedule"
        ],
        "keyInsights": [
          {
            "name": "PK Sampling Schedule",
            "description": "Intensive and sparse PK timepoints",
            "dataPath": "pk_sampling.timepoints[]",
            "downstreamUses": [
              "Site PK procedure guides",
              "Central lab setup",
              "Visit schedule"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure bioanalytical lab sample requirements",
          "Create PK sampling procedure guides"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "biospecimen_handling",
            "arms_design",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "PC",
          "PP"
        ],
        "regulatoryRelevance": "FDA Clinical Pharmacology Guidance",
        "schemaFile": "pkpd_sampling_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    }
  },
  "provenanceSummary": {
    "totalPagesReferenced": 42,
    "pageRange": [
      1,
      55
    ],
    "sectionPageCounts": {
      "studyMetadata": 8,
      "studyDesign": 3,
      "endpointsEstimandsSAP": 8,
      "adverseEvents": 6,
      "safetyDecisionPoints": 5,
      "concomitantMedications": 2,
      "biospecimenHandling": 4,
      "laboratorySpecifications": 4,
      "informedConsent": 16,
      "proSpecifications": 8,
      "dataManagement": 5,
      "siteOperationsLogistics": 16,
      "qualityManagement": 8,
      "withdrawalProcedures": 3,
      "imagingCentralReading": 5,
      "pkpdSampling": 10
    },
    "pageToSections": {
      "1": [
        "studyMetadata",
        "studyDesign",
        "endpointsEstimandsSAP",
        "informedConsent",
        "siteOperationsLogistics",
        "imagingCentralReading",
        "pkpdSampling"
      ],
      "3": [
        "siteOperationsLogistics"
      ],
      "4": [
        "studyMetadata"
      ],
      "5": [
        "studyMetadata"
      ],
      "10": [
        "studyMetadata",
        "studyDesign",
        "endpointsEstimandsSAP",
        "informedConsent",
        "proSpecifications",
        "qualityManagement"
      ],
      "11": [
        "studyMetadata",
        "studyDesign",
        "endpointsEstimandsSAP",
        "proSpecifications",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "14": [
        "informedConsent"
      ],
      "15": [
        "endpointsEstimandsSAP"
      ],
      "16": [
        "endpointsEstimandsSAP",
        "safetyDecisionPoints"
      ],
      "17": [
        "studyMetadata",
        "informedConsent",
        "qualityManagement",
        "pkpdSampling"
      ],
      "18": [
        "studyMetadata",
        "laboratorySpecifications",
        "informedConsent",
        "pkpdSampling"
      ],
      "19": [
        "safetyDecisionPoints",
        "informedConsent",
        "withdrawalProcedures"
      ],
      "20": [
        "safetyDecisionPoints",
        "siteOperationsLogistics",
        "withdrawalProcedures"
      ],
      "21": [
        "studyMetadata",
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "22": [
        "siteOperationsLogistics"
      ],
      "23": [
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "24": [
        "informedConsent"
      ],
      "26": [
        "concomitantMedications",
        "informedConsent",
        "proSpecifications",
        "pkpdSampling"
      ],
      "27": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "proSpecifications",
        "pkpdSampling"
      ],
      "28": [
        "proSpecifications",
        "pkpdSampling"
      ],
      "29": [
        "biospecimenHandling",
        "informedConsent",
        "proSpecifications",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement",
        "imagingCentralReading"
      ],
      "30": [
        "biospecimenHandling"
      ],
      "31": [
        "imagingCentralReading",
        "pkpdSampling"
      ],
      "32": [
        "imagingCentralReading",
        "pkpdSampling"
      ],
      "33": [
        "imagingCentralReading",
        "pkpdSampling"
      ],
      "34": [
        "concomitantMedications",
        "laboratorySpecifications",
        "siteOperationsLogistics"
      ],
      "35": [
        "adverseEvents",
        "safetyDecisionPoints"
      ],
      "36": [
        "adverseEvents",
        "safetyDecisionPoints",
        "qualityManagement"
      ],
      "37": [
        "adverseEvents",
        "informedConsent"
      ],
      "38": [
        "adverseEvents"
      ],
      "39": [
        "adverseEvents"
      ],
      "40": [
        "adverseEvents"
      ],
      "41": [
        "endpointsEstimandsSAP"
      ],
      "42": [
        "endpointsEstimandsSAP",
        "proSpecifications",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "43": [
        "endpointsEstimandsSAP",
        "dataManagement",
        "siteOperationsLogistics"
      ],
      "44": [
        "proSpecifications",
        "dataManagement",
        "siteOperationsLogistics"
      ],
      "45": [
        "dataManagement",
        "siteOperationsLogistics"
      ],
      "46": [
        "siteOperationsLogistics",
        "qualityManagement",
        "withdrawalProcedures"
      ],
      "47": [
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "48": [
        "informedConsent",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "53": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "dataManagement"
      ],
      "55": [
        "pkpdSampling"
      ]
    }
  },
  "agentDocumentation": {
    "description": "Agent documentation for downstream system automation. Each agent's documentation describes its purpose, key insights, downstream system integrations, and automation use cases.",
    "agents": {
      "study_metadata": {
        "agentId": "study_metadata",
        "displayName": "Study Metadata",
        "instanceType": "Study",
        "wave": 0,
        "priority": 0,
        "purpose": "Extracts foundational study-level metadata that all other agents depend on.\n    This agent runs first and provides the context (protocol ID, phase, therapeutic area,\n    population characteristics) that enables accurate extraction by downstream agents.",
        "scope": "- Protocol identification (NCT, EudraCT, IND numbers)\n    - Study phase, type, and design overview\n    - Sponsor information\n    - Target population characteristics (disease, age, sex, biomarkers)\n    - Key milestones and timelines\n    - Design metadata (randomization, blinding, enrollment targets)",
        "keySectionsAnalyzed": [
          "Title Page / Cover",
          "Synopsis",
          "Section 1: Introduction and Background",
          "Section 3: Study Objectives",
          "Section 4: Study Design",
          "Section 5: Study Population"
        ],
        "keyInsights": [
          {
            "name": "Protocol Identifiers",
            "description": "NCT number, EudraCT, IND numbers for regulatory cross-referencing",
            "dataPath": "studyIdentifiers[]",
            "downstreamUses": [
              "CTMS study registration",
              "Regulatory submission linking",
              "ClinicalTrials.gov sync"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "CTMS_REG_001",
                "ruleType": "derivation",
                "targetSystem": "Clinical Trial Management System",
                "description": "Auto-populate CTMS study record from protocol identifiers",
                "sourceDataPath": "studyIdentifiers[].identifier",
                "ruleLogic": "FOR EACH id IN studyIdentifiers: SET ctms.registry[id.type] = id.identifier",
                "example": "NCT number \u2192 CTMS.NCT_ID field"
              }
            ],
            "validationChecks": [
              "All identifiers must match ClinicalTrials.gov registry"
            ]
          },
          {
            "name": "Study Phase",
            "description": "Clinical trial phase with NCI Thesaurus code",
            "dataPath": "studyPhase",
            "downstreamUses": [
              "Regulatory pathway determination",
              "Site qualification criteria",
              "Budget estimation"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_PHASE_001",
                "ruleType": "validation",
                "targetSystem": "Interactive Response Technology",
                "description": "Validate IRT complexity requirements based on phase",
                "sourceDataPath": "studyPhase.decode",
                "ruleLogic": "IF phase IN ['Phase 1', 'Phase 1/2'] THEN require dose_escalation_module",
                "example": "Phase 1 \u2192 Enable dose escalation cohort management"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Target Population",
            "description": "Disease, age range, sex, biomarker requirements, performance status",
            "dataPath": "studyPopulation",
            "downstreamUses": [
              "Site feasibility scoring",
              "Patient recruitment targeting",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_ELIG_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate age range edit check for eligibility form",
                "sourceDataPath": "studyPopulation.ageRange",
                "ruleLogic": "IF subject_age < min_age OR subject_age > max_age THEN RAISE eligibility_failure",
                "example": "Age 18-75 \u2192 Edit check: BRTHDT must result in age between 18 and 75 at screening"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Study Milestones",
            "description": "Screening period, enrollment duration, treatment duration, follow-up",
            "dataPath": "studyMilestones",
            "downstreamUses": [
              "CTMS timeline configuration",
              "Site contract milestones",
              "Resource planning"
            ],
            "automationCategory": "Visit Schedule Programming",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Design Metadata",
            "description": "Randomization ratio, blinding type, target enrollment, countries",
            "dataPath": "studyDesignInfo",
            "downstreamUses": [
              "IRT configuration",
              "Drug supply planning",
              "Regulatory strategy"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_RAND_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT randomization ratio",
                "sourceDataPath": "studyDesignInfo.randomizationRatio",
                "ruleLogic": "SET irt.allocation_ratio = randomizationRatio; SET irt.block_size = CALCULATE(ratio)",
                "example": "2:1 ratio \u2192 IRT blocks of 3 or 6"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System",
          "Interactive Response Technology",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Pre-populate EDC study header and demographics forms",
          "Configure CTMS study record with identifiers and milestones",
          "Set IRT enrollment caps by country/region",
          "Generate ClinicalTrials.gov registration data",
          "Auto-configure site feasibility questionnaires"
        ],
        "integration": {
          "dependsOn": [],
          "enriches": [
            "arms_design",
            "endpoints_estimands_sap",
            "eligibility_criteria"
          ],
          "crossReferences": [
            "quality_management",
            "data_management"
          ]
        },
        "cdiscDomains": [
          "DM",
          "DS"
        ],
        "regulatoryRelevance": "Foundation for ICH M11 sections 1-5, CTD Module 5",
        "schemaFile": "study_metadata_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_STUDY_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate study-level EDC configuration",
            "sourceDataPath": "*",
            "ruleLogic": "CREATE study_config FROM (protocolId, studyTitle, studyPhase, therapeuticArea)",
            "example": null
          },
          {
            "ruleId": "CTMS_REG_001",
            "ruleType": "derivation",
            "targetSystem": "Clinical Trial Management System",
            "description": "Auto-populate CTMS study record from protocol identifiers",
            "sourceDataPath": "studyIdentifiers[].identifier",
            "ruleLogic": "FOR EACH id IN studyIdentifiers: SET ctms.registry[id.type] = id.identifier",
            "example": "NCT number \u2192 CTMS.NCT_ID field"
          },
          {
            "ruleId": "IRT_PHASE_001",
            "ruleType": "validation",
            "targetSystem": "Interactive Response Technology",
            "description": "Validate IRT complexity requirements based on phase",
            "sourceDataPath": "studyPhase.decode",
            "ruleLogic": "IF phase IN ['Phase 1', 'Phase 1/2'] THEN require dose_escalation_module",
            "example": "Phase 1 \u2192 Enable dose escalation cohort management"
          },
          {
            "ruleId": "EDC_ELIG_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate age range edit check for eligibility form",
            "sourceDataPath": "studyPopulation.ageRange",
            "ruleLogic": "IF subject_age < min_age OR subject_age > max_age THEN RAISE eligibility_failure",
            "example": "Age 18-75 \u2192 Edit check: BRTHDT must result in age between 18 and 75 at screening"
          },
          {
            "ruleId": "IRT_RAND_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT randomization ratio",
            "sourceDataPath": "studyDesignInfo.randomizationRatio",
            "ruleLogic": "SET irt.allocation_ratio = randomizationRatio; SET irt.block_size = CALCULATE(ratio)",
            "example": "2:1 ratio \u2192 IRT blocks of 3 or 6"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_META_ARMS_001",
            "name": "Study Context + Arms \u2192 IRT Complete Configuration",
            "agentsInvolved": [
              "study_metadata",
              "arms_design"
            ],
            "description": "Combining study design info with arm definitions enables complete IRT setup",
            "combinedInsight": "Randomization ratio + arm definitions + stratification = Complete IRT randomization module",
            "automationEnabled": "One-click IRT vendor specification generation",
            "exampleOutput": "{\"randomization\": {\"ratio\": \"2:1\", \"arms\": [\"Drug A\", \"Placebo\"], \"stratification\": [\"ECOG\", \"Prior Therapy\"]}}"
          },
          {
            "synergyId": "SYN_META_ELIG_001",
            "name": "Population + Eligibility \u2192 Smart Screening",
            "agentsInvolved": [
              "study_metadata",
              "eligibility_criteria",
              "laboratory_specifications"
            ],
            "description": "Population characteristics + criteria + lab values = intelligent screening tool",
            "combinedInsight": "Age/sex + inclusion/exclusion + lab ranges = Complete eligibility calculator",
            "automationEnabled": "Site-facing eligibility screening app with real-time validation",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_META_001",
            "name": "Phase-Design Consistency",
            "agentsInvolved": [
              "study_metadata",
              "arms_design"
            ],
            "validationType": "consistency",
            "description": "Verify study phase is consistent with arm complexity",
            "checkLogic": "IF phase='Phase 1' THEN arms.count SHOULD BE <= 3",
            "severity": "warning"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "study_header",
            "description": "EDC study-level configuration derived from metadata",
            "dataSources": [
              "protocolId",
              "studyTitle",
              "studyPhase",
              "sponsorName"
            ],
            "outputFormat": "EDC vendor import format (Medidata Rave, Oracle InForm, Veeva Vault)",
            "exampleConfig": {
              "study_id": "{protocolId}",
              "study_name": "{studyTitle}",
              "phase": "{studyPhase.decode}",
              "sponsor": "{sponsorName}",
              "therapeutic_area": "{therapeuticArea}"
            }
          }
        ]
      },
      "arms_design": {
        "agentId": "arms_design",
        "displayName": "Treatment Arms & Study Design",
        "instanceType": "StudyDesign",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts the complete treatment design including study arms, epochs, dosing regimens,\n    randomization configuration, and drug supply requirements. This is the primary source\n    for IRT/IWRS and drug supply management system configuration.",
        "scope": "- Study arms (experimental, comparator, placebo)\n    - Treatment epochs (screening, treatment, follow-up)\n    - Study cells (arm \u00d7 epoch matrix)\n    - Dosing regimens (dose, frequency, route, cycle length)\n    - Dose modification rules and triggers\n    - Randomization details (ratio, stratification, block size, algorithm)\n    - Drug supply kit configurations",
        "keySectionsAnalyzed": [
          "Section 4: Study Design",
          "Section 5: Study Population",
          "Section 6: Study Drug/Treatment",
          "Section 7: Dose Modifications",
          "Section 9: Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "Study Arms",
            "description": "Complete arm definitions with interventions, types, and allocation ratios",
            "dataPath": "studyArms[]",
            "downstreamUses": [
              "IRT arm configuration",
              "EDC treatment assignment forms",
              "Drug supply forecasting"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Generate IRT arm configuration from study arms",
                "sourceDataPath": "studyArms[]",
                "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
                "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
              },
              {
                "ruleId": "EDC_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate treatment assignment dropdown options",
                "sourceDataPath": "studyArms[].name",
                "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dosing Regimens",
            "description": "Dose, unit, frequency, route, cycle length, dose calculation basis",
            "dataPath": "studyArms[].interventions[].dosingRegimen",
            "downstreamUses": [
              "Drug accountability forms",
              "IRT dispensing rules",
              "Pharmacy manual generation"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DISP_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT dispensing rules from dosing regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
                "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
                "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
              },
              {
                "ruleId": "EDC_DOSE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dispensed dose against protocol regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
                "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stratification Factors",
            "description": "Randomization stratification with levels and definitions",
            "dataPath": "designMetadata.stratificationFactors[]",
            "downstreamUses": [
              "IRT stratification setup",
              "EDC stratification CRF",
              "Analysis programming"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT stratification from protocol factors",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
                "example": "ECOG (0-1, 2) \u00d7 Prior Therapy (Yes, No) = 4 strata"
              },
              {
                "ruleId": "EDC_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate stratification CRF fields",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dose Modification Rules",
            "description": "Reduction levels, triggers, hold/resume criteria",
            "dataPath": "studyArms[].interventions[].doseModifications",
            "downstreamUses": [
              "EDC dose modification forms",
              "Safety alert rules",
              "Medical monitor dashboards"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DOSEMOD_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dose modification follows protocol levels",
                "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
                "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Supply Configuration",
            "description": "Kit types, dispensing schedule, supply model",
            "dataPath": "designMetadata.drugSupply",
            "downstreamUses": [
              "IRT kit management",
              "Depot configuration",
              "Supply chain forecasting"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Randomization & Trial Supply Management",
                "description": "Generate kit configuration and depot requirements",
                "sourceDataPath": "designMetadata.drugSupply",
                "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Interactive Response Technology",
          "Interactive Web Response System",
          "Randomization & Trial Supply Management",
          "Electronic Data Capture",
          "Drug Supply Management"
        ],
        "automationUseCases": [
          "Auto-generate IRT randomization and drug dispensing configuration",
          "Create EDC treatment assignment and dose modification CRFs",
          "Configure drug supply forecasting models",
          "Generate pharmacy manuals and dispensing instructions",
          "Set up stratification factor data entry forms",
          "Configure enrollment caps by stratum/region"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "safety_decision_points",
            "pkpd_sampling",
            "biospecimen_handling"
          ],
          "crossReferences": [
            "concomitant_medications",
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "TA",
          "TE",
          "TI",
          "TV",
          "EX",
          "EC"
        ],
        "regulatoryRelevance": "ICH M11 Section 6 (Treatment), CTD Module 2.7.1",
        "schemaFile": "arms_design_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Generate IRT arm configuration from study arms",
            "sourceDataPath": "studyArms[]",
            "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
            "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
          },
          {
            "ruleId": "EDC_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate treatment assignment dropdown options",
            "sourceDataPath": "studyArms[].name",
            "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
            "example": null
          },
          {
            "ruleId": "IRT_DISP_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT dispensing rules from dosing regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
            "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
            "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
          },
          {
            "ruleId": "EDC_DOSE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dispensed dose against protocol regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
            "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
            "example": null
          },
          {
            "ruleId": "IRT_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT stratification from protocol factors",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
            "example": "ECOG (0-1, 2) \u00d7 Prior Therapy (Yes, No) = 4 strata"
          },
          {
            "ruleId": "EDC_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate stratification CRF fields",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
            "example": null
          },
          {
            "ruleId": "EDC_DOSEMOD_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dose modification follows protocol levels",
            "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
            "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
            "example": null
          },
          {
            "ruleId": "IRT_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Randomization & Trial Supply Management",
            "description": "Generate kit configuration and depot requirements",
            "sourceDataPath": "designMetadata.drugSupply",
            "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_ARMS_SAFETY_001",
            "name": "Dosing + Safety Rules \u2192 Complete Dose Management",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining dosing regimens with safety thresholds and lab triggers enables intelligent dose management",
            "combinedInsight": "Protocol doses + reduction levels + lab thresholds = Automated dose recommendation engine",
            "automationEnabled": "EDC can suggest appropriate dose level based on current labs and AEs",
            "exampleOutput": "{\"current_dose\": \"400mg\", \"recommended_action\": \"REDUCE to 300mg\", \"trigger\": \"ANC < 1000\", \"confidence\": 0.95}"
          },
          {
            "synergyId": "SYN_ARMS_SOA_001",
            "name": "Arms + SOA \u2192 Visit-Based Dispensing",
            "agentsInvolved": [
              "arms_design",
              "soa_schedule"
            ],
            "description": "Arm-specific dosing matched to visit schedule enables precise dispensing rules",
            "combinedInsight": "Which drug, what dose, at which visits = Complete dispensing matrix",
            "automationEnabled": "IRT auto-dispense based on visit and arm assignment",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_ARMS_001",
            "name": "Arm Allocation Total",
            "agentsInvolved": [
              "arms_design"
            ],
            "validationType": "consistency",
            "description": "Verify arm allocations sum to 100%",
            "checkLogic": "SUM(studyArms[].allocationPercentage) == 100",
            "severity": "error"
          },
          {
            "ruleId": "VAL_ARMS_002",
            "name": "Dose Levels Consistency",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels in arms match safety decision points",
            "checkLogic": "arms.doseModifications.levels SUBSET_OF safety.dose_modification_levels.levels",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Interactive Response Technology",
            "configType": "randomization_module",
            "description": "Complete IRT randomization configuration",
            "dataSources": [
              "studyArms[].id",
              "studyArms[].name",
              "studyArms[].allocationPercentage",
              "designMetadata.stratificationFactors[]",
              "designMetadata.randomizationRatio"
            ],
            "outputFormat": "IRT vendor import (Medidata RTSM, Oracle Siebel CTMS, Parexel ClinPhone)",
            "exampleConfig": {
              "study_arms": [
                {
                  "code": "A",
                  "name": "Drug A + Chemo",
                  "ratio": 2
                },
                {
                  "code": "B",
                  "name": "Placebo + Chemo",
                  "ratio": 1
                }
              ],
              "stratification_factors": [
                {
                  "name": "ECOG Status",
                  "levels": [
                    "0-1",
                    "2"
                  ]
                },
                {
                  "name": "Prior Therapy",
                  "levels": [
                    "Yes",
                    "No"
                  ]
                }
              ],
              "block_size": [
                3,
                6
              ],
              "randomization_method": "permuted_block"
            }
          }
        ]
      },
      "endpoints_estimands_sap": {
        "agentId": "endpoints_estimands_sap",
        "displayName": "Endpoints, Estimands & SAP",
        "instanceType": "EndpointsEstimandsSAP",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts study objectives, endpoints, estimands (per ICH E9 R1), analysis populations,\n    and statistical analysis specifications. This is the definitive source for programming\n    analysis datasets and statistical outputs.",
        "scope": "- Primary, secondary, and exploratory objectives\n    - Endpoint definitions with outcome types and assessment methods\n    - ICH E9(R1) compliant estimands with intercurrent event strategies\n    - Analysis populations (ITT, mITT, PP, Safety)\n    - Sensitivity and subgroup analyses\n    - Multiplicity adjustment strategy\n    - Missing data handling",
        "keySectionsAnalyzed": [
          "Section 2: Study Objectives and Endpoints",
          "Section 3: Study Objectives",
          "Section 8: Statistical Considerations",
          "Section 9: Statistical Analysis Plan",
          "Appendix: Statistical Analysis Plan (if separate)"
        ],
        "keyInsights": [
          {
            "name": "Primary Endpoints",
            "description": "Primary efficacy endpoints with outcome type, timepoints, and assessment method",
            "dataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "downstreamUses": [
              "Primary analysis programming",
              "Sample size validation",
              "DSMB reporting"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_EP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADaM ADEFF specification from primary endpoint",
                "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
                "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Estimands",
            "description": "ICH E9(R1) estimands with treatment comparison, population, variable, ICE strategies",
            "dataPath": "protocol_endpoints.estimands[]",
            "downstreamUses": [
              "Analysis programming specifications",
              "SAP finalization",
              "Regulatory submission narrative"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAP_EST_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate SAP estimand section from extracted estimands",
                "sourceDataPath": "protocol_endpoints.estimands[]",
                "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Analysis Populations",
            "description": "ITT, mITT, PP, Safety population definitions with inclusion/exclusion criteria",
            "dataPath": "protocol_endpoints.analysis_populations[]",
            "downstreamUses": [
              "ADSL derivation",
              "Population flag programming",
              "CSR population tables"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_POP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADSL population flags from definitions",
                "sourceDataPath": "protocol_endpoints.analysis_populations[]",
                "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
                "example": "ITTFL = 'Y' if randomized and received \u22651 dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Statistical Methods",
            "description": "Model specifications, covariates, multiplicity adjustment",
            "dataPath": "sap_analyses.statistical_methods[]",
            "downstreamUses": [
              "Analysis program templates",
              "Validation programming",
              "TLF shells"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Subgroup Analyses",
            "description": "Pre-specified subgroup definitions and analysis methods",
            "dataPath": "sap_analyses.subgroup_analyses[]",
            "downstreamUses": [
              "Forest plot programming",
              "Subgroup TLF generation",
              "Regulatory response preparation"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate CDISC ADaM dataset specifications from estimands",
          "Auto-create TLF shells from endpoint definitions",
          "Pre-configure statistical analysis programs",
          "Generate SAP templates with population definitions",
          "Create endpoint assessment CRFs in EDC",
          "Configure DSMB reporting data cuts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "pro_specifications",
            "imaging_central_reading"
          ],
          "crossReferences": [
            "adverse_events",
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "ADSL",
          "ADEFF",
          "ADTTE"
        ],
        "regulatoryRelevance": "ICH E9(R1), ICH M11 Sections 2-3, CTD Module 2.7.3/2.7.6",
        "schemaFile": "endpoints_estimands_sap_schema.json",
        "automationRules": [
          {
            "ruleId": "ADAM_EP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADaM ADEFF specification from primary endpoint",
            "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
            "example": null
          },
          {
            "ruleId": "SAP_EST_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate SAP estimand section from extracted estimands",
            "sourceDataPath": "protocol_endpoints.estimands[]",
            "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
            "example": null
          },
          {
            "ruleId": "ADAM_POP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADSL population flags from definitions",
            "sourceDataPath": "protocol_endpoints.analysis_populations[]",
            "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
            "example": "ITTFL = 'Y' if randomized and received \u22651 dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_EP_SOA_001",
            "name": "Endpoints + SOA \u2192 Assessment Schedule Validation",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "soa_schedule"
            ],
            "description": "Endpoint timepoints matched to SOA visits ensures all assessments are scheduled",
            "combinedInsight": "Primary endpoint at Week 12 + SOA Week 12 visit with efficacy assessment = Validated schedule",
            "automationEnabled": "Auto-verify SOA includes all required endpoint assessments",
            "exampleOutput": null
          },
          {
            "synergyId": "SYN_EP_AE_001",
            "name": "Endpoints + AEs + Withdrawal \u2192 Complete Estimand Definition",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "adverse_events",
              "withdrawal_procedures"
            ],
            "description": "Combining endpoint definitions with AE handling and withdrawal reasons enables complete ICE specification",
            "combinedInsight": "What happens to endpoint when subject discontinues due to AE = Complete intercurrent event strategy",
            "automationEnabled": "Generate regulatory-ready estimand framework documentation",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_EP_001",
            "name": "Endpoint-Objective Linkage",
            "agentsInvolved": [
              "endpoints_estimands_sap"
            ],
            "validationType": "completeness",
            "description": "Every endpoint must link to at least one objective",
            "checkLogic": "FOR EACH endpoint: EXISTS objective WHERE endpoint.id IN objective.endpoint_ids",
            "severity": "error"
          }
        ],
        "systemConfigurations": []
      },
      "adverse_events": {
        "agentId": "adverse_events",
        "displayName": "Adverse Events",
        "instanceType": "AdverseEvents",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts comprehensive adverse event management specifications including AE/SAE definitions,\n    grading systems, causality assessment, reporting timelines, and AESI lists. Critical for\n    safety database configuration and pharmacovigilance workflows.",
        "scope": "- AE and TEAE definitions\n    - SAE criteria per ICH E2A\n    - CTCAE grading system version and definitions\n    - Causality assessment methodology\n    - MedDRA coding specifications\n    - Reporting timelines (routine AE, SAE, SUSAR, pregnancy)\n    - AESI list with special monitoring requirements\n    - DLT criteria (oncology protocols)\n    - Safety committees (DSMB, SMC)",
        "keySectionsAnalyzed": [
          "Section 7: Safety Reporting",
          "Section 8: Adverse Events",
          "Section 9: Safety Assessments",
          "Appendix: CTCAE Grading Tables",
          "Appendix: AESI Definitions"
        ],
        "keyInsights": [
          {
            "name": "AE Collection Period",
            "description": "When AE collection starts and ends relative to study drug",
            "dataPath": "ae_definitions.collection_start, ae_definitions.collection_end",
            "downstreamUses": [
              "EDC AE form display logic",
              "Safety database query rules",
              "Site training"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_AE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate AE dates within collection period",
                "sourceDataPath": "ae_definitions",
                "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
                "example": "AE start date must be >= first dose date for TEAE flag"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "SAE Criteria",
            "description": "ICH E2A serious criteria with protocol-specific exceptions",
            "dataPath": "sae_criteria.criteria[]",
            "downstreamUses": [
              "Safety database serious flag logic",
              "EDC serious field validation",
              "Expedited reporting triggers"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_SAE_001",
                "ruleType": "alert",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure SAE detection and expedited reporting workflow",
                "sourceDataPath": "sae_criteria.criteria[]",
                "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
                "example": "Death \u2192 24hr initial report, 7-day follow-up"
              },
              {
                "ruleId": "EDC_SAE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Enforce SAE documentation requirements",
                "sourceDataPath": "sae_criteria",
                "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Reporting Timelines",
            "description": "Hours/days for initial SAE report, follow-up, SUSAR",
            "dataPath": "reporting_procedures",
            "downstreamUses": [
              "Safety database workflow rules",
              "Site alert configuration",
              "PV team SLAs"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_TIMELINE_001",
                "ruleType": "workflow",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure safety reporting timeline workflows",
                "sourceDataPath": "reporting_procedures",
                "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "AESI List",
            "description": "Adverse events of special interest with monitoring requirements",
            "dataPath": "aesi_list[]",
            "downstreamUses": [
              "Safety database AESI flags",
              "EDC AESI prompts",
              "Medical monitor alerts"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_AESI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Prompt for AESI-specific data collection",
                "sourceDataPath": "aesi_list[]",
                "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
                "example": "Hepatotoxicity \u2192 Prompt for Hy's Law labs, trigger medical monitor alert"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "DLT Criteria",
            "description": "Dose-limiting toxicity definitions, observation period, MTD rules",
            "dataPath": "dlt_criteria",
            "downstreamUses": [
              "Dose escalation committee dashboards",
              "IRT dose assignment rules",
              "Safety stopping rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_DLT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure DLT-based dose escalation rules",
                "sourceDataPath": "dlt_criteria",
                "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
                "example": "3+3 design with 28-day DLT window"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Safety Database (Pharmacovigilance)",
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure safety database with protocol-specific SAE criteria",
          "Set up expedited reporting workflows and timelines",
          "Create EDC AE/SAE CRFs with proper grading dropdowns",
          "Configure AESI flag logic in safety database",
          "Generate site training materials on AE reporting",
          "Set up DLT tracking dashboards for dose escalation"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management",
            "withdrawal_procedures"
          ],
          "crossReferences": [
            "safety_decision_points",
            "concomitant_medications"
          ]
        },
        "cdiscDomains": [
          "AE",
          "MH",
          "FA"
        ],
        "regulatoryRelevance": "ICH E2A, ICH E6(R2), ICH M11 Section 8",
        "schemaFile": "adverse_events_extraction_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_AE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate AE dates within collection period",
            "sourceDataPath": "ae_definitions",
            "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
            "example": "AE start date must be >= first dose date for TEAE flag"
          },
          {
            "ruleId": "SAFETY_SAE_001",
            "ruleType": "alert",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure SAE detection and expedited reporting workflow",
            "sourceDataPath": "sae_criteria.criteria[]",
            "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
            "example": "Death \u2192 24hr initial report, 7-day follow-up"
          },
          {
            "ruleId": "EDC_SAE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Enforce SAE documentation requirements",
            "sourceDataPath": "sae_criteria",
            "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
            "example": null
          },
          {
            "ruleId": "SAFETY_TIMELINE_001",
            "ruleType": "workflow",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure safety reporting timeline workflows",
            "sourceDataPath": "reporting_procedures",
            "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
            "example": null
          },
          {
            "ruleId": "EDC_AESI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Prompt for AESI-specific data collection",
            "sourceDataPath": "aesi_list[]",
            "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
            "example": "Hepatotoxicity \u2192 Prompt for Hy's Law labs, trigger medical monitor alert"
          },
          {
            "ruleId": "IRT_DLT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure DLT-based dose escalation rules",
            "sourceDataPath": "dlt_criteria",
            "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
            "example": "3+3 design with 28-day DLT window"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_AE_SAFETY_001",
            "name": "AE Grading + Safety Thresholds \u2192 Automated Dose Decisions",
            "agentsInvolved": [
              "adverse_events",
              "safety_decision_points"
            ],
            "description": "CTCAE grades combined with safety thresholds enable automated dose recommendations",
            "combinedInsight": "Grade 3 neutropenia + safety rules = Hold dose, check ANC in 1 week",
            "automationEnabled": "EDC displays recommended action when AE grade is entered",
            "exampleOutput": "{\"ae\": \"Neutropenia Grade 3\", \"action\": \"Hold dose\", \"recheck\": \"7 days\", \"resume_criteria\": \"ANC >= 1500\"}"
          },
          {
            "synergyId": "SYN_AE_CM_001",
            "name": "AE + Concomitant Meds \u2192 Drug Interaction Alerts",
            "agentsInvolved": [
              "adverse_events",
              "concomitant_medications"
            ],
            "description": "AE patterns combined with prohibited medications enables interaction detection",
            "combinedInsight": "QT prolongation AE + QT-prolonging concomitant med = Potential drug interaction",
            "automationEnabled": "Real-time drug interaction alert when entering concomitant medications",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_AE_001",
            "name": "CTCAE Version Consistency",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "consistency",
            "description": "Verify CTCAE version is specified and consistent throughout",
            "checkLogic": "ctcae_version IS NOT NULL AND ctcae_version == data_standards.ctcae_version",
            "severity": "error"
          },
          {
            "ruleId": "VAL_AE_002",
            "name": "AESI-SAE Overlap",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "completeness",
            "description": "Check if AESIs have SAE reporting guidance",
            "checkLogic": "FOR EACH aesi: EXISTS sae_guidance OR aesi.always_serious == true",
            "severity": "warning"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Safety Database (Pharmacovigilance)",
            "configType": "protocol_profile",
            "description": "Safety database protocol-specific configuration",
            "dataSources": [
              "sae_criteria.criteria[]",
              "reporting_procedures",
              "aesi_list[]",
              "dlt_criteria"
            ],
            "outputFormat": "Safety database import (Argus, ARISg, Oracle Empirica)",
            "exampleConfig": {
              "sae_criteria": [
                {
                  "criterion": "Death",
                  "code": "C48275",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Life-threatening",
                  "code": "C84266",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Hospitalization",
                  "code": "C84268",
                  "timeline_hours": 72
                }
              ],
              "aesi_list": [
                {
                  "term": "Hepatotoxicity",
                  "meddra_codes": [
                    "10019670"
                  ],
                  "enhanced_collection": true
                }
              ],
              "meddra_version": "26.0",
              "ctcae_version": "5.0"
            }
          }
        ]
      },
      "safety_decision_points": {
        "agentId": "safety_decision_points",
        "displayName": "Safety Decision Points",
        "instanceType": "SafetyDecisionPoints",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts actionable safety decision rules including dose modification triggers,\n    study stopping rules, and organ-specific adjustments. These translate directly\n    into EDC edit checks and medical monitor alert configurations.",
        "scope": "- Safety parameter categories discovered in protocol\n    - Decision points with conditions and actions\n    - Dose modification levels (reduction percentages, absolute doses)\n    - Re-escalation criteria\n    - Study stopping rules (individual and aggregate)\n    - Organ-specific dose adjustments (hepatic, renal, cardiac)\n    - Recovery/rechallenge criteria",
        "keySectionsAnalyzed": [
          "Section 6: Dose Modifications",
          "Section 7: Dose Reductions",
          "Section 8: Study Drug Discontinuation",
          "Section 9: Stopping Rules",
          "Appendix: Dose Modification Tables"
        ],
        "keyInsights": [
          {
            "name": "Dose Reduction Levels",
            "description": "Defined dose levels (-1, -2, etc.) with absolute or percentage reductions",
            "dataPath": "dose_modification_levels.levels[]",
            "downstreamUses": [
              "IRT dose assignment options",
              "EDC dose level dropdown",
              "Drug accountability forms"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DOSELEVEL_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure allowed dose levels in IRT",
                "sourceDataPath": "dose_modification_levels.levels[]",
                "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
                "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Decision Rules",
            "description": "If-then rules mapping safety findings to required actions",
            "dataPath": "decision_points[].decision_rules[]",
            "downstreamUses": [
              "EDC edit checks",
              "Medical monitor alerts",
              "Safety dashboard rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_DECISION_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate edit checks from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
                "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
              },
              {
                "ruleId": "ALERT_DECISION_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Configure real-time safety alerts from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stopping Rules",
            "description": "Individual and study-level stopping conditions",
            "dataPath": "stopping_rules_summary.stopping_conditions[]",
            "downstreamUses": [
              "DSMB monitoring triggers",
              "Sponsor alert rules",
              "IRT enrollment stops"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STOP_001",
                "ruleType": "workflow",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure enrollment stops based on stopping rules",
                "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
                "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Organ-Specific Adjustments",
            "description": "Hepatic, renal, cardiac, hematologic dose adjustments",
            "dataPath": "organ_specific_adjustments[]",
            "downstreamUses": [
              "Lab-triggered alerts",
              "Dose recommendation logic",
              "Site guidance documents"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_ORGAN_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate lab-triggered dose recommendations",
                "sourceDataPath": "organ_specific_adjustments[]",
                "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
                "example": "CrCl 30-50 mL/min \u2192 Reduce to 75% of dose"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Interactive Response Technology",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Generate EDC edit checks for dose modification triggers",
          "Configure IRT dose assignment validation rules",
          "Set up medical monitor safety alert thresholds",
          "Create dose modification decision trees for site training",
          "Configure DSMB stopping rule monitoring",
          "Generate lab-triggered safety alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management"
          ],
          "crossReferences": [
            "adverse_events",
            "laboratory_specifications",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "DS",
          "EX",
          "LB"
        ],
        "regulatoryRelevance": "ICH E6(R2), ICH M11 Section 6-7",
        "schemaFile": "safety_decision_points_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_DOSELEVEL_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure allowed dose levels in IRT",
            "sourceDataPath": "dose_modification_levels.levels[]",
            "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
            "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
          },
          {
            "ruleId": "EDC_DECISION_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate edit checks from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
            "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
          },
          {
            "ruleId": "ALERT_DECISION_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Configure real-time safety alerts from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
            "example": null
          },
          {
            "ruleId": "IRT_STOP_001",
            "ruleType": "workflow",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure enrollment stops based on stopping rules",
            "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
            "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
            "example": null
          },
          {
            "ruleId": "EDC_ORGAN_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate lab-triggered dose recommendations",
            "sourceDataPath": "organ_specific_adjustments[]",
            "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
            "example": "CrCl 30-50 mL/min \u2192 Reduce to 75% of dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_SAFETY_LAB_001",
            "name": "Safety Thresholds + Lab Specs \u2192 Smart Lab Alerts",
            "agentsInvolved": [
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining safety thresholds with lab panel definitions enables intelligent lab alerting",
            "combinedInsight": "Which labs to monitor + what thresholds trigger action = Complete lab safety system",
            "automationEnabled": "EDC auto-calculates if labs trigger dose modification upon data entry",
            "exampleOutput": "{\"lab\": \"ANC\", \"value\": 800, \"threshold\": \"<1000\", \"action\": \"Hold dose\", \"triggered\": true}"
          },
          {
            "synergyId": "SYN_SAFETY_ARMS_001",
            "name": "Safety Rules + Arms \u2192 Arm-Specific Modifications",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "description": "Safety rules applied to specific arm dosing enables precise modification tracking",
            "combinedInsight": "Which dose level applies to which arm = Accurate dose tracking per subject",
            "automationEnabled": "IRT knows exact dose options for each arm based on safety rules",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_SAFETY_001",
            "name": "Dose Level Consistency",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels align with arm dosing regimens",
            "checkLogic": "FOR EACH level: level.absolute_dose IN arms.interventions.possible_doses",
            "severity": "error"
          },
          {
            "ruleId": "VAL_SAFETY_002",
            "name": "Stopping Rule Completeness",
            "agentsInvolved": [
              "safety_decision_points"
            ],
            "validationType": "completeness",
            "description": "Verify all stopping rules have clear conditions and actions",
            "checkLogic": "FOR EACH stop_rule: condition IS NOT NULL AND action IS NOT NULL",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "edit_check_library",
            "description": "Complete set of safety-related edit checks",
            "dataSources": [
              "decision_points[].decision_rules[]",
              "dose_modification_levels.levels[]",
              "organ_specific_adjustments[]"
            ],
            "outputFormat": "EDC edit check specification (Medidata, Oracle, Veeva)",
            "exampleConfig": {
              "edit_checks": [
                {
                  "id": "EC_ALT_001",
                  "condition": "ALT > 5 * ULN",
                  "action": "FIRE",
                  "message": "ALT elevation requires dose hold per protocol section 6.2",
                  "severity": "HARD_STOP"
                },
                {
                  "id": "EC_ANC_001",
                  "condition": "ANC < 1000",
                  "action": "FIRE",
                  "message": "Neutropenia requires dose modification per Table 6-1",
                  "severity": "SOFT_STOP"
                }
              ]
            }
          }
        ]
      },
      "concomitant_medications": {
        "agentId": "concomitant_medications",
        "displayName": "Concomitant Medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts medication restrictions, drug interactions, washout requirements, and required\n    premedications. Essential for site guidance, eligibility verification, and drug\n    interaction checking in EDC.",
        "scope": "- Prohibited medications (with reasons and periods)\n    - Restricted medications (with conditions for use)\n    - Required premedications and prophylaxis\n    - Rescue medications\n    - Washout requirements\n    - Drug-drug interactions (CYP450, QT, etc.)\n    - Vaccine policy\n    - Herbal/supplement restrictions",
        "keySectionsAnalyzed": [
          "Section 5: Prohibited/Restricted Medications",
          "Section 6: Concomitant Medications",
          "Section 7: Prior Medications",
          "Appendix: Drug Interaction Tables"
        ],
        "keyInsights": [
          {
            "name": "Prohibited Medications",
            "description": "Completely banned drug classes with prohibition reasons and periods",
            "dataPath": "prohibited_medications[]",
            "downstreamUses": [
              "EDC CM edit checks",
              "Site reference cards",
              "Eligibility screening"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_PROHIB_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Alert when prohibited medication is entered",
                "sourceDataPath": "prohibited_medications[]",
                "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
                "example": "Strong CYP3A4 inhibitor during treatment \u2192 Protocol deviation query"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Washout Requirements",
            "description": "Required washout periods before study entry",
            "dataPath": "washout_requirements[]",
            "downstreamUses": [
              "Eligibility calculator",
              "Screening visit scheduling",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_WASHOUT_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate washout period for prior medications",
                "sourceDataPath": "washout_requirements[]",
                "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
                "example": "Prior chemotherapy end date + 28 days must be before first dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Interactions",
            "description": "CYP450 inhibitors/inducers, QT prolonging agents with management",
            "dataPath": "drug_interactions[]",
            "downstreamUses": [
              "EDC drug interaction alerts",
              "Medical monitor reviews",
              "Pharmacy guidance"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DDI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Real-time drug interaction checking",
                "sourceDataPath": "drug_interactions[]",
                "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Required Premedications",
            "description": "Mandatory premedications with dosing and timing",
            "dataPath": "required_medications[]",
            "downstreamUses": [
              "Treatment day CRFs",
              "Site procedures",
              "Drug supply planning"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_PREMED_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Verify required premedications were administered",
                "sourceDataPath": "required_medications[]",
                "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
                "example": "Diphenhydramine 50mg IV required 30 min before infusion"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Configure EDC concomitant medication edit checks",
          "Generate site reference cards for prohibited/restricted meds",
          "Create eligibility screening tools with washout calculators",
          "Set up drug interaction alerts in safety database",
          "Auto-populate premedication requirements in visit forms"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria"
          ],
          "crossReferences": [
            "adverse_events",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "CM"
        ],
        "regulatoryRelevance": "ICH M11 Section 6.6",
        "schemaFile": "concomitant_medications_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_PROHIB_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Alert when prohibited medication is entered",
            "sourceDataPath": "prohibited_medications[]",
            "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
            "example": "Strong CYP3A4 inhibitor during treatment \u2192 Protocol deviation query"
          },
          {
            "ruleId": "EDC_WASHOUT_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate washout period for prior medications",
            "sourceDataPath": "washout_requirements[]",
            "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
            "example": "Prior chemotherapy end date + 28 days must be before first dose"
          },
          {
            "ruleId": "EDC_DDI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Real-time drug interaction checking",
            "sourceDataPath": "drug_interactions[]",
            "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
            "example": null
          },
          {
            "ruleId": "EDC_PREMED_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Verify required premedications were administered",
            "sourceDataPath": "required_medications[]",
            "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
            "example": "Diphenhydramine 50mg IV required 30 min before infusion"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_CM_ELIG_001",
            "name": "Washouts + Eligibility \u2192 Complete Screening Tool",
            "agentsInvolved": [
              "concomitant_medications",
              "eligibility_criteria"
            ],
            "description": "Washout requirements combined with eligibility criteria enables smart screening",
            "combinedInsight": "Prior therapy exclusions + washout periods = Earliest eligible date calculator",
            "automationEnabled": "Site tool that calculates when patient becomes eligible based on prior meds",
            "exampleOutput": "{\"prior_med\": \"Irinotecan\", \"last_dose\": \"2024-01-15\", \"washout\": \"28 days\", \"earliest_eligible\": \"2024-02-12\"}"
          }
        ],
        "validationRules": [],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "drug_dictionary_config",
            "description": "Configure drug dictionary with protocol-specific flags",
            "dataSources": [
              "prohibited_medications[]",
              "restricted_medications[]",
              "drug_interactions[]"
            ],
            "outputFormat": "WHODrug/MedDRA mapping with protocol flags",
            "exampleConfig": {
              "drug_flags": [
                {
                  "atc_class": "L01",
                  "flag": "PRIOR_CHEMO",
                  "washout_days": 28
                },
                {
                  "drug_name": "Ketoconazole",
                  "flag": "CYP3A4_INHIBITOR",
                  "status": "PROHIBITED"
                }
              ]
            }
          }
        ]
      },
      "biospecimen_handling": {
        "agentId": "biospecimen_handling",
        "displayName": "Biospecimen Handling",
        "instanceType": "BiospecimenHandling",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts specimen collection, processing, storage, and shipping requirements for central lab and biobank setup.",
        "scope": "Specimen types, tube types/volumes, processing instructions, storage conditions, shipping requirements, biobanking.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 8: Specimen Collection",
          "Appendix: Laboratory Manual"
        ],
        "keyInsights": [
          {
            "name": "Specimen Collection Requirements",
            "description": "Tubes, volumes, special handling for each sample type",
            "dataPath": "specimens[]",
            "downstreamUses": [
              "Central lab kit configuration",
              "Site lab manual",
              "Supply ordering"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate lab kit contents from specimen requirements",
                "sourceDataPath": "specimens[]",
                "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Biospecimen Repository",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Generate central lab sample collection kits",
          "Configure biobank sample tracking",
          "Create site laboratory manuals"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "laboratory_specifications"
          ],
          "crossReferences": [
            "pkpd_sampling"
          ]
        },
        "cdiscDomains": [
          "LB",
          "IS",
          "MB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.3",
        "schemaFile": "biospecimen_handling_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate lab kit contents from specimen requirements",
            "sourceDataPath": "specimens[]",
            "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_BIO_SOA_001",
            "name": "Specimens + SOA \u2192 Visit-Based Lab Kits",
            "agentsInvolved": [
              "biospecimen_handling",
              "soa_schedule"
            ],
            "description": "Specimen requirements + visit schedule = visit-specific lab kit configurations",
            "combinedInsight": "What samples at which visits = Complete lab kit manifest per visit",
            "automationEnabled": "Central lab auto-generates visit-specific kit labels",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "laboratory_specifications": {
        "agentId": "laboratory_specifications",
        "displayName": "Laboratory Specifications",
        "instanceType": "LaboratorySpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts laboratory panel definitions, eligibility criteria, and lab-triggered dose modifications for central lab and EDC setup.",
        "scope": "Lab panels, individual tests, eligibility lab criteria, lab-triggered dose modifications, hepatotoxicity monitoring.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 5: Eligibility Criteria",
          "Section 6: Dose Modifications"
        ],
        "keyInsights": [
          {
            "name": "Laboratory Panels",
            "description": "Panel definitions with constituent tests",
            "dataPath": "panels[]",
            "downstreamUses": [
              "Central lab requisition forms",
              "EDC lab CRF design",
              "Cost estimation"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_PANEL_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate central lab requisition from panel definitions",
                "sourceDataPath": "panels[]",
                "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Eligibility Lab Criteria",
            "description": "Lab values required for study entry",
            "dataPath": "eligibility_lab_criteria[]",
            "downstreamUses": [
              "EDC eligibility edit checks",
              "Site screening tools",
              "Subject ID verification"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_LABELIG_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate screening labs against eligibility criteria",
                "sourceDataPath": "eligibility_lab_criteria[]",
                "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
                "example": "ANC >= 1500/\u00b5L required for eligibility"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central lab panel requisitions",
          "Set up EDC lab data entry",
          "Create eligibility screening lab checklists"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria",
            "safety_decision_points"
          ],
          "crossReferences": [
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "LB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.2",
        "schemaFile": "laboratory_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_PANEL_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate central lab requisition from panel definitions",
            "sourceDataPath": "panels[]",
            "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
            "example": null
          },
          {
            "ruleId": "EDC_LABELIG_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate screening labs against eligibility criteria",
            "sourceDataPath": "eligibility_lab_criteria[]",
            "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
            "example": "ANC >= 1500/\u00b5L required for eligibility"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_LAB_SAFETY_001",
            "name": "Lab Panels + Safety Thresholds \u2192 Lab Alert System",
            "agentsInvolved": [
              "laboratory_specifications",
              "safety_decision_points"
            ],
            "description": "Lab test definitions + safety thresholds = complete lab alerting system",
            "combinedInsight": "Normal ranges + dose modification thresholds = Tiered lab alerts (normal, caution, action required)",
            "automationEnabled": "EDC displays color-coded lab values with action recommendations",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "informed_consent": {
        "agentId": "informed_consent",
        "displayName": "Informed Consent Elements",
        "instanceType": "InformedConsentElements",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts key informed consent content elements for ICF template generation and IRB submission.",
        "scope": "Key risks, potential benefits, treatment alternatives, compensation, genetic/biobanking consents, witness requirements.",
        "keySectionsAnalyzed": [
          "Section 10: Informed Consent",
          "Section 11: Subject Information",
          "Appendix: Informed Consent Form"
        ],
        "keyInsights": [
          {
            "name": "Key Risks",
            "description": "Common, serious, and unknown risks to communicate",
            "dataPath": "risks[]",
            "downstreamUses": [
              "ICF template generation",
              "IRB submission",
              "Site training"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Optional Consents",
            "description": "Biobanking, genetic testing, future research options",
            "dataPath": "optional_consents[]",
            "downstreamUses": [
              "ICF optional sections",
              "EDC consent tracking",
              "Biobank enrollment"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Trial Master File",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate ICF templates with protocol-specific risks",
          "Create consent tracking CRFs"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR 50",
        "schemaFile": "informed_consent_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "pro_specifications": {
        "agentId": "pro_specifications",
        "displayName": "PRO/eCOA Specifications",
        "instanceType": "PROSpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts patient-reported outcome specifications for ePRO/eCOA vendor configuration.",
        "scope": "PRO instruments, ePRO system config, ClinRO/ObsRO/PerfO instruments, daily diaries, compliance thresholds.",
        "keySectionsAnalyzed": [
          "Section 7: Efficacy Assessments",
          "Section 8: Patient-Reported Outcomes",
          "Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "PRO Instruments",
            "description": "Questionnaires with administration mode, timing, scoring",
            "dataPath": "pro_instruments[]",
            "downstreamUses": [
              "ePRO vendor setup",
              "Site training",
              "Compliance monitoring"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EPRO_CONFIG_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Patient-Reported Outcomes",
                "description": "Generate ePRO vendor configuration from PRO specifications",
                "sourceDataPath": "pro_instruments[]",
                "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Patient-Reported Outcomes",
          "Electronic Clinical Outcome Assessment",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure ePRO/eCOA vendor systems",
          "Set up compliance monitoring and alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "endpoints_estimands_sap"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "QS",
          "RS"
        ],
        "regulatoryRelevance": "FDA PRO Guidance, ICH M11 Section 7.4",
        "schemaFile": "pro_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "EPRO_CONFIG_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Patient-Reported Outcomes",
            "description": "Generate ePRO vendor configuration from PRO specifications",
            "sourceDataPath": "pro_instruments[]",
            "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_PRO_SOA_001",
            "name": "PRO + SOA \u2192 Complete ePRO Schedule",
            "agentsInvolved": [
              "pro_specifications",
              "soa_schedule"
            ],
            "description": "PRO instruments + visit timing = exact ePRO administration schedule",
            "combinedInsight": "Which PRO at which visit with what window = Complete ePRO schedule",
            "automationEnabled": "ePRO system auto-schedules assessments based on subject visit dates",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "data_management": {
        "agentId": "data_management",
        "displayName": "Data Management",
        "instanceType": "DataManagement",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts data management specifications for EDC setup and data management planning.",
        "scope": "EDC requirements, CDISC standards versions, data entry timelines, query management, database lock procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Data Management",
          "Section 11: Quality Assurance",
          "Appendix: Data Management Plan"
        ],
        "keyInsights": [
          {
            "name": "CDISC Standards",
            "description": "Required CDASH, SDTM, ADaM versions",
            "dataPath": "cdisc_standards",
            "downstreamUses": [
              "CRF standards library selection",
              "SDTM mapping",
              "ADaM specifications"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure EDC data entry timelines",
          "Set up CDISC standards compliance checks"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "All"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR Part 11",
        "schemaFile": "data_management_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "site_operations_logistics": {
        "agentId": "site_operations_logistics",
        "displayName": "Site Operations & Logistics",
        "instanceType": "SiteOperationsLogistics",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts site operational requirements for site initiation planning and CTMS configuration.",
        "scope": "Site equipment, training requirements, drug storage, IP accountability, vendor coordination.",
        "keySectionsAnalyzed": [
          "Section 9: Study Procedures",
          "Section 10: Drug Supply",
          "Appendix: Site Requirements"
        ],
        "keyInsights": [
          {
            "name": "Equipment Requirements",
            "description": "Site equipment needs for assessments",
            "dataPath": "equipment_requirements[]",
            "downstreamUses": [
              "Site feasibility",
              "Site initiation checklist",
              "Budget planning"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Trial Master File"
        ],
        "automationUseCases": [
          "Generate site initiation checklists",
          "Configure LMS training assignments"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "arms_design",
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "site_operations_logistics_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "quality_management": {
        "agentId": "quality_management",
        "displayName": "Quality Management",
        "instanceType": "QualityManagement",
        "wave": 2,
        "priority": 1,
        "purpose": "Extracts quality management specifications including RBQM, KRIs, and QTLs for CTMS monitoring configuration.",
        "scope": "Monitoring approach, RBQM, Key Risk Indicators, Quality Tolerance Limits, SDV extent, audit procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Quality Management",
          "Section 11: Monitoring",
          "Appendix: Monitoring Plan"
        ],
        "keyInsights": [
          {
            "name": "Key Risk Indicators",
            "description": "KRIs with thresholds and escalation procedures",
            "dataPath": "kris[]",
            "downstreamUses": [
              "Central monitoring dashboards",
              "Site risk scores",
              "Escalation rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "CTMS_KRI_001",
                "ruleType": "derivation",
                "targetSystem": "Clinical Trial Management System",
                "description": "Configure KRI monitoring thresholds",
                "sourceDataPath": "kris[]",
                "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure CTMS monitoring schedules",
          "Set up KRI dashboards"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events",
            "safety_decision_points"
          ],
          "enriches": [],
          "crossReferences": [
            "data_management"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2) 5.0, ICH E8(R1)",
        "schemaFile": "quality_management_schema.json",
        "automationRules": [
          {
            "ruleId": "CTMS_KRI_001",
            "ruleType": "derivation",
            "targetSystem": "Clinical Trial Management System",
            "description": "Configure KRI monitoring thresholds",
            "sourceDataPath": "kris[]",
            "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_QM_ALL_001",
            "name": "All Agents \u2192 Complete RBQM Dashboard",
            "agentsInvolved": [
              "quality_management",
              "adverse_events",
              "safety_decision_points",
              "data_management"
            ],
            "description": "KRI definitions + safety events + data quality = comprehensive central monitoring",
            "combinedInsight": "Site-level risk scores based on all protocol-defined indicators",
            "automationEnabled": "Automated site risk scoring and monitoring prioritization",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "withdrawal_procedures": {
        "agentId": "withdrawal_procedures",
        "displayName": "Withdrawal Procedures",
        "instanceType": "WithdrawalProcedures",
        "wave": 2,
        "priority": 2,
        "purpose": "Extracts study discontinuation procedures for EDC disposition forms and protocol deviation tracking.",
        "scope": "Discontinuation types, consent withdrawal, early termination visits, survival follow-up, lost to follow-up.",
        "keySectionsAnalyzed": [
          "Section 5: Subject Withdrawal",
          "Section 6: Early Termination",
          "Section 9: Follow-up Procedures"
        ],
        "keyInsights": [
          {
            "name": "Discontinuation Types",
            "description": "Treatment vs study discontinuation with criteria",
            "dataPath": "discontinuation_types[]",
            "downstreamUses": [
              "EDC disposition forms",
              "Analysis programming",
              "DSMB reporting"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Create EDC disposition forms",
          "Configure survival follow-up tracking"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "withdrawal_procedures_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "imaging_central_reading": {
        "agentId": "imaging_central_reading",
        "displayName": "Imaging & Central Reading",
        "instanceType": "ImagingCentralReading",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts imaging specifications for oncology and imaging-endpoint studies.",
        "scope": "Response criteria (RECIST, RANO), imaging modalities, central vs local reading, adjudication procedures.",
        "keySectionsAnalyzed": [
          "Section 7: Tumor Assessments",
          "Section 8: Response Criteria",
          "Appendix: Imaging Charter"
        ],
        "keyInsights": [
          {
            "name": "Response Criteria",
            "description": "RECIST/iRECIST/RANO version and modifications",
            "dataPath": "response_criteria",
            "downstreamUses": [
              "Central imaging vendor setup",
              "Endpoint adjudication",
              "Analysis programming"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IMAGING_RESP_001",
                "ruleType": "derivation",
                "targetSystem": "Central Imaging",
                "description": "Configure central imaging for response assessment",
                "sourceDataPath": "response_criteria",
                "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Imaging",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central imaging vendor systems",
          "Set up response assessment workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "TU",
          "TR",
          "RS"
        ],
        "regulatoryRelevance": "FDA Oncology Guidance, ICH M11 Section 7",
        "schemaFile": "imaging_central_reading_schema.json",
        "automationRules": [
          {
            "ruleId": "IMAGING_RESP_001",
            "ruleType": "derivation",
            "targetSystem": "Central Imaging",
            "description": "Configure central imaging for response assessment",
            "sourceDataPath": "response_criteria",
            "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_IMG_EP_001",
            "name": "Imaging + Endpoints \u2192 Response-Based Efficacy",
            "agentsInvolved": [
              "imaging_central_reading",
              "endpoints_estimands_sap"
            ],
            "description": "Response criteria + primary endpoint = complete efficacy assessment workflow",
            "combinedInsight": "RECIST definitions + ORR/PFS endpoints = Imaging-derived efficacy programming",
            "automationEnabled": "Central imaging outputs directly feed efficacy analysis datasets",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "pkpd_sampling": {
        "agentId": "pkpd_sampling",
        "displayName": "PK/PD Sampling",
        "instanceType": "PKPDSampling",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts pharmacokinetic and pharmacodynamic sampling specifications for clinical pharmacology studies.",
        "scope": "PK sampling timepoints, PD biomarker sampling, bioanalytical methods, population PK specifications.",
        "keySectionsAnalyzed": [
          "Section 7: Pharmacokinetic Assessments",
          "Section 8: Pharmacodynamic Assessments",
          "Appendix: PK Sampling Schedule"
        ],
        "keyInsights": [
          {
            "name": "PK Sampling Schedule",
            "description": "Intensive and sparse PK timepoints",
            "dataPath": "pk_sampling.timepoints[]",
            "downstreamUses": [
              "Site PK procedure guides",
              "Central lab setup",
              "Visit schedule"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure bioanalytical lab sample requirements",
          "Create PK sampling procedure guides"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "biospecimen_handling",
            "arms_design",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "PC",
          "PP"
        ],
        "regulatoryRelevance": "FDA Clinical Pharmacology Guidance",
        "schemaFile": "pkpd_sampling_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "downstreamSystemCoverage": {
      "Electronic Data Capture": [
        "study_metadata",
        "arms_design",
        "endpoints_estimands_sap",
        "adverse_events",
        "safety_decision_points",
        "concomitant_medications",
        "biospecimen_handling",
        "laboratory_specifications",
        "informed_consent",
        "pro_specifications",
        "data_management",
        "quality_management",
        "withdrawal_procedures",
        "imaging_central_reading",
        "pkpd_sampling"
      ],
      "Clinical Trial Management System": [
        "study_metadata",
        "adverse_events",
        "data_management",
        "site_operations_logistics",
        "quality_management",
        "withdrawal_procedures"
      ],
      "Interactive Response Technology": [
        "study_metadata",
        "arms_design",
        "safety_decision_points"
      ],
      "Regulatory Submission Systems": [
        "study_metadata",
        "endpoints_estimands_sap",
        "informed_consent"
      ],
      "Interactive Web Response System": [
        "arms_design"
      ],
      "Randomization & Trial Supply Management": [
        "arms_design"
      ],
      "Drug Supply Management": [
        "arms_design"
      ],
      "Safety Database (Pharmacovigilance)": [
        "adverse_events",
        "safety_decision_points",
        "concomitant_medications"
      ],
      "Central Laboratory": [
        "biospecimen_handling",
        "laboratory_specifications",
        "pkpd_sampling"
      ],
      "Biospecimen Repository": [
        "biospecimen_handling"
      ],
      "Trial Master File": [
        "informed_consent",
        "site_operations_logistics"
      ],
      "Electronic Patient-Reported Outcomes": [
        "pro_specifications"
      ],
      "Electronic Clinical Outcome Assessment": [
        "pro_specifications"
      ],
      "Central Imaging": [
        "imaging_central_reading"
      ]
    },
    "automationCategories": {
      "Regulatory Document Generation": [
        {
          "agent": "study_metadata",
          "insight": "Protocol Identifiers",
          "priority": "critical"
        },
        {
          "agent": "study_metadata",
          "insight": "Study Phase",
          "priority": "critical"
        },
        {
          "agent": "informed_consent",
          "insight": "Key Risks",
          "priority": "critical"
        }
      ],
      "Eligibility Verification": [
        {
          "agent": "study_metadata",
          "insight": "Target Population",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Prohibited Medications",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Washout Requirements",
          "priority": "critical"
        },
        {
          "agent": "laboratory_specifications",
          "insight": "Eligibility Lab Criteria",
          "priority": "critical"
        }
      ],
      "Visit Schedule Programming": [
        {
          "agent": "study_metadata",
          "insight": "Study Milestones",
          "priority": "high"
        }
      ],
      "Randomization Configuration": [
        {
          "agent": "study_metadata",
          "insight": "Design Metadata",
          "priority": "critical"
        },
        {
          "agent": "arms_design",
          "insight": "Study Arms",
          "priority": "critical"
        },
        {
          "agent": "arms_design",
          "insight": "Stratification Factors",
          "priority": "critical"
        }
      ],
      "Drug Supply & Kit Management": [
        {
          "agent": "arms_design",
          "insight": "Dosing Regimens",
          "priority": "critical"
        },
        {
          "agent": "arms_design",
          "insight": "Drug Supply Configuration",
          "priority": "high"
        }
      ],
      "Safety Monitoring Rules": [
        {
          "agent": "arms_design",
          "insight": "Dose Modification Rules",
          "priority": "high"
        },
        {
          "agent": "adverse_events",
          "insight": "SAE Criteria",
          "priority": "critical"
        },
        {
          "agent": "adverse_events",
          "insight": "Reporting Timelines",
          "priority": "critical"
        },
        {
          "agent": "adverse_events",
          "insight": "AESI List",
          "priority": "high"
        },
        {
          "agent": "adverse_events",
          "insight": "DLT Criteria",
          "priority": "high"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Dose Reduction Levels",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Decision Rules",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Stopping Rules",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Organ-Specific Adjustments",
          "priority": "high"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Drug Interactions",
          "priority": "high"
        },
        {
          "agent": "quality_management",
          "insight": "Key Risk Indicators",
          "priority": "high"
        }
      ],
      "CDISC Data Standards Mapping": [
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Primary Endpoints",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Estimands",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Analysis Populations",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Statistical Methods",
          "priority": "high"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Subgroup Analyses",
          "priority": "medium"
        },
        {
          "agent": "data_management",
          "insight": "CDISC Standards",
          "priority": "high"
        },
        {
          "agent": "imaging_central_reading",
          "insight": "Response Criteria",
          "priority": "critical"
        }
      ],
      "EDC Form Design & Edit Checks": [
        {
          "agent": "adverse_events",
          "insight": "AE Collection Period",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Required Premedications",
          "priority": "high"
        },
        {
          "agent": "informed_consent",
          "insight": "Optional Consents",
          "priority": "high"
        },
        {
          "agent": "pro_specifications",
          "insight": "PRO Instruments",
          "priority": "critical"
        },
        {
          "agent": "withdrawal_procedures",
          "insight": "Discontinuation Types",
          "priority": "high"
        }
      ],
      "Laboratory Panel Configuration": [
        {
          "agent": "biospecimen_handling",
          "insight": "Specimen Collection Requirements",
          "priority": "critical"
        },
        {
          "agent": "laboratory_specifications",
          "insight": "Laboratory Panels",
          "priority": "critical"
        },
        {
          "agent": "pkpd_sampling",
          "insight": "PK Sampling Schedule",
          "priority": "high"
        }
      ],
      "Site Training Materials": [
        {
          "agent": "site_operations_logistics",
          "insight": "Equipment Requirements",
          "priority": "medium"
        }
      ]
    },
    "integrationGraph": {
      "nodes": [
        {
          "id": "study_metadata",
          "displayName": "Study Metadata",
          "wave": 0,
          "priority": 0
        },
        {
          "id": "arms_design",
          "displayName": "Treatment Arms & Study Design",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "endpoints_estimands_sap",
          "displayName": "Endpoints, Estimands & SAP",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "adverse_events",
          "displayName": "Adverse Events",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "safety_decision_points",
          "displayName": "Safety Decision Points",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "concomitant_medications",
          "displayName": "Concomitant Medications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "biospecimen_handling",
          "displayName": "Biospecimen Handling",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "laboratory_specifications",
          "displayName": "Laboratory Specifications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "informed_consent",
          "displayName": "Informed Consent Elements",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "pro_specifications",
          "displayName": "PRO/eCOA Specifications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "data_management",
          "displayName": "Data Management",
          "wave": 1,
          "priority": 2
        },
        {
          "id": "site_operations_logistics",
          "displayName": "Site Operations & Logistics",
          "wave": 1,
          "priority": 2
        },
        {
          "id": "quality_management",
          "displayName": "Quality Management",
          "wave": 2,
          "priority": 1
        },
        {
          "id": "withdrawal_procedures",
          "displayName": "Withdrawal Procedures",
          "wave": 2,
          "priority": 2
        },
        {
          "id": "imaging_central_reading",
          "displayName": "Imaging & Central Reading",
          "wave": 2,
          "priority": 3
        },
        {
          "id": "pkpd_sampling",
          "displayName": "PK/PD Sampling",
          "wave": 2,
          "priority": 3
        }
      ],
      "edges": [
        {
          "source": "study_metadata",
          "target": "arms_design",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "endpoints_estimands_sap",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "data_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "arms_design",
          "type": "depends_on"
        },
        {
          "source": "arms_design",
          "target": "safety_decision_points",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "pkpd_sampling",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "biospecimen_handling",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "concomitant_medications",
          "type": "cross_references"
        },
        {
          "source": "arms_design",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "endpoints_estimands_sap",
          "type": "depends_on"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "pro_specifications",
          "type": "enriches"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "imaging_central_reading",
          "type": "enriches"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "adverse_events",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "quality_management",
          "type": "enriches"
        },
        {
          "source": "adverse_events",
          "target": "withdrawal_procedures",
          "type": "enriches"
        },
        {
          "source": "adverse_events",
          "target": "safety_decision_points",
          "type": "cross_references"
        },
        {
          "source": "adverse_events",
          "target": "concomitant_medications",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "safety_decision_points",
          "type": "depends_on"
        },
        {
          "source": "safety_decision_points",
          "target": "quality_management",
          "type": "enriches"
        },
        {
          "source": "safety_decision_points",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "safety_decision_points",
          "target": "laboratory_specifications",
          "type": "cross_references"
        },
        {
          "source": "safety_decision_points",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "concomitant_medications",
          "type": "depends_on"
        },
        {
          "source": "concomitant_medications",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "concomitant_medications",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "concomitant_medications",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "biospecimen_handling",
          "type": "depends_on"
        },
        {
          "source": "biospecimen_handling",
          "target": "laboratory_specifications",
          "type": "enriches"
        },
        {
          "source": "biospecimen_handling",
          "target": "pkpd_sampling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "laboratory_specifications",
          "type": "depends_on"
        },
        {
          "source": "laboratory_specifications",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "laboratory_specifications",
          "target": "safety_decision_points",
          "type": "enriches"
        },
        {
          "source": "laboratory_specifications",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "informed_consent",
          "type": "depends_on"
        },
        {
          "source": "informed_consent",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "pro_specifications",
          "type": "depends_on"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "pro_specifications",
          "type": "depends_on"
        },
        {
          "source": "pro_specifications",
          "target": "endpoints_estimands_sap",
          "type": "cross_references"
        },
        {
          "source": "pro_specifications",
          "target": "soa_schedule",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "data_management",
          "type": "depends_on"
        },
        {
          "source": "data_management",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "site_operations_logistics",
          "type": "depends_on"
        },
        {
          "source": "site_operations_logistics",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "site_operations_logistics",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "safety_decision_points",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "quality_management",
          "target": "data_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "withdrawal_procedures",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "withdrawal_procedures",
          "type": "depends_on"
        },
        {
          "source": "withdrawal_procedures",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "imaging_central_reading",
          "type": "depends_on"
        },
        {
          "source": "imaging_central_reading",
          "target": "endpoints_estimands_sap",
          "type": "cross_references"
        },
        {
          "source": "imaging_central_reading",
          "target": "soa_schedule",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "pkpd_sampling",
          "type": "depends_on"
        },
        {
          "source": "pkpd_sampling",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "pkpd_sampling",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "pkpd_sampling",
          "target": "soa_schedule",
          "type": "cross_references"
        }
      ]
    }
  }
}